,id,ticker,title,category,content,date,provider,url,article_id
3885,225400,CERN,Stocks   Dow Racks up Triple Digit Gains as Trade Hopes Trigger Rally,news,"Investing com   The Dow rallied Wednesday on growing hopes the U S  and China will reach an agreement after President Donald Trump said trade talks were going  very well  
The Dow Jones Industrial Average rose 0 46   or 117 points  The S P 500 added 0 30  and the Nasdaq Composite rose 0 08   The S P 500 and Nasdaq were each higher for a third straight day  the Dow s gain was its second in a row  The indexes are higher by about 1 7  so far this week 
Trump said the high level parley on trade between U S  and China was progressing  well   easing investor worries that the two nations would be unable to reach a trade agreement by end of the current trade war truce on March 1 
The president s somewhat reassuring remarks on trade come a day after he told reporters he was open to extending the deadline beyond March 1 if there is sufficient progress on the talks 
The upbeat hopes of a trade deal and strong gains in  General Electric   NYSE GE  supported the trade sensitive industrials sector 
GE rose 3 91  a day after Reuters reported the conglomerate had secured the most orders for electricity generating gas turbines in 2018  But Mitsubishi Hitachi Power Systems beat General Electric to the top spot for orders of the largest and most advanced turbines 
Beyond trade  rising energy stocks powered the broader market higher  The gains reflected rising oil prices as Saudi Arabia s pledge to continue cutting output offset data showing a larger than expected build in domestic crude stockpiles 
Tech stocks struggled to get in on the rally  weighed down by weakness in FANG stocks 
Apple reportedly is nearing the launch of a new streaming service that will feature free original content for device owners  but may not include Netflix  CNBC reported  citing people familiar with the matter 
Apple  NASDAQ AAPL  fell 0 42   and Netflix  NASDAQ NFLX  dropped 2 3  
The CNBC report comes as Goldman Sachs said it expects the iPhone maker to launch a streaming service this spring or summer to plug the gap from a decline in service revenue on expectations of a material drop in traffic acquisition costs 
Traffic acquisition costs  the fee Google  NASDAQ GOOGL  pays companies for diverting traffic to its website  are expected to drop significantly this year  according to the bank 
 We forecast that traffic acquisition costs growth drops materially to about 29  in 2019 from 46  in 2018   Goldman Sachs  NYSE GS  said 
On the economic front  mixed U S  inflation data also supported the broader market amid expectations subdued price pressures would strengthen the Federal Reserve s case to hold off monetary policy tightening 
The Labor Department said on Thursday its consumer price index was flat January  after edging up 0 1  in the prior month  But core CPI  which excludes food and energy  rose 2 2  for the year through January  above forecasts for a 2 1  increase 
In Washington  Trump told reporters he would  take a very serious look  at the border security deal and reiterated he does not want the see a second government shutdown 
Top S P 500 Gainers and Losers Today 
Freeport McMoran Copper   Gold  NYSE FCX   Activision Blizzard  NASDAQ ATVI  and  Hilton Worldwide  Holdings  NYSE HLT  were among the top S P 500 gainers for the session 
 DISH Network   NASDAQ DISH   TripAdvisor  NASDAQ TRIP  and Cerner  NASDAQ CERN  were among the worst S P 500 performers of the session ",2019-02-13,Investing.com,https://www.investing.com/news/stock-market-news/stocks--dow-racks-up-tripledigit-gains-as-trade-hopes-trigger-rally-1778843,1778843
3886,225401,CERN,Stocks   Wynn  Novartis Fall in Premarket  American Airlines  Cerner Rise,news,"Investing com    Stocks in focus in premarket trade on Tuesday include 
  Novartis ADRs  NYSE NVS  fell 10 6  after the company spun off its eye care unit Alcon  Alcon s shares listed in New York and Zurich Tuesday with a market value of some  25 billion 
  American Airlines  NASDAQ AAL  stock rose 1 2  after the company s downwardly revised guidance  for the first quarter was less severe than feared 
  Cerner  NASDAQ CERN  stock surged 8 2  after the company shook up its board and increased its buyback program under pressure from activist investor Starboard Capital 
  Apple  NASDAQ AAPL  stock rose 0 4  after Wedbush raised its target price to  225 from  215  citing a  slow turnaround  in demand in China 
   General Electric   NYSE GE  continued to fall  losing 1 7  after a 5 2  drop on Monday in the wake of a downgrade by analysts at JPMorgan  NYSE JPM  
  Wynn Resorts  NASDAQ WYNN was down 2 6  after confirming it offered  7 1 billion for Australian based casino operator Crown Resorts ",2019-04-09,Investing.com,https://www.investing.com/news/stock-market-news/stocks--wynn-novartis-fall-in-premarket-american-airlines-cerner-rise-1831149,1831149
146384,367899,CERN,Cerner Earnings  Revenue inline in Q3,news,"Investing com   Cerner  NASDAQ CERN  reported third quarter earnings  that matched analysts  expectations on Thursday and revenue that was inline with forecasts 
The firm reported earnings per share of  0 66 on revenue of  1 43B  Analysts polled by Investing com expected EPS of  0 66 on revenue of  1 43B  That compared to EPS of  0 63 on revenue of  1 34B in the same period a year earlier  The company had reported EPS of  0 66 on revenue of  1 43B in the previous quarter 
Cerner follows other major Technology sector earnings this monthOn Wednesday  Microsoft reported first quarter EPS of  1 38 on revenue of  33 06B  compared to forecasts of EPS of  1 24 on revenue of  32 14B 
Taiwan Semiconductor earnings beat analysts  expectations on October 17  with third quarter EPS of  0 64 on revenue of  9 58B  Investing com analysts expected EPS of  0 61 on revenue of  9 25B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-24,Investing.com,https://www.investing.com/news/stock-market-news/cerner-earnings-revenue-inline-in-q3-2003648,2003648
146385,367900,CERN,Better Buy  Veeva Systems vs  Cerner,news,"Veeva Systems  NYSE VEEV  and Cerner  NASDAQ CERN  offer investors some unique opportunities to invest not only in healthcare but in technology as well  These two stocks can give investors the best of both worlds    growth and stability  But deciding between the two is no easy task  as investors will need to determine just how much growth they re looking for versus how much stability they require 
Veeva has been on fire and could be headed higher
Veeva s stock has skyrocketed over the past five years  rising a whopping 400   well in excess of the 62  returns that the S P 500 has generated during that time  The cloud software company works in healthcare  but Veeva isn t your typical healthcare stock  With significant technical capabilities  the company is tech giant salesforce com s  preferred worldwide partner for the pharmaceutical and biotech industry   The two companies have a partnership that extends into 2025  allowing Veeva to develop unique applications for the healthcare industry  
One of the applications that Veeva has developed with Salesforce is a customer relationship management  CRM  application designed with care providers in mind  Currently  more than 50 biopharmaceutical companies around the world use the software  It s a great growth opportunity for Veeva to reach even more healthcare providers  especially those that may not be all that familiar with CRM 

What investors will love about Veeva is that not only did the stock s revenue climb 25  in the company s fiscal third quarter  but a big chunk of its revenue came from subscriptions  Subscription services totaled  227 million during Q3 and made up 81  of the company s top line  and that s up from 79  in the prior year quarter 
The company s commercial cloud revenue  which includes CRM  makes up a little less than half  48   of Veeva s top line  Veeva Vault  a suite of apps that focuses on data management  had a slight majority this past quarter  but that wasn t the case a year ago when commercial cloud sales had the upper hand with 52  of revenue 
Cerner is more diversified but offers far less growth
Cerner is also a big player in healthcare and tech and generates significantly more revenue than Veeva does  The company released its third quarter results in October  and with revenue of more than  1 4 billion  Cerner makes more than Veeva does in 12 months  But where Cerner falls short is growth  revenue last quarter grew by just 6 7  from the prior year quarter  And over the past nine months things aren t any better as sales are up only 6 3  from a year ago  
The one strength in Cerner s financials  however  is that the company has a lot of diversification in its top line  Professional services make up the bulk of Cerner s sales  and that s still only a little more than one third of its revenue through the first nine months of 2019  The downside is that while the company has multiple segments that are growing at more than double digits  there s not one segment that s driving Cerner s growth and that investors can rally behind the way they can around Veeva 
One benefit for income investors is that Cerner pays a dividend of around 1  per year  While it may be well below the S P 500 average of 1 85   it compares favorably against Veeva  which doesn t offer investors any payout 
Why Veeva is the better stock today
Over the long term  Veeva looks like it has the edge over Cerner  especially when looking at future growth  Veeva has some exciting products that are showing terrific growth  and a partnership with Salesforce is bound to lead to even more potential down the road  The company may only be scratching the surface of its potential 
The one negative for Veeva is that the stock is very expensive  trading at 76 times earnings and a price to book multiple of 14  Cerner  however  isn t a cheap stock  either  While its P E multiple of 49 is lower than Veeva s  it s still a high price tag given the modest growth the company has generated 
When it comes to picking a good growth stock  it s key that a company has an exciting product that can drive home some strong results  And in Veeva s case  it has two    CRM and Vault ",2020-01-21,The Motley Fool,https://invst.ly/pk-0g,2064269
146386,367901,CERN,CERN drops Facebook s Slack competitor  citing privacy issues and low usage,news,CERN  the European Organization for Nuclear Research  on Friday ended its use of Workplace by Facebook  the company s communications tool for companies The organization disclosed its decision to stop using the enterprise Facebook tool on Tuesday  citing a lack of usage by CERN members and concern about data privacy ,2020-01-31,CNBC,https://invst.ly/ppmhw,2073546
146387,367902,CERN,Cerner Earnings Beat  Revenue Inline In Q4,news,"Investing com   Cerner  NASDAQ CERN  reported on Tuesday fourth quarter earnings  that beat analysts  forecasts and revenue that was inline with expectations 
Cerner announced earnings per share of  0 75 on revenue of  1 44B  Analysts polled by Investing com anticipated EPS of  0 74 on revenue of  1 44B  That with comparison to EPS of  0 63 on revenue of  1 37B in the same period a year before  Cerner had reported EPS of  0 66 on revenue of  1 43B in the previous quarter  Analysts are expecting EPS of  0 7 and revenue of  1 43B in the upcoming quarter 
Cerner shares are up 7 19  from the beginning of the year   still down 2 97  from its 52 week high of  76 47 set on July 12  2019  They are outperforming the S P 500 which is up 1 65  year to date 
Cerner shares gained 3 10  in after hours trade following the report 
Cerner follows other major Technology sector earnings this monthCerner s report follows an earnings beat by Apple  on January 28  who reported EPS of  4 99 on revenue of  91 82B   compared to forecasts EPS of  4 54 on revenue of  88 51B 
Microsoft had beat expectations on January 29 with second quarter EPS of  1 51 on revenue of  36 91B  compared to forecast for EPS of  1 05 on revenue of  32 512M 
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-02-04,Investing.com,https://www.investing.com/news/stock-market-news/cerner-earnings-beat-revenue-inline-in-q4-2075953,2075953
146392,367907,CERN,Cerner Corp  CERN  Q4 2019 Earnings Call Transcript,news,"Cerner Corp  NASDAQ CERN Q4 2019 Earnings CallFeb 4  2020  4 30 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorWelcome to the Cerner Corporation Fourth Quarter 2019 Conference Call  Today s date is February 4  2020 and this call is being recorded  The Company has asked me to remind you that various remarks made here today constitute forward looking statements  including without limitation  those regarding projections of future revenues or earnings  operating margins  operating and capital expenses  bookings  new solutions  services  and offering development  and capital allocation plans  cost optimization  and operational improvement initiatives  future business outlook  including new markets or prospects for the Company s solutions and services  and expected benefits of certain of our acquisition or other collaborations  Actual results may differ materially from those indicated by the forward looking statements Please see Cerner earnings release  which was filed with the SEC today and posted to the Investor section of cerner com and other filings with the SEC for additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements  A reconciliation of non GAAP financial measures discussed in the earnings call can also be found in the Company s earnings release  Cerner assumes no obligation to update any forward looking statements or information  except as required by law At this time  I d like to turn the call over to Brent Shafer  Chairman and CEO of Cerner Corporation Brent Shafer    Chairman and Chief Executive OfficerThank you  Delim and good afternoon everyone and welcome to the call  I am joining the call from a client event  so I ll start the call with a few comments then hand it over to the team in Kansas City  including our CFO  Marc Naughton  Chief Client Officer  John Peterzalek  and EVP of Strategic Growth  Don Trigg 2019 was an important and productive year for Cerner  We began the year by introducing a new operating model to refine our organizational alignment  enhance our client focus  and to accelerate scalable innovation to make Cerner easier to do business with  We also initiated a Companywide transformation focused on operating efficiencies  business simplification  portfolio management  and refining our growth strategy to position Cerner for long term  profitable growth  Further  we enhanced our governance through the addition of four strong Board members  who  along with our existing members  have been invaluable as we work through our transformation Our 2019 progress is reflected in our fourth quarter results  which included good performance across all key metrics  including exceeding our adjusted operating margin target and delivering record free cash flow  We also returned  1 4 billion of capital to shareholders in 2019 through our share buyback program and our first two dividend payments  all reflecting our commitment to delivering value to shareholders Also significant in 2019 was the announcement of our multi faceted collaboration with AWS and Amazon  We view this relationship as an enabler to many of the growth strategies we ve discussed on previous calls  including Cerner s development of a cognitive platform and our evolution to becoming the Software as a Service healthcare IT partner  Leveraging the powerful combination of Cerner technology  the AWS infrastructure  their artificial intelligence and machine learning capabilities  we expect to create next generation user experiences and innovations to deliver more predictive  patient centric care      Now before turning the call over to Marc  I d like to discuss Cerner s position on the topic of interoperability  data security  and privacy  For several decades  Cerner has been a trusted steward of health information and a leader in the pursuit of data interoperability  We ve seen a vocal proponent of    we have been  excuse me  a vocal proponent of the 21st Century Cures Act  and look forward to continuing our work with the ONC  with clients  and with other key stakeholders to ensure a secure flow of information across disparate systems and healthcare entities  We do this because it s the right thing to do And I m reminded of it today  I started my career at Intermountain Healthcare  And this is where I spent the day today talking with other leaders about the future of health and care  And we talk a lot about the fact that healthcare is too important to stay the same  And I love the chance to get together and collaborate with other organizations like Intermountain  who are working to help people live the healthiest lives possible  We fundamentally believe it s wrong to ask patients striving to get better to manage a collection of faxes  PDFs and paper filled shopping bags  It s wrong to ask providers to leave their workflows to review and leverage relevant patient information  It s wrong to waste hundreds of billions of dollars on the highest administrative costs in the world when we re in the middle of an affordability crisis in United States healthcare  So we re going to continue to be a positive voice for change in the industry  Access to the right information at the right time in the right place continues to drive our advocacy in Washington and in the global markets we serve In summary  I m very pleased with everything we accomplished in 2019  We consistently delivered against expectations we set while driving a significant amount of change throughout Cerner  This was hard work and I specifically appreciate all the Cerner associates  hard work throughout the year and their contributions to this progress  We have a lot more to do in 2020  but we re off to a good start and I m optimistic we ll continue to advance our transformation  And more importantly  I believe the work we re doing will position us to create meaningful value in healthcare  while also driving good long term growth for Cerner And now I ll turn the call over to Marc Marc Naughton    Chief Financial OfficerThanks  Brent  Good afternoon  everyone  Before I begin  I did want to cover the most important numbers from the weekend  which are 31 and 20 reflecting the 11 point win for the Super Bowl champion  Kansas City Chiefs  Go Chiefs Now I ll cover our Q4 results and future period guidance  This quarter we delivered all key metrics at or above our guidance  I ll start with bookings  which were  1 665 billion in Q4  exceeding the high end of our guidance  This is down from Q4  18 which was the second highest bookings quarter in our history  Full year bookings were  5 99 billion  which is down from  6 721 billion in 2018  Decline in Q4 and for the year was primarily due to a decline in long term bookings related to us being more selective on our outsourcing contracts as we ve discussed throughout the year  We ended the quarter with a revenue backlog of  13 71 billion  which is down 10  from a year ago  primarily due to the termination of a RevWorks agreement that I discussed on our Q3 call  Also recall that our backlog calculation of the new revenue standard excludes revenue from contracts with termination clauses  even though such clauses are rarely exercised  When you combine the expected revenue from our backlog and the additional revenue expected from contracts not included in our backlog  our revenue visibility remains at nearly 85  over the next 12 months  Revenue in the quarter was  1 442 billion  up 6  over Q4 of  18 and in line with our expectations  Total revenue for the year was  5 693 billion  reflecting growth of 6  over 2018 Now I ll go through the business model detail and year over year growth compared to Q4  18 and full year 2018  Licensed software revenue in Q4 grew 5  over Q4 of  18 million to  174 million and full year licensed software revenue grew 11  over 2018 to  681 million  both primarily due to strong growth in our SaaS offerings Technology resale of  60 million in Q4 increased 31  compared to a weak Q4 of 2018  Full year technology resale revenue was up 1  to  247 million  Subscriptions revenue grew 7  in Q4 to  93 million  Full year subscriptions revenue was  359 million  up 10  from  326 million in 2018 Professional services revenue grew 9  in Q4 to  509 million  primarily driven by solid growth in implementation services and partially offset by approximately  23 million less revenue due to termination of the RevWorks agreement we previously discussed  Full year professional services revenue grew 10  to  1 992 billion  Managed services was up 3  in Q4 to  309 million  Full year managed services revenue was  1 214 billion  an increase of 5  over 2018  Support and maintenance was down 1  to  274 million for the quarter  which is our expectation range and reflects the impact of some past attrition that we discussed last quarter  Full year support and maintenance revenue was also down 1  from 2018 at  1 105 billion  And finally reimbursed travel of  22 million was down 9  in Q4 and down 2  for the full year at  95 million Looking at revenue by geographic segment  domestic revenue was up 6  from the year ago quarter at  1 276 billion and non US revenue of  166 million was up 3  from the year ago quarter  For the full year  domestic revenue grew 7  and non US revenue grew 3  Moving to gross margin  Our gross margin for Q4 was 80 8   down from 81  in Q3 of  19 and 82 6  year over year  Full year gross margin of 81 2  is down from 82 5  in 2018  The declines in our quarterly and full year gross margin are both driven by higher third party services largely related to our federal business and a lower margin mix within technology resale Now I ll discuss spending  operating margin and net earnings  For these items  we provide both GAAP and adjusted or non GAAP results  The adjusted results exclude share based compensation expense  acquisition related adjustments  organizational restructuring and other expenses and other adjustments that are detailed and reconciled to GAAP in our earnings release Looking at our operating spending  our fourth quarter GAAP operating expenses of  982 million were up 2  compared to  965 million in the year ago period  Full year GAAP operating expenses were  4 021 billion  up 10  from  3 654 billion in 2018  Our adjusted operating expenses were up 4  for the full year with the fourth quarter essentially flat compared to Q4 of  18  reflecting good progress on our cost optimization efforts  Looking at the line items for Q4  sales and client service expense increased 1  in Q4  Software development expense increased 4  over Q4 of  18  driven by 1  increase in gross R D  a 7  increase in amortization and a 3  decrease in capitalized software  G A expense was 15  driven by decline in both personnel and non personnel expenses Amortization of acquisition related intangibles decreased slightly year over year  Moving to operating margins  our GAAP operating margin in Q4 was 12 7  compared to 12  in the year ago period  Our adjusted operating margin for the quarter was 20 3   up from 18 7  in Q4 of  18 and 18 1  last quarter  Our Q4 adjusted operating margin is in line with our expectations and above the 20  adjusted operating margin target for Q4 of  19 that we committed to last April Our GAAP operating margin for full year of 2019 was 10 6  compared to 14 4  in 2018 and full year adjusted operating margin was 18 5  which is down slightly from 18 8  last year  We believe our ongoing business optimization efforts keep us on track for delivering our targeted Q4  20 adjusted operating margin of 22 5   I d note that some of the margin expansion is expected to be back end loaded like last year due to the timing of our initiatives and some seasonality  However  our guidance  which I ll discuss in a minute  does reflect a full year adjusted operating margin of approximately 21   which is about 250 basis points higher than 2019 and reflects the cumulative impact of all of the optimization work we have done and expect to do this year  We also believe we can continue improving profitability beyond 2020 through ongoing optimization efforts and a longer term opportunity to benefit from platform modernization As we discussed  the benefits from platform modernization will be a multi year process  particularly for Millennium and most near term benefits are largely offset by modernization investments  However  we expect the lower operating costs associated with this move  along with efficiencies and improvements we are driving in our development process  to meaningfully contribute to our profitability while also helping us deliver a differentiated solution to our clients at a lower total cost of ownership  Moving to net earnings and EPS  Our GAAP net earnings in Q4 were  154 million or  0 49 per diluted share  It is up from  0 40 in Q4 of  18  For the full year GAAP net earnings were  529 million  or  1 65 per diluted share  Adjusted net earnings in Q4 were  237 million and adjusted diluted EPS was  0 75 compared with  0 63 in Q4 of  18 For the full year adjusted net earnings were  862 million and adjusted diluted EPS was  2 68  up 9  from 2018  Our GAAP tax rate was 19  for the quarter and year  Our non GAAP tax rate was 20  for the quarter and year  For 2020  we expect our GAAP and non GAAP tax rates to be between 20  and 22  Moving to our balance sheet  we ended Q4 with  542 million of cash and short term investments  which is down from  633 million last quarter with our free cash flow being offset by our  75 million acquisition of AbleVets and  300 million of share repurchases in Q4 For the year  we repurchased 18 8 million shares for  1 3 billion at an average price of  69 06  keeping us on track against our plan to repurchase 1 5 billion by the end of Q1 of  20  Phonetic   Moving to debt  our total debt remained flat to last quarter at  1 038 billion  Total receivables ended the quarter at  1 14 billion  down from  1 155 billion in Q3 of  19  Our Q4 DSO was 72 days  which is down from 74 days in Q3 of  19 and 79 days in the year ago period  Operating cash flow for the quarter was  438 million  Q4 capital expenditures were  83 million and capitalized software was  63 million  Free cash flow  defined as operating cash flow less capital purchases and capitalized software development costs  was  292 million for the quarter For the full year  operating cash flow was  1 313 billion  capital expenditures were  472 million and capitalized software was  274 million  Full year free cash flow was  568 million  which is down  166 million from 2018  driven by higher capital expenditures and restructuring costs For 2020  we expect some level of restructuring cost to continue  but we still expect higher operating cash flow and lower capex to drive strong free cash flow growth  Moving to capital allocation  as I indicated  we repurchased  1 3 billion shares of stock in 2019 and we remain on track to meet our targeted level of  1 5 billion by the end of Q1  In December  we announced that our Board authorized the repurchase of an additional  1 5 billion of stock  bringing the total authorized amount available for repurchase up to  1 7 billion  We intend to continue funding these repurchases with a combination of cash from operations and debt and the timing and amount of repurchases will depend on how much funding is used for other purposes  such as acquisitions or investments Moving to our dividend program  we paid our first three quarterly dividends of  0 18 per share on July 26th  October 9th and January 9th  Our quarterly dividend payments and the increased authorization in our share repurchase plan reflect our continued commitment to return capital to shareholders and our belief in Cerner s long term potential  I d also note that we completed our acquisition of AbleVets in Q4 and have begun to integrate their service offerings into our portfolio to accelerate our success in the federal space  As we ve discussed  we expect to be more active in M A as we believe there are opportunities that could be foundational to our growth in several of the markets our strategic growth organization is pursuing  I d also note that our portfolio management efforts are expected to lead to some divestiture activity as we look to create more focus in areas most aligned with our refined growth strategy Now I ll go through guidance  We expect revenue in Q1 to be between  1 415 billion and  1 465 billion  The midpoint of this range reflects growth of 4  over Q1 of  19  For the full year  we expect revenue between  5 725 billion and  5 975 billion with a  5 85 billion midpoint reflecting 3  growth over 2019  The midpoint of this range is slightly below consensus growth of 4   We suspect  Phonetic  this could be due to estimates not fully factoring in the impact of reduced levels of outsourcing bookings in 2019 and our continued approach of being more selective with those types of contracts Also I d like to walk you through an organic growth view of 2020  If you adjust for our exit from the Adventist Health contract by taking that revenue out of 2019  our 2020 growth would be over 5   Adjusting out AbleVets revenue would bring pure organic growth back to 4   but we don t view all of the revenue from AbleVets as inorganic because we expect to leverage their associates and performing on the VA contract as it ramps up  This normally would have been done through organic hiring  But we believe there is value in leveraging their highly qualified workforce  As we ve discussed there will likely be additional actions we take this year that could result in revenue reductions  There is also the potential that we do M A which could serve as an offset to divestiture activity  Overall  we do expect there to be several moving parts on the top line in 2020  But we believe the actions we take will set us up for solid and profitable growth Moving to EPS  We expect Q1 adjusted diluted EPS to be  0 69 to  0 71 per share  The midpoint of this range is 15  higher than Q1 of  19  Our adjusted diluted EPS guidance reflects a ramp up throughout the year that is similar to last year  With the biggest sequential increase in Q4  this reflects the expected timing of ongoing efficiency and operation efforts For the full year  we expect adjusted diluted EPS to be  3 09 to  3 19 with a  3 14 midpoint  reflecting 70  growth over 2019  As I mentioned  we also expect our adjusted operating margin to ramp during the year  With Q4  we are expected to be slightly higher than our 22 5   target due primarily to a lower mix of outsourcing revenue  I d also note that our expected full year non GAAP tax rates were approximately 21  and is 1  higher than 2019  impacting EPS by about  0 04 Moving to bookings guidance  We expect bookings revenue in Q1 of  1 1 billion to  1 3 billion  The midpoint of this range reflects a 3  decrease compared to the first quarter of 2019  driven by an expected decline in long term bookings  In summary  we are pleased with our strong results in the fourth quarter and believe we made a lot of progress this year  There is a lot of hard work left to meet our profitability and growth targets  but we have a good plan in place and expect to execute it in 2020 and beyond Before I wrap up  I d like to remind you that we will host our annual investment community meeting at HIMSS on Tuesday March 10  If you plan to attend and have not registered  please do so through the link at the top of the Investors section of cerner com  If you re unable to attend in person  there will be a webcast available With that  I ll turn the call over to John John Peterzalek    Chief Client OfficerThanks  Marc  Good afternoon  everyone  Today  I will provide results  highlights and an update on our federal business  I ll start with our bookings  As Marc mentioned  we delivered bookings ahead of our guidance range for the quarter  driven by strong contributions across multiple segments such as investor owned  academic and IDNs  We also had good contributions from revenue cycle solutions and across our strategic growth businesses which Don will discuss Consistent with recent quarters  we had a lower level of long term bookings compared to last year  which drove the decline in overall bookings  For the quarter  the percent of bookings coming from long term contracts was 29  compared to 38  in Q4 of last year  Long term bookings for the year represented 28  of total bookings  compared to 36  last year  with this decline in long term bookings  driving total bookings down for the year  Bookings excluding long term contracts increased slightly for the full year Looking at the broader marketplace  many of the same trends continued to play out during 2019  with healthcare cost growth outpacing the economy  elevated levels of industry consolidation  rising consumer expectations around cost  convenience  and service  and the continued gradual evolution of reimbursement models adding to pressure on providers to lower costs and advance their risk based strategies These forces are contributing to an overall challenging macro environment  Providers are simultaneously seeking to grow key service lines  drive operational efficiencies to make money at Medicare rates  and build out the competencies required to take and effectively manage risk and participate in value based reimbursement models  Information technology is seen as an enabler of these efforts  which represents an opportunity for Cerner  At the same time  the low margin nature of provider businesses can make it difficult to fund required investment  making it important for solutions and services to have a clear return on investment As we look at 2020  we see solid opportunity both in our installed base as well as continuing to gain new clients  This opportunity is reflected in our pipeline  which is up year over year for both new business and opportunities for sales back into our base  In our base  we are focused on getting our clients current while also filling out their Cerner solution suite  with a focus on increasing penetration of revenue cycle solutions  and solutions supported by our CareAware and HealtheIntent platforms  Our CommunityWorks pipeline remains strong and we have opportunities outside of our traditional provider base in areas such as state government  employer  and long term  post acute care  We also have opportunities to continue growing the presence of our EHR agnostic CareAware and HealtheIntent solutions beyond our EHR base Moving to our Federal business  we continued to advance both our VA and DoD projects  On the VA project  Cerner along with the VA and our partners  remain focused on the Initial Operating Capability  or IOC  go live  We have completed initial integration validation and are doing a significant amount of training and site preparation activities ahead of the scheduled go live in March  Looking beyond the initial go live  we also expect to go live at additional IOC sites in 2020 and continue to steadily scale our work to provide additional value and capabilities to the VA in upcoming quarters  As Marc mentioned  we expect to leverage the AbleVets team as these activities ramp throughout the year We are also making good progress on DoD  We successfully completed a code upgrade during the quarter and kicked off the Coast Guard project and two additional deployment waves  Go lives for these waves are slated for late 2020 With that  I ll turn the call over to Don Donald Trigg    Executive Vice President  Strategic GrowthThanks  John  Good afternoon everyone  Our Strategic Growth organization launched in 2019  Our ambition was a simple one  scale a set of focused business units that position Cerner beyond the hospital  beyond our Cerner Millennium EMR and beyond the traditional fee for service payment model The six business units that make up Strategic Growth each target large addressable markets in excess of  3 billion with a path to meaningful share in each market  They gain leverage from existing Cerner assets ranging from the industry leading data processing and aggregation capabilities of HealtheIntent to our subject matter expertise around the last mile EMR workflow  Regulatory requirements are understood  surmountable and offer opportunities for differentiation  All six businesses overweight on recurring revenue and have high gross margin potential  And finally  Strategic Growth leaders focus squarely on speed to revenue as they pursue their larger category leading positions For full year 2019  our Strategic Growth businesses generated  520 million in revenue  representing 22  growth year over year  We believe we can deliver similar growth in 2020 and look forward to our Investor Day at HIMSS in Orlando which will afford us an opportunity to review the long term targets for each business As we look at areas of particular strength in 2019  cybersecurity frames our strategic approach  U S  healthcare is seeing data breaches at a rate of one per day  Our technologies are core to how CIOs and CSIOs are building out their enterprise strategies  Cyber is an area of growing internal competence driven  in part  by our critical work to support our armed services and veterans  As a result  our security revenue from health systems grew nearly 40  in 2019 Our provider communication business  leveraging our EMR agnostic CareAware platform  also benefited from strong market tailwinds and delivered record bookings in 2019  CareAware Connect solution adoption was strong with an over 100  year over year increase in utilization to almost 75 000 monthly users We also were pleased with the full year progress in the Long Term and Post Acute Care market with 23  year over year growth  Our Behavioral Health solution  within our LTPAC solution suite  was a particular bright spot  It delivered almost forty new footprints with 80  of total bookings revenue coming from outside our Millennium base Our unified Behavioral Health solution is not only strongly differentiated in the market  it also was announced Friday as the 2019 Best in KLAS category leader  For individuals and families that seek help  our unified Cerner solution strives to make it easier for providers to deliver the integrated care that successful treatment demands While LTPAC is an area where we sell at the point solution level  it also fits solidly into our larger strategic push to build out Health Network strategies across every MSA in the U S  and all five of our focused global regions At the technical platform level  our HealtheIntent platform is a strategic linchpin of our Health Network efforts  Our market facing push to drive adoption of HealtheIntent continued to progress in 2019 bringing us to 175 HealtheIntent clients worldwide including the addition of leading providers like Prospect Health and Davita Health As Brent noted in describing our AWS partnership  HealtheIntent was built as a native cloud platform  is EMR agnostic and has been recognized by industry analysts like Chillmark as having the best product capabilities in the category  It also has been at the heart of our work with AWS  As we move nearly all of our non federal HealtheIntent clients to the AWS public cloud in the first half of 2020  it will establish the clear value proposition of the cloud technology approach for provider healthcare  We also see it as a key enabler of our Health Network strategy in focused global markets  such as England as the NHS accelerates its push to advance Integrated Care Systems Finally  with the content of healthcare digitized  we also are advancing a set of strategies around data services  Art Glasgow and team our Learning Health Network to make it easier for patients to be identified and participate in clinical trials  The Duke Clinical Research Institute partnership announced in 2019 played a central role in generating research opportunities for Cerner clients  Top health systems  such as Medstar announced yesterday  are helping us activate a network we believe can make it less expensive to create the next generation of life saving therapeutics Across all six business units  our efforts to drive strategic growth fit into an emerging enterprise discipline around portfolio management across Cerner  In 2019  we were as intentional about the things we decided not to do as the things we decided to do Several important Strategic Growth partnerships help tell this story  Our partnership with ResMed offers new revenue generating opportunities in the post acute care and also advanced analytics round sleep and respiratory  It also featured a decision to make ResMed s Brightree home health offering our preferred go to market solution  Similarly  our partnership with GetWellNetwork embedded their HealthLoop asset into our consumer application framework  It also came with a portfolio decision to not invest further in our MyStation patient engagement solution in favor of GetWell s industry leading offering We believe a combination of thoughtful build  buy  partner assessment will bring us closer to our long standing vision to build a system of health and care with the individual at the center  It is a system where consumers not only have a right to their data  but also have the ability to mobilize it in pursuit of better health We believe the entrepreneurial opportunities at the intersection of healthcare and IT have never been greater  We are excited about what 2020    and the 2020s    hold for a setting an emerging area of strategic growth for Cerner  2019 performance for its part laid a solid foundation for moving further  faster in the quarters to come With that  let me turn the call over to the operator for questions Questions and Answers OperatorThank you  sir   Operator Instructions  Our first question comes from Robert Jones from Goldman Sachs  Please go ahead Robert Jones    Goldman Sachs    AnalystGreat  Thanks for all the comments tonight and for taking the questions  I guess  Marc  just to go back to some of your comments  you highlighted 4  growth ex AbleVets addition and less the revenue cycle service contract that you guys exited  I guess just out of curiosity as we frame the year and understanding that 2020 has been put aside as kind of a transition year  how much of that remaining growth came from federal  And then clearly more importantly and I know we ll hear more in March  maybe just some of the major building blocks as you think about returning to profitable growth in the future  what are the pieces we should be at least starting to frame out as we think about growth beyond 2020 Marc Naughton    Chief Financial OfficerYeah  no this is Marc  I think from a    certainly as we look at the year and trying to get apples to apples  we ll be a little bit challenged in 2020  We re going to do our best job to do that  That s a  Phonetic  little bit why we try to talk a little bit about organic growth  I think if we get back to the overall view of top line growth  we ve talked last year about kind of that being in the 6  to 9  range  Clearly the outsourcing selectivity and certainly the Adventist contract could impact that  And I think as we look through that that s probably a 100 basis point potential impact  which would put you some place in a 5  to 8  top line growth level  I think that s certainly something that we would expect to be doable for us  I think from a    from the things that are going to continue driving  certainly federal will be part of that growth  As that contract  the VA contract ramps its way up to  1 billion a year of annual revenue  that s  250 million or so of additional annual growth in revenue that s just coming out of the VA contract depending on the time period  So that s certainly a good driver And then strategic growth is obviously another area that we re expecting to see growth out of that will take the    to  500 million to  600 million business it is today  and continue to grow that at strong growth rates  We also look at the opportunity that we have just within our existing base business  So  our core business  the opportunity to sell revenue cycle solutions back into that base  the ability to go attack the white space  all of those are things that we think overall are elements that can contribute to us having overall top line growth  And that really all of those things I talked about are primarily organic  We ve talked in the past that we also expect there to be a level of inorganic growth for us and some M A that will support primarily the opportunities and strategic growth and depending on the size of those opportunities an the size    the revenue impact they bring that certainly could be accretive to those    to the top line growth that we ve talked about But certainly as we go    get to HIMSS and can have a little bit more time with everyone  we ll try to take you through a more detailed view of strategic growth and the elements of those businesses and how we ve got    how we ve got the opportunities for growing the top line kind of just in the range that we ve traditionally discussed  But I think to your point  we have talked about 2020 being a reset year  We are looking at opportunities to divest certain things as we do our portfolio management  That s going to negatively impact revenue  The M A will positively impact revenue  And what we will try to do on a quarterly basis is kind of give you an update as to where we re going  Obviously  we ll be giving you quarterly guidance to if there is any adjustments  But right now we think the guidance we provided for the year is really solid Robert Jones    Goldman Sachs    AnalystNo  Marc  I appreciate all that  I guess  just a quick follow up on your comments then would be around those potential further divestitures and potential M A  Are those contemplated in the 2020 guidance or is this kind of best case of what we know today is just where the business stands Marc Naughton    Chief Financial OfficerYeah  the way we did our guidance was basically kind of on a same store basis  So it does not contemplate any of the divestitures  It does not contemplate any of the M A potential activity because that s still  as of today  something to be determined  We think it s going to be more effective as those items occur that we can talk about them at that point Keep in mind the AH  if you will  divestiture or that RevWorks business going away  is by far the largest item that was on the list  the items after that would be smaller items  So whether they even impact the overall guidance to a great extent will be something we determine that the point they occur  But right now  the guidance is based on current course and speed and then we will adjust as we    as anything comes up in that space  one way or the other Robert Jones    Goldman Sachs    AnalystThanks for all that Marc Naughton    Chief Financial OfficerSure OperatorThank you  Our next question comes from Kevin Caliendo from UBS  Please go ahead Kevin Caliendo    UBS    AnalystHi  Thanks for    thanks for taking our call  I know you don t guide for bookings for the full year  But given the shift away from LT service bookings when do you think it s reasonable for you to assume you can return to year over year bookings growth  And when I look at the 1Q guide  is there any additional comp headwind for the shift or do you view the year over year long term bookings compares already normalized entering the year Brent Shafer    Chairman and Chief Executive OfficerYeah  I mean  I think clearly we don t guide beyond the Q1 because we do want to be pretty accurate relative to our guidance  I think as you    the solid results that we delivered in Q4 actually delivering above our guidance range with the opportunity    based on some opportunities to pull things in to the quarter based on some of the timing of our clients and their year ends  This is going to impact Q1 a little bit because those things would have normally been landed in Q1  But I think we re still normalizing for some of the outsourcing elements in the bookings  So I think for 2020 what s kind of a year for resetting the top line from a growth perspective  I think it s fair to say that the bookings we ll get through the full year of 2020 and then we should get some pretty comparable bookings to be able to do apples to apples growth thereafter  But Q1 is still being impacted by the more focused view of anything that we re going to do on the services side that might be in the outsourcing space Kevin Caliendo    UBS    AnalystOkay  And one quick follow up if I might  So we are reading the VA deputy secretary was let go yesterday and I guess he was the one who is technically in charge VA implementations  I was wondering if you had been in contact with them  with leadership over there since that decision was made  Is there any concern or any issues about timing or potential bottlenecks for the implementation of the VA contract John Peterzalek    Chief Client OfficerYeah  this is John  I won t comment specifically on the    on that activity  but what I would say is that both the veterans VA  the modernization project they have significant bipartisan support  And the fact that there are changes and political activity  it s not a surprise or unexpected  And from the beginning of this project  we took great effort in making sure that we had broad support throughout the hill  The VA  veterans groups and other constituents and supporters to ensure when things like this do happen or political activity occurs  it doesn t impact where we re going  So we don t anticipate any impact from that and we think that our broad base of support is incredibly solid and we re just going to continue on Kevin Caliendo    UBS    AnalystGreat  Thanks so much for the color on that OperatorThank you  Our next question comes from Charles Rhyee from Cowen  Please go ahead Charles Rhyee    Cowen     AnalystYeah  thanks for taking the question  Maybe you want to touch on    I think at the beginning  you guys talked about the interoperability rules  the final rules right expected soon  Any thoughts on sort of the    I know there were some concerns  particularly on providers around compress timelines or perceived compressed timelines for implementation  How do you view those challenges  And what would you  I guess  say about your preparedness to help clients to work through that  And any thoughts on maybe seeing a phased implementation schedule put in place instead Donald Trigg    Executive Vice President  Strategic GrowthYeah  So  this is Don  I think first and foremost  just to echo Brent s comments  this is a space that we ve been very vocal on and pushed aggressively on for a number of years  So we have a lot of  I think  personal passion around interoperability  Semantic interoperability and what this space needs to look like for patients and providers and payers  so that s first and foremost  I think Secondly  we feel like we re very well positioned to meet the implementation timelines that are being discussed  both from a technical and a non technical business perspective  We ll obviously finalize those strategies as the final rule comes out and they re completely understood  But we think they re manageable and that we re well positioned to do that  And I think finally  just to reiterate some of the framing on the call  we think there is going to be a ton of business opportunities associated with these elevated rates of data liquidity  So when I think about the types of things that we re doing to enable our strategies around Medicare Advantage  alternative payment models like bundled payments and BPCIA  the opportunity to think through the technical strategies required to help provider organizations make those business models work  we think  create tons of opportunity for Cerner and frankly for the industry as a whole Charles Rhyee    Cowen     AnalystGreat  And maybe if I could just follow on  in terms of sort of the strategic    the new model that you are working on  I m not sure    I might have missed it  but didn t hear any mention of Lumeris  Just curious on an update on how that partnership is working  Thanks Donald Trigg    Executive Vice President  Strategic GrowthNo  I appreciate it  We think we re making a ton of progress there and I ll tether back to the comments I just made  So  first and foremost  really the thing that was    one of the things that was super exciting to us was to take the methodology  sort of the best in class methodology of Lumeris for Medicare Advantage  our technical capabilities and their service expertise and use it to bring a total solution offering to the market In terms of progress made around that  we were very excited to use HealtheIntent as a foundational platform for running a provider sponsored plan focused on MA  And we over attained against those IP milestones over the course of 2019  And now we re deploying the solution as part of the go to market strategy for Lumeris and Cerner And again just to come back to the topic around information sharing  if you think about the Forestar MA plan that Lumeris runs in the St  Louis market  14 different practices  high degrees of technology heterogeneity and how do you think about elevated rates of data liquidity both to drive through your strategies for activating that network as well as integrating their best practice capabilities into the last mile workflow of the physician  it s nicely complementary to the regulatory trends that are playing out  And we think it represents one of several very big business model opportunities for us going forward Charles Rhyee    Cowen     AnalystGreat  Thank you OperatorThank you  Our next question comes from Ricky Goldwasser from Morgan Stanley  Please go ahead Ricky Goldwasser    Morgan Stanley    AnalystYeah  hi  Good evening  Going back to the revenue growth guidance and some of the comments  Marc  that you made  So first of all  just to clarify  because I might have missed it  I think at some point you said 5  to 8  is doable for longer term revenue growth  And just trying to understand the building block there  That s one Second of all  I think you highlighted that the VA is a long term revenue opportunity  So just wanted to make sure that we hear it right that you expected to grow that  250 million that you mentioned beyond the term of the initial contract And then lastly as we think about the potential divestitures that are not included in this guidance range that you provided us today  who is making this bit of decision  Is this a decision that you are making based on the margin mix or is this something that the client when the contract is up for renewal decides to not renew  I just    just if you can just clarify why is this taking such a long time to make a decision of what contracts are being divested or not Marc Naughton    Chief Financial OfficerSure  First of all  the 5  to 8  was really just discussing the long term growth we kind of provided last year at HIMSS of 6  to 9  with a little bit of a    100 bps haircut based on the lower amount of outsourcing activity that s going to happen  So we re going to be  as I indicated a little bit earlier  at HIMSS we will be taking you through that long term growth rate  what that looks like  where it s coming relative to our core businesses  our strategic growth businesses  our federal business  So you ll be able to see how it lays out  And then we ll give you some more details as to the strategic growth businesses that underpin all of those growth assumptions  So our goal is to lay out a very clear path that kind of falls within that range with the opportunity to over attain depending on what we do from an M A perspective Relative to the VA contract  when we first talked about it  be the  10 billion contract and it s a 10 year contract  the math would say that s  1 billion a year  Obviously there is a ramp up period  And when we talk about it    and when we talked about it  we said it ramps up over a four year period growing about  250 million a year until we get to the  1 billion  So my reference to that  250 million increase was basically the revenue we re going to be ramping up to in that contract that gets us to the  1 billion run rate  We have talked about the opportunities to certainly sell more of our solutions and services to the VA  which could increase the  1 billion to a bigger number  but certainly the  250 million I referenced is just kind of current course and speed ramping up the projects  doing more and more on implementations and how that drives that revenue stream forward  So nothing new there  That s just really reiterating what we ve talked about but it s another piece of the growth puzzle that is    we ve talked about  and does drive a good amount of growth And finally on the divestitures  AH was a little bit of an anomaly in that space  That was really a business we re looking to kind of decide whether we want to be in or not  They were our largest client in that outsourcing  So that was more of a client contractual agreement  Going forward  it will be much more of us reviewing relative to our portfolio management  relative to our growth options for the business  where do we want to focus our attention  And those areas that we don t want to    don t think are the growth areas for the Company we want to focus on  we re going to consider divesting as one of the options  We ll consider divesting  we will consider partnering  There are a variety of things that we will consider  but those divestitures will be in many cases of an existing business  It won t be a specific client relationship that will be unwound in some way  It will be an existing business that we will basically go out to market and look for opportunities to say here is this asset  it s something we re willing to let go and some of these    some of these assets have significant value So I think    and from why is it taking so long standpoint  there is a lot of work we ve done in our portfolio management to decide what are the key things we want to drive as we talk that work really was a lot of the 2019 work and really it was kind of finalizing as we ended the year  And certainly some of these activities on divestitures are already under way and ideally will be things that we can share with you in the very near future Ricky Goldwasser    Morgan Stanley    AnalystThank you OperatorThank you  Our next question comes from Jeff Garro from William Blair  Please go ahead Jeff Garro    William Blair    AnalystYeah  good evening  and thanks for taking the questions  I want to ask a little bit more about the AWS partnership and maybe putting aside the very important work around migration and those long term benefits of efficiency and lower TCO for clients  More curious on the consumer experience innovation side and what type of milestones either IP milestones or bookings related milestones that we can look for in 2020 from that partnership Marc Naughton    Chief Financial OfficerYeah  it s a great question  Jeff  Thanks  So let me talk to kind of multiple pieces of it  Just in terms of  one  the framework for the relationship  I think one of the things that we were excited about from a AWS and Amazon perspective was not just the opportunity to think through technical migration to the public cloud  but to really think about broader opportunities around the Amazon relationship and what it would look like  in particular to leverage their deep competencies around the consumer  coupled with their strong interest in being part of the healthcare ecosystem  So that was  I think  a design feature of the relationship  and I think we ve been very happy with our opportunity to kind of engage with them and to look at key strategies around approach  whether those are publicly disclosed activities around how they think about their employee population and some of the things that they re doing in concert with JPM and with Berkshire portfolio companies or acquisitions that they ve made around capabilities like PillPack  So we ve had good visibility to that  We think it s an exciting piece  potential piece of the relationship and an important part of how we want to think about making the partnership work going forward Secondly  from a technical perspective  I talked a little bit about the fact that HealtheIntent has really been a tip of the spear  if you will  relative to the migration to the public cloud  most of that work will be completed in the first half of the year  CareAware similarly is part of that early strategy and path  And I think we ve been very transparent in terms of saying that the time frames around Millennium will be more elongated Finally  in terms of what this is going to look like in terms of targeted bookings or revenue impact  I think there s businesses within strategic growth that are very excited about the potential pull through impact relative to revenue  I would say our consumer and employer businesses in particular have a lot of energy here and have been real drivers around the strategic collaboration  but we re probably not at a point in the life cycle of the dialog where I could put out a revenue target or a bookings target that we would feel confident we could hit or over attain Jeff Garro    William Blair    AnalystGreat  That s very helpful  One quick follow up maybe on the technical side on HealtheIntent and CareAware and those this first half migrations  maybe just some more specifics around where the benefits are for Cerner with those migrations and where the benefits are for clients Marc Naughton    Chief Financial OfficerYeah  well  first of all  I think just the ability to be able to stage and think through the migration to the public cloud has had a real value proposition for us as we try to think really comprehensively about not only the technical components but also how we have this conversation with our clients  how we think about innovation potentials in concert with our provider clients as part of the dialog and the approach In terms of benefits  I think there are clear and demonstrable benefits that our clients are going to see  There is a performance    system performance benefit that s very real  There is a benefit around latency and how we think about the path to near real time data assets that I think could be very important around strategies like hospital operations  And I think this is also relevant as we start thinking about growth opportunities like cyber security where clients need our competency and expertise around how they manage hybrid environments with on prem and cloud So I think real benefits that we re deriving from a performance perspective  from a data and utilization of the data against business strategy and some really interesting  from my perspective  conversations around capability that we have that create white space opportunities for growth Jeff Garro    William Blair    AnalystExcellent  Thanks again OperatorThank you  Our next question comes from Sean Wieland from Piper Sandler  Please go ahead Sean Wieland    Piper Sandler    AnalystHi  Thanks so much  So on the restructuring cost that you re talking about  Marc  you said 2020 your restructuring costs are going to continue  Can you quantify the impact that these costs are to the operating margin that you re forecasting both in 2019 and 2020 Marc Naughton    Chief Financial OfficerWell the operating    the restructuring costs that we re incurring that are the restructuring costs currently are being adjusted out of earnings  So  our adjusted earnings  there is zero impact on that  And that is the number on which we have based our operating margin targets Sean Wieland    Piper Sandler    AnalystOkay  Thanks  And then    that s helpful  And then a quick clarifying question  you said you re going to move almost all your hosting clients to AWS in the first half of  20 that s consistent with what you ve said  But does that impact the revenue or profitability cadence throughout the year or are you going to be back filling that with government tenants Marc Naughton    Chief Financial OfficerWell  for the most part the    moving them to AWS the primary impact is freeing up hardware and space in our data center and that will absolutely be used to support our federal clients as well as other clients we have that are hosted by us on Millennium platform  All of these devices are basically interchangeable relative to the various architectures we use  So that will be the savings  the impact on  Indecipherable  Sean Wieland    Piper Sandler    AnalystOkay  Thanks very much OperatorThank you  Our next question comes from Sean Dodge from RBC Capital Markets  Please go ahead Sean Dodge    RBC Capital Markets    AnalystHi  Good afternoon  Thanks for taking the questions  Maybe staying within the platform modernization for a moment  understanding the entire project is going to be multi year effort and ultimately long term positive for margin  can you give us a little more insight into the impact it will have on margins in the interim  the investments you re going to have to make as part of it  Can you put some bookings around how big  how much  are they going to be consistent or chunky and are there efficiencies you re going to be able to garner in the meantime that will help offset some of it or is this something where the margin lift really doesn t come until the entire project is done Marc Naughton    Chief Financial OfficerYeah  this is Marc  As John kind of went through  each time we move an element to AWS there is some savings garnered  So certainly from a    as we move HealtheIntent being able to manage that in the AWS environment it s    it has a savings on the people it takes for us to run those environments in our data centers  So there are incremental  they aren t significant  but they are incremental The investment we re going to make relative to our cloud investment on the other platform  primarily Millennium  that s part of our R D expense  right  Part of our portfolio management goal is to free up dollars that we re spending on things that we don t see as long term growth opportunities and put that in to some of the things that are going to be growth opportunities such as the cloud environment  We are still actually going through the exercise in the process of deciding exactly what the path to modernization is going to entail  exactly what s going to move and exactly the timing  So it s a little bit hard for me right now to give you an idea of what those dollars are  But our expectation is that much of that work is going to get funded out of our normal R D spend that we will be focused on those efforts as opposed to potentially some other efforts on things that we re going to not be moving forward with So there is    that s    it s going to be a refocus on it  So we re not going to garner some of the savings that we might have from some of those divestitures  although we will get    gather some  But we shouldn t have a large influx of costs relative to this effort  And it will  as Don said  be a period of time before that gets there No  once we get there the benefits are significant  We ve got well over  100 million of annualized costs for hosting our clients in our data center just from software that we run them on in our data center that we won t need to use when they go to the cloud  There will    the advantages of running a single version of the software in the cloud is a significant decrease in the cost we have for supporting our clients  They will get a much better experience  so clients stat goes higher  So the appetite for more solutions goes higher So those are harder to quantify at this point other than the actual cost savings from sub licensed software  But I think for the most part  that s the goal  Those benefits aren t going to happen in the next two or three years  That s    we have to get through a lot of work and would be able to give you more of an update on that as we do our work to make    to identify the path forward  But it isn t something I think is going to be a big expense impact  but the benefits will be a little bit longer term relative to margin improvement  And that s one of the things we ve kind of talked about is we ve got our path  We did    we delivered  19  we have our path to 2020  How you keep delivering thereafter you continue on the optimization and then the next iteration is going to be basically platform based that you bring these other additions and other opportunities to increase operating margins Sean Dodge    RBC Capital Markets    AnalystOkay  that s great  Thanks  Marc  And then maybe on margins more broadly  you are still expecting to exit 2020 around the 22 5  level  you said maybe even a little bit better  I think you touched on it briefly in the prepared remarks  but could you just walk us kind of quickly through what you see being the primary levers or buckets of opportunities you can take out to get you from the 20  you just printed to something north of 22 5  in the next four quarters Marc Naughton    Chief Financial OfficerYeah  I think the key to remember is a lot of what we did in  19 really started impacting us late in the year  right  It really    the margin improvement from Q3 to Q4 was significant  So    but we have in place over 50  of the actions we need to go drive the margin uplift for 2020  The next set of things that are going to happen are going to happen toward the end of 2020 as we do things based on location of associates and things like that that will drive kind of some of those next year benefits for us So the reason that Q4 and 2020 will be a little bit of a back end loaded once again is because those are the next tranches and it takes time and effort to go get those in place  But I would point out that basically after Q1  we ll be delivering about 250 basis points of margin improvement each quarter year over year Q2  Q3 and Q4 and actually for the full year  So that level    those margin improvements are the continuation of what we put in place in  19 and delivering on the next phases that occur in 2020 Sean Dodge    RBC Capital Markets    AnalystGot it  Okay  Thanks again Marc Naughton    Chief Financial OfficerHey  just to clarify before we get to the next question  My comments around 5  to 8   it seemed like there is a little bit of confusion on people that talking about that comment  I m just trying to    the indication that I was trying to portray is that if you took our previous 6  to 9  target and lowered it for the impact of outsourcing it would reduce the range by 100 basis points  So I was just doing math and subtraction is one of the skills I do have  And we basically were taking those down to the 5     8  just based on what our prior view was and kind of what the impact of the outsourcing that we ve talked to you about is  But certainly at HIMMS we will give you a more detailed view of what we think the right answer is and how we get to that right answer  So I just want to clarify that because there s a little bit of confusion OperatorThank you  Our next question comes from George Hill from Deutsche Bank  Please go ahead George Hill    Deutsche Bank    AnalystGood morning  guys  Thanks for taking the question  This might be one for Don  I know Don  historically    this is an interoperability question  historically interface management has been an attractive part of the business with pretty good margins  And as we think about kind of changing interoperability regulations that will probably create some opportunities  So can you talk about how much business risk there might be departing the legacy business Donald Trigg    Executive Vice President  Strategic GrowthYeah  it s a good question  George  I think we re pretty comfortable that that business    I mean you re right  it s relatively small and it does have a good margin profile  I think we re relatively comfortable that the things that we ve been doing on SMART on FHIR enablement and our code program mean that the net impact is de minimis  And I think more to my earlier point  we think it s actually enabling to some of the bigger swing business strategies that we re advancing inside strategic growth So while I can t perfectly net that out for you  I think we look at it and say it enters  Phonetic  to our advantage into the upside relative to where we want to go from a top line perspective George Hill    Deutsche Bank    AnalystOkay  that s super helpful  And then Marc maybe just two quick number follow ups  Can you talk about    can you give maybe any color around the capex guidance for 2020  You talked about the number coming down from the  471 million number in 2019  Maybe just something about that  And is any share repo assumed in the 2020 EPS guidance Marc Naughton    Chief Financial OfficerYeah  I think that from a capex perspective  you can take  100 million out of that number to be kind of the range that we would expect as we look at 2020 for capex based on our buildings being slowed down or basically being completed  And I think the repurchase  we obviously have  200 million scheduled for Q1 to complete our 12 months  And I think going forward  certainly our capital allocation will look at M A opportunities and other things relative to the use of capital  but I would think  at least  200 million a quarter of repurchases would seem to be kind of a base amount that we would then adjust relative to what our M A is George Hill    Deutsche Bank    AnalystOkay  I appreciate that color  Thank you Marc Naughton    Chief Financial OfficerWhy don t we take one last question OperatorThank you  Our last question comes from Eric Percher from Nephron Research  Please go ahead Eric Percher    Nephron Research    AnalystThank you  Question on federal contracts and I know that early in the uptake  you ve had third party service that appears to be weighing on the margin  As we think about 2020 versus 2019  does that level of third party support remain about stable or is there any increase or decrease Marc Naughton    Chief Financial OfficerYeah  this is Marc  For 2020 it will be about the same  We continue to leverage our partners in that space  Clearly AbleVets was one example of us working to bring a larger workforce quickly inside Cerner that we can then move to focus on the VA as some of the    as we work through their existing projects which are relatively short term and get them on the VA that will allow us to bring that down  But that s probably more of a 2021 event at this point Eric Percher    Nephron Research    AnalystThat s helpful  And then last on the ex US 3  growth last year as you look to 2020  I don t think that was part of the items you ticked off on growth opportunity  But what is your perspective on growth ex US John Peterzalek    Chief Client OfficerThis is John  I will answer that  I think it will be consistent with previous years  There s still a lot of opportunity outside the US in the form of new business  new regions and countries and those type of things  which we will look at pursuing each one of those opportunities and make a decision  But similar to the US we are also doing portfolio analysis on non US as well  So we re going to look to be follow the same process and become much more focused and    outside the US as well  So we may see both ups and downs outside the US as well Eric Percher    Nephron Research    AnalystThanks Marc Naughton    Chief Financial OfficerHey  this is Marc  I want to thank everybody for participating  One last comment there is still might be a little confusion about our long term top line growth target  The 5  to 8  I mentioned is absolutely something  I think  we can  Phonetic  deliver  absolutely  And in fact  I think there is upside to that  So I think the number something closer to the 7  range is probably more reasonable  But once again my point is  we really want to take you through it in detail  show you what the building blocks are so you re not just blindly putting the number in  But 5  to 8  level is a level that I have a great deal of confidence in  So with that I want to thank you for attending this afternoon and look forward to getting together with you at HIMSS on March 10th  Until then have a good evening Operator Operator Closing Remarks Duration  68 minutesCall participants Brent Shafer    Chairman and Chief Executive OfficerMarc Naughton    Chief Financial OfficerJohn Peterzalek    Chief Client OfficerDonald Trigg    Executive Vice President  Strategic GrowthRobert Jones    Goldman Sachs    AnalystKevin Caliendo    UBS    AnalystCharles Rhyee    Cowen     AnalystRicky Goldwasser    Morgan Stanley    AnalystJeff Garro    William Blair    AnalystSean Wieland    Piper Sandler    AnalystSean Dodge    RBC Capital Markets    AnalystGeorge Hill    Deutsche Bank    AnalystEric Percher    Nephron Research    Analyst
More CERN analysis
All earnings call transcripts",2020-02-04,The Motley Fool,https://invst.ly/pr5hw,2076258
146394,367909,CERN,Here s Why Investors Liked Cerner s Q4 Earnings Results,news,"Cerner  NASDAQ CERN  wowed investors in 2019 by racking up a 40  gain in share price  So far this year  though  there hasn t been much excitement from the big health information technology provider 
But Cerner gave investors something to like when it announced its fourth quarter results after the market closed on Tuesday  Here are the highlights of the company s Q4 update 

By the numbers
Cerner announced Q4 revenue of  1 44 billion  a 6  increase from the  1 37 billion reported in the same quarter of the previous year  This matched the average analyst Q4 revenue estimate 
The company reported net income of  154 3 million  or  0 49 per share  based on generally accepted accounting principles  GAAP   This reflected a solid increase from GAAP earnings of  131 3 million  or  0 40 per share  recorded in the prior year period  
Cerner posted Q4 adjusted net income of  237 2 million  or  0 75 per share  up from adjusted net income of  208 1 million  or  0 63 per share  in the same quarter of 2018  The consensus Wall Street estimate was for Q4 adjusted earnings of  0 74 per share 
Behind the numbers
CEO Brent Shafer said   I am pleased with our strong finish to the year  with all of our key operating metrics at or above our expectations in the fourth quarter   Shafer had a good reason to like what he saw in Q4  since Cerner delivered solid revenue growth in nearly every category and topped Wall Street s earnings estimate for only the second time in the last five quarters 
Cerner makes 35  of its total revenue from professional services  That revenue jumped 9  year over year to  509 3 million  All other revenue sources for the company also delivered year over year growth except for support and maintenance and reimbursed travel 
The company s bottom line improvement in Q4 was largely through revenue growth  It also helped that Cerner s operating expenses rose by only 1 8  year over year  In addition  the company paid around  3 million less in taxes in the fourth quarter of 2019 than it did in the prior year period 
Cerner reported bookings in the fourth quarter of  1 665 billion  above its expectations  Its total backlog at the end of 2019 was  13 71 billion  
Looking ahead
The company expects revenue for full year 2020 between  1 415 billion and  1 465 billion  It anticipates adjusted non GAAP  adjusted  EPS between  3 09 and  3 19  First quarter 2020 new business bookings are forecast between  1 1 billion and  1 3 billion 
The 2020 presidential election could be pivotal for how healthcare stocks perform this year  Cerner s customers could be affected by various proposals from the candidates  and anything that impacts its customers would likely impact Cerner as well ",2020-02-05,The Motley Fool,https://invst.ly/prcyo,2076555
146419,367934,CERN,Elliott bid for athenahealth buoys medical IT players,news,Elliott Management s  160 share bid for  athenahealth   ATHN  20 8   has stirred buying in Cerner  CERN  1 9    Quality Systems  QSII  1 6   and Allscripts Healthcare Solutions  MDRX  1 8   Previously  Athenahealth up 21  premarket on Elliot bid of  155   160  May 7 Now read ,2018-05-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/elliott-bid-for-athenahealth-buoys-medical-it-players-1434244,1434244
146420,367935,CERN,Cerner collabs on prescription price transparency,news,Cerner  NASDAQ CERN  is collaborating with CoverMyMeds on prescription price transparency in electronic health records The setup  which integrates Cerner s ePrescribe workflow with CoverMyMeds  RxBenefit Clarity solution  allows providers to review pricing info with the patient at the point of care before the prescription is written The Cerner functionality is now live across 261 hospitals and health systems and nearly 1 600 clinics Cerner shares are down 0 9  premarket to  51 41 Now read ,2019-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/cerner-collabs-on-prescription-price-transparency-1736298,1736298
146421,367936,CERN,Cerner settles with hedge fund Starboard  to add new directors  increase buybacks,news, Reuters    Healthcare information company Cerner Corp  NASDAQ CERN  said on Tuesday it reached a settlement with activist hedge fund Starboard Value LP to add new directors to its board and buy back more of its shares  sending the stock up as much as 15 6 percent  Cerner has agreed to improving operations and committing to hitting certain operating targets  Cerner said it hired consulting firm AlixPartners to review operations and costs  Cerner said it will increase its share repurchase program by  1 2 billion and has targeted operating margins of 20 percent for the fourth quarter  The company plans to pay for the buybacks with cash from operations and by issuing debt    We are committed to delivering significant operating margin improvement and returning capital to our shareholders  while maintaining an unwavering focus on delivering value to our clients   Cerner Chairman and Chief Executive Officer Brent Shafer said in a statement   Cerner s stock  which has gained 1 2 percent in the last 52 weeks  rose 12 percent to  64 56 after hitting a session high of  66 02  John Greisch  Halsey Wise  Melinda Mount and George Riedel will join the board immediately and serve on its newly formed Finance and Strategy Committee that will be chaired by Greisch  He and Wise were chosen by the company while Riedel and Mount were nominated by the hedge fund  according to a regulatory filing  Starboard  which owns about 1 2 percent of Cerner s shares  mounted seven new campaigns in the first quarter and received board seats at eBay Inc  NASDAQ EBAY  and Papa John s International Inc  On Friday it withdrew its slate of directors at  Dollar Tree Inc   NASDAQ DLTR  ,2019-04-09,Reuters,https://www.investing.com/news/stock-market-news/cerner-settles-with-hedge-fund-starboard-to-add-new-directors-increase-buybacks-1831434,1831434
146440,367955,CERN,Cerner nabs contract with VA to develop EHR system  shares ahead 1 ,news,Cerner  CERN  0 8   perks up on average volume in response to the news that it has been tapped by the U S  Department of Veterans Affairs to develop an electronic health record  EHR  system to replace its legacy VistA system  Cerner says its offering will facilitate the exchange of data between military care facilities and civilian providers  where many service member receive care The size of the contract is not disclosed but it should be sizable considering the VA consists of 168 hospitals and 1 053 outpatient clinics that serve almost 9M veterans each year Now read ,2017-06-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/cerner-nabs-contract-with-va-to-develop-ehr-system;-shares-ahead-1-491959,491959
146441,367956,CERN,Cerner  4 9  on word of large Amazon cloud deal coming,news,Shares in Cerner  NASDAQ CERN  have spiked 4 9  after a CNBC report says Amazon com  AMZN  0 8   is set to announce a huge cloud deal with the healthcare tech provider  Amazon Web Services and Cerner will announce a deep team up at AWS re Invent next week  to be announced by AWS CEO Andy Jassy  according to the report  The two will work together on helping providers use data to make health predictions about patient populations The deal s said to focus first on Cerner s  population health  product HealtheIntent  Now read ,2017-11-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/cerner-49-on-word-of-large-amazon-cloud-deal-coming-902132,902132
146442,367957,CERN,Premarket analyst action   healthcare,news,Homology Medicines  NASDAQ FIXX  initiated with Buy rating and  27  32  upside  price target at BofAMerrill Lynch  Initiated with Outperform rating at Cowen and Company  Shares up 3  premarket Knight Therapeutics  OTC KHTRF  initiated with Outperform rating and C 9 50  22  upside  price target at RBC Unum Therapeutics  NASDAQ UMRX  initiated with Overweight rating and  20  67  upside  price target at  Morgan Stanley   NYSE MS   Initiated with Market Perform rating at Cowen  Shares up 3  premarket Cerner  NASDAQ CERN  upgraded to Buy at  Citigroup   NYSE C   Shares up 3  premarket  Insmed   NASDAQ INSM  upgraded to Outperform at  Credit Suisse   SIX CSGN   Shares up 4  premarket Merck  NYSE MRK  upgraded to Buy with a  73  24  upside  price target at Goldman Sachs  NYSE GS  citing Keytruda upside  sales target doubled to  4B in 2025   Added to Conviction List  Shares up 2  premarket Spark Therapeutics  NASDAQ ONCE  downgraded to Neutral with an  85  4  upside  price target at Chardan Capital Markets  Shares down 1  premarket Now read ,2018-04-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1408350,1408350
146451,367966,CERN,Here s Why You Should Hold On To OPKO Health Stock For Now,opinion,OPKO Health  Inc    NASDAQ OPK   continues to benefit from lucrative RAYALDEE and BioReference platforms  solid focus on research and development  R D   and optimistic outlook for fourth quarter 2019  However  operating losses remain a concern Shares of OPKO Health have lost 58 8  against the  s growth of 8 4  in a year s time  Meanwhile  the S P 500 Index rallied 17 4  in the same timeframe The company  with a market capitalization of  965 1 million  engages in the diagnostics and pharmaceuticals business in the United States  Ireland  Chile  Spain  Israel and Mexico  It anticipates earnings to improve 42 9  in the next quarter Let s take a closer look at the factors that substantiate the company s Zacks Rank  3  Hold  What s Deterring the Stock OPKO Health has an infamous record of incurring huge operating losses  To date  the company has generated limited revenues from pharmaceutical operations in the United States  Chile  Mexico  Israel  Spain and Ireland In third quarter 2019  OPKO Health incurred an operating loss of  39 million  For the fourth quarter  the company projects operating loss between  42 million and  69 million  including  25 million of non cash  depreciation and amortization  What s Favoring the Stock Lucrative prospects in RAYALDEE and BioReference platforms have been providing a competitive edge to OPKO Health in the MedTech Industry  RAYALDEE has been witnessing decent momentum  courtesy of successful efforts from the sales team The company expects the BioReference R D pipeline to increase throughout 2019  backed by improving cash flows from Bio Reference and RAYALDEE OPKO Health s focus on R D is a positive factor  The company s strong commitment toward innovation led to product introductions  improvement in existing products  and product line expansion  Moreover  its commitment resulted in the enhancement of R D facilities and procurement of new equipment for the same Per management  the company will continue to make solid investments in R D programs throughout 2019  OPKO Health projects R D expenses of  28  31 million for the fourth quarter Strong outlook for fourth quarter 2019 instills optimism in the stock  Management anticipates fourth quarter revenues from Services between  165 million and  175 million  excluding revenues from 4kscore from Medicare beneficiaries   The company expects Product revenues of  25  29 million  including  8  9 million revenues from RAYALDEE Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  894 4 million  The same for earnings stands at a loss of 43 cents per share Stocks to ConsiderSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    HealthEquity  Inc    NASDAQ HQY   and Chegg  Inc    NYSE CHGG    each carrying a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is estimated at 13 6  HealthEquity s long term earnings growth rate is pegged at 25  Chegg s long term earnings growth rate is estimated at 30  Free  Zacks  Single Best Stock Set to Double Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-opko-health-stock-for-now-200504037,200504037
146452,367967,CERN,Cerner  CERN  Tops Q4 Earnings And Revenue Estimates,opinion,"Cerner  CERN  came out with quarterly earnings of  0 75 per share  beating the Zacks Consensus Estimate of  0 74 per share  This compares to earnings of  0 63 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 35   A quarter ago  it was expected that this health care information technology company would post earnings of  0 65 per share when it actually produced earnings of  0 66  delivering a surprise of 1 54  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Cerner  which belongs to the Zacks Medical Info Systems industry  posted revenues of  1 44 billion for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 0 56   This compares to year ago revenues of  1 37 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cerner shares have lost about 0 3  since the beginning of the year versus the S P 500 s gain of 0 6  
What s Next for Cerner 
While Cerner has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cerner was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 70 on  1 43 billion in revenues for the coming quarter and  3 14 on  5 90 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical Info Systems is currently in the top 40  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-tops-q4-earnings-and-revenue-estimates-200504553,200504553
146453,367968,CERN,ResMed  RMD  Stock Hits New 52 Week High  What s Driving It ,opinion,"Shares of ResMed Inc    NYSE RMD   reached a new 52 week high of  167 65 on Feb 4  before closing the session marginally lower at  166 85  The stock has rallied 0 9  since its second quarter fiscal 2020 earnings announcement on Jan 30 The company s strong second quarter fiscal 2020 earnings results  backed by robust segmental and global revenue growth  prompted the rally  Currently  ResMed is reinforcing focus toward its core sleep apnea franchise  digital health technology and international markets Let us delve deeper 

Fiscal Q2 PerformanceResMed exited second quarter fiscal 2020 on a solid note  with better than expected numbers  It is encouraging to note that ResMed registered growth at CER across both its key operating segments   Total Sleep and Respiratory Care and Software as a Service  or SaaS  Mask sales were particularly strong in Europe and Asia  The double digit geographic revenue improvement backed by robust performance of the company s mask and device product portfolios in the United States  Canada and Latin America  excluding SaaS  buoys optimism  Within SaaS  it recorded continued momentum in the Brightree service portfolio and an additional contribution from the MatrixCare buyout  Global revenues from SaaS also witnessed robust growth Other Growth DriversPotential in Digital Health  Investors are upbeat about ResMed s focus on digital health technology  The Brightree and MatrixCare software systems are significantly contributing to the company s capabilities of managing 90 million more people outside the hospital setting  Given that digital health technology is an integrator across everything that the company does  AirView  myAir  Propeller and a portfolio of other digital health solutions support its plans of reaching out to more customers and partners Partnerships  Within its SaaS portfolio  the company inked a collaboration deal with Cerner  NASDAQ CERN  as a new preferred provider for home health and hospice software  This partnership strengthens ResMed s position as an industry leading provider of digital health solutions for out of hospital healthcare  Investors are optimistic about the partnership progressing well  even though it is in early stage Emphasis on Product Development  ResMed s focus on product development and innovation to maintain leadership position in the sleep disordered breathing  SDB  market and to expand its sales base buoys optimism  The company recently expanded its AirFit mask portfolio by introducing the world s first tube down nasal cradle CPAP mask with a front facing tube  AirFit N30  in the United States  Later  it will be available in other countries as well Zacks Rank   Other Key PicksCurrently  the company carries a Zacks Rank  2  Buy  Some other top ranked stocks from the broader medical space are Stryker Corporation   NYSE SYK    Hill Rom Holdings  Inc    NYSE HRC   and Myomo  Inc    NYSE MYO   Stryker currently sports a Zacks Rank  2 and has a projected long term earnings growth rate of 9 9   You can see Hill Rom s long term earnings growth rate is estimated at 11 1   The company presently carries a Zacks Rank of 2 Myomo s long term earnings growth rate is expected at 25   It currently has a Zacks Rank  2 Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/resmed-rmd-stock-hits-new-52week-high-whats-driving-it-200504972,200504972
146454,367969,CERN,Cerner  CERN  Earnings And Revenues Beat Estimates In Q4,opinion,Cerner Corporation   NASDAQ CERN   reported fourth quarter 2019 adjusted earnings of 75 cents per share  which beat the Zacks Consensus Estimate of 74 cents by 1 4   The bottom line also improved from the prior year quarter figure by 19   The company reported revenues of  1 44 billion  which improved 5 6  year over year and outpaced the Zacks Consensus Estimate by 0 6  Revenues by Geography Per management  U S  revenues grossed  1 28 billion  up 6  from the prior year quarter Non U S  revenues increased 3  to  166 million from the year ago quarter  Bookings In the reported quarter  the company s bookings totaled  1 67 billion  down 15 1  from the year ago quarter Segmental PerformanceLicensed software revenues improved 4 8  to  174 5 million  driven by strong growth in SaaS offerings  Technology resale revenues were  60 4 million  up 31 2  on a year over year basis  Revenues from Subscriptions grossed  92 8 million  up 6 6  year over year  Professional services  revenues totaled  509 3 million  up 9 3  from the prior year quarter number  on the back of solid growth in implementation services  Revenues at the Managed services unit amounted to  309 4 million  up 3 5  from the prior year quarter  Support and maintenance revenues were  273 9 million  down 1  year over year  Reimbursed travel revenues amounted to  21 9 million  reflecting a year over year decrease of 8 9  Cerner Corporation Price  Consensus and EPS Surprise    Margins In the quarter under review  gross profit summed  1 16 billion  up 3 2  year over year  Gross margin was 80 8   down 180 bps on a year over year basis  General and administrative expenses increased 23 6  to  122 3 million  Further  software development expenses rose 3 7  to  188 2 million  Adjusted operating margin expanded 160 bps to 20 3  during the reported quarter 2020 Guidance For the first quarter of 2020  Cerner expects revenues between  1 42 billion and  1 47 billion  The Zacks Consensus Estimate for revenues stands at  1 43 billion  within management s guided range For the first quarter 2020 adjusted earnings per share is projected between 69 cents and 71 cents New business bookings for first quarter 2020 are estimated between  1 10 billion and  1 30 billion For the full year 2020  the company anticipates revenues in the range of  5 72  5 98 billion For the full year  adjusted earnings per share are expected between  3 09 and  3 19  The Zacks Consensus Estimate stands at  3 14  lies within the company s guided range Wrapping Up Cerner exited the fourth quarter on a strong note  The company continues to witness strong contributions from key areas like Population Health  Revenue Cycle and IT Works  Further  gains in Licensed software  Technology resale  Professional and Managed Services units buoy optimism  International revenues also moved up in the quarter  The company benefited from electronic health record  EHR   electronic patient record  EPR  or electronic medical record  EMR  platforms that provide patient care in acute inpatient and outpatient settings  Meanwhile  bookings witnessed a noticeable decline in the quarter under review  Contraction in operating margins remains a concern  Furthermore  competition in the global MedTech space is a woe Zacks RankCurrently  Cerner carries a Zacks Rank  2  Buy  Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Accuray Incorporated   NASDAQ ARAY   and AmerisourceBergen Corporation   NYSE ABC    You can see  Stryker delivered fourth quarter 2019 adjusted EPS of  2 49  outpacing the Zacks Consensus Estimate by 1 2   Fourth quarter reported revenues of  4 13 billion surpassed the Zacks Consensus Estimate by 0 7   The company carries a Zacks Rank  2 Accuray reported second quarter fiscal 2020 adjusted earnings per share  EPS  of a penny  improving from the Zacks Consensus Estimate of a loss of 7 cents  Net revenues of  98 8 million outpaced the Zacks Consensus Estimate by 0 3   The company sports a Zacks Rank  1 AmerisourceBergen reported first quarter fiscal 2020 adjusted EPS of  1 76  which beat the Zacks Consensus Estimate of  1 67 by 5 4   The company has an expected long term earnings growth rate of 7 4   AmerisourceBergen carries a Zacks Rank of 2 Biggest Tech Breakthrough in a Generation Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-earnings-and-revenues-beat-estimates-in-q4-200504702,200504702
146456,367971,CERN,Cerner  CERN  Catches Eye  Stock Jumps 5 9 ,opinion,Cerner Corporation   NASDAQ CERN   was a big mover last session  as the company saw its shares rise nearly 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  71 83 to  75 86 in the past one month time frame The move came after the company reported better than expected fourth quarter 2019 results The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Cerner currently has a Zacks Rank  2  Buy  while its  is 0 00  Cerner Corporation Price   Investors interested in the Medical Info Systems industry may consider Change Healthcare Inc    NASDAQ CHNG    which has a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Is CERN going up  Or down  Predict to see what others think Up or DownMore Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-catches-eye-stock-jumps-59-200505169,200505169
146492,368007,CERN,ResMed  RMD  Hits A 52 Week High  What s Driving The Stock ,opinion,On Dec 16  shares of ResMed   NYSE RMD   scaled a new 52 week high of  156 20  closing the session marginally lower at  156   In fact  the stock has rallied nearly 22 5  since its first quarter fiscal 2020 earnings announcement on Oct 24 Double digit global revenue growth in the first quarter  led by strong sales in Software as a Service  SaaS  businesses  launch of mask products and devices as well as robust geographic expansion have prompted the rally Let us take a closer look at the factors driving growth Robust Q1 EarningsThe fiscal first quarter revenues in the combined EMEA and APAC region witnessed an 8  rise at CER from the year earlier tally  A massive 83  surge in global SaaS revenues  driven by continued expansion of Brightree offerings and the MatrixCare buyout  has buoyed optimism Gross margin for the quarter was 59 5   translating into a 115 basis point  bps  expansion from the year ago number  Adjusted operating margin in the reported quarter rose 115 bps to 27 8   Other Encouraging FactorsInvestors are optimistic about the company s recently inked collaboration deal with Cerner  NASDAQ CERN  as a new preferred provider for home health and hospice software  This partnership strengthens ResMed s position as an industry leading provider of digital health solutions for out of hospital healthcare  In fact  ResMed s MatrixCare team is steadily progressing toward signing a contract with a major healthcare system Market is upbeat about ResMed s expansion of its AirFit mask portfolio with the introduction of its first top of head connected nasal CPAP mask  AirFit N30i  in the United States  The company s flagship masks  AirFit F20 in the full face category and AirFit N20 in the nasal category  witnessed solid momentum across global markets in the first quarter of fiscal 2020  The company s three most recent mask launches  namely  the F30  the N30i and the P30i  have started contributing to the top line significantly  In October 2019  the company launched its latest innovation  N30   the world s first ever tube down nasal cradle CPAP mask in a new product subcategory  which is being called the minimalist category  Meanwhile  ResMed has been having a great run on the bourses in the past year  The stock has rallied 39 7   higher than the broader  s growth of 13 4   The company currently has a market cap of  22 09 billion Zacks Rank   Other Stocks Worth a LookResMed carries a Zacks Rank  1  Strong Buy  A few other top ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and Omnicell   NASDAQ OMCL    each carrying a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  Omnicell has a long term earnings growth rate of 12 5  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/resmed-rmd-hits-a-52week-high-whats-driving-the-stock-200493097,200493097
146493,368008,CERN,5 Promising Growth Stocks In MedTech To Invest In 2020,opinion,Investors have commenced 2020 with caution and apprehension  thanks to the looming atmosphere of uncertainty prevailing at the moment  The investment world is particularly wary of the end to the ongoing bull market  which witnessed the longest bull run till July 2019  Further  the 59th presidential election  scheduled in late 2020  and related political uproar are only aggravating the uncertainty present in the equity market In 2019  the MedTech industry witnessed an impressive on the back of increased healthcare awareness and purchasing power in the emerging markets  exceptional progress in innovation and technological advancement However  the U S  China trade war  which resulted in both the countries levying tariffs worth thousands of billions of dollars on each other  dragged on for almost 18 months and was a dampener  Nonetheless  investors are looking forward to a brighter 2020 and have pinned hopes on the recent  phase one  trade deal between the United States and China  which has hopefully put a break in the trade war Meanwhile  per a report by Fitch Solutions published on   the U S  medical device market is expected to see a CAGR of 4 9  over the coming years that can exceed  200 billion in 2023 MedTech Sector  2020 Looks PromisingIn 2019  top MedTech companies increased R D spending across the board  This is likely to continue in 2020 as well  Higher R D expenditure is putting more MedTech products into a faster approval cycles  thereby leading to more new products being marketed  According to a report by   total MedTech R D spending is projected to improve by 4 5  at  39 billion by 2024 Moreover  value based payment or outcomes based pricing and reimbursement models that join prices to value are garnering attention  These models will help providers  payers and patients to get the best outcomes at the lowest cost Further  interest in digital health is palpable from significant growth in investments in the space over the last five years  Geriatric population with prevalence of chronic diseases and current and upcoming changes to regulations and reimbursements will drive adoption of digital health services and technologies in 2020 and beyond Interestingly  In vitro Diagnostics  IVD  has been gaining prominence  IVD has been a game changer when it comes to early detection of a patient s health condition and the risk associated with the same  thereby resulting in creation of new opportunities for early intervention and prevention  According to   IVD is likely to become a niche in the industry by 2020  accounting for 14 1   or  67 3 billion in sales Why Growth Stocks Taking into account the aforementioned trends  the MedTech industry appears to be a lucrative investment proposition for 2020  The industry s momentum is expected to continue through year on sustained demand strength across major end markets and significant capital investment  Amid such a backdrop  it would be a prudent idea to invest in MedTech stocks with compelling growth prospects if you are looking to reap solid returns from your portfolio in 2020 5 MedTech Growth Stocks in FocusHere we will take a look into five growth stocks are fundamentally strong businesses that ensure solid portfolio returns  We have used the Zacks  to pick such stocks  Our research shows that stocks with the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  offer good investment opportunities You can see We have taken the help of the  to zero in on five MedTech stocks with favorable Zacks Rank and Growth Score HMS Holdings Corp    NASDAQ HMSY    with a Zacks Rank  2  provides cost containment solutions in the United States healthcare marketplace  This  2 69 billion company has a Growth Score of B  Its long term historical growth rate was 7   The company s long term expected earnings growth rate is pegged at 11  HMS Holdings Corp Price    West Pharmaceutical Services  Inc    NYSE WST   currently has a Zacks Rank of 2 and a Growth Score of B  The company manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States  Germany  France  Other European countries  South Korea  and internationally  The company  with a market capitalization of  11 54 billion  has a five year historical growth rate of 11 9   It expects a long term earnings growth rate of 14  West Pharmaceutical Services  Inc  Price    LHC Group  Inc    NASDAQ LHCG    with a Zacks Rank of 1  serves as a post acute care partner for hospitals  physicians and families in the United States  From home health and hospice care to long term acute care and community based services  the company delivers high quality  cost effective care that helps patients manage their health at home  This  4 5 billion company has a Growth Score of A  The company has a five year historical growth rate of 19 7   It expects a long term earnings growth rate of 13 9  LHC Group  Inc  Price    Cerner Corporation   NASDAQ CERN   currently has a Zacks Rank of 2 and a Growth Score of B  The company provides healthcare information technology  HCIT  solutions worldwide  The company  with a market capitalization of  22 95 billion  has a five year historical growth rate of 10 7   It expects a long term earnings growth rate of 13 6  Cerner Corporation Price    Omnicell  Inc    NASDAQ OMCL    with a Zacks Rank  2 and a Growth Score of A  develops and markets end to end automation solutions for the medication use process  The company  with a market capitalization of  3 49 billion  has a five year historical growth rate of 13 7   It expects a long term earnings growth rate of 12 5  Omnicell  Inc  Price    Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/5-promising-growth-stocks-in-medtech-to-invest-in-2020-200498546,200498546
146514,368029,CERN,Cerner  CERN  Surpasses Q3 Earnings Estimates,opinion,"Cerner  CERN  came out with quarterly earnings of  0 66 per share  beating the Zacks Consensus Estimate of  0 65 per share  This compares to earnings of  0 63 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 54   A quarter ago  it was expected that this health care information technology company would post earnings of  0 64 per share when it actually produced earnings of  0 66  delivering a surprise of 3 13  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Cerner  which belongs to the Zacks Medical Info Systems industry  posted revenues of  1 43 billion for the quarter ended September 2019  missing the Zacks Consensus Estimate by 0 03   This compares to year ago revenues of  1 34 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cerner shares have added about 28 9  since the beginning of the year versus the S P 500 s gain of 19 9  
What s Next for Cerner 
While Cerner has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cerner was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 75 on  1 47 billion in revenues for the coming quarter and  2 68 on  5 72 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical Info Systems is currently in the top 15  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-surpasses-q3-earnings-estimates-200477958,200477958
146516,368031,CERN,Here s Why You Should Add ResMed  RMD  To Your Portfolio,opinion,"ResMed Inc    NYSE RMD   has been gaining investors  confidence on consistently positive results  Over the past year  the company s shares have outperformed its   The stock has gained 38 3  during the same time compared with 6 4  growth of the industry  Also  the company has outperformed the S P 500 s 12 7  rise during this period The renowned cloud connected medical devices and out of hospital software as a service   SaaS   business provider  which specializes in sleep apnea devices  has a market cap of  20 91 billion  The company s five year projected growth rate looks impressive at 10 6   It is expected to scale new highs in the near term  The company has average positive earnings surprise of 5 3  for the trailing four quarters With solid prospects  the Zacks Rank  2  Buy  company is a worthy investment choice right now 

What Makes the Stock an Attractive Pick Product Launches  ResMed successfully launched its portable oxygen concentrator  Mobi  in the United States for Chronic Obstructive Pulmonary Disease   COPD   or other chronic diseases  Following this  it is planning a complete launch in other countries in 2019  after acquiring the necessary clearances  The company also launched an automated ReSupply solution for all U S  home medical equipment   HME   providers in the United States Further  it recently expanded the AirFit mask portfolio by introducing AirFit N30i  a nasal CPAP mask  in the United States  For 2019  the company has more launches planned for other geographies  The company s three most recent mask launches  namely  F30  N30i and P30i  have been contributing to the top line significantly  In October 2019  it launched N30  a tube down nasal cradle CPAP mask   which is its latest offering Acquisitions and Partnerships to Add Value  ResMed recently formed an alliance with Cerner Corporation  NASDAQ CERN  within ResMed s SaaS portfolio to help care providers take more informed treatment decisions  thereby reducing costs and delivering hassle free healthcare In March  ResMed acquired home medical equipment provider HB Healthcare in South Korea  ResMed intends to reach millions of patients through HB Healthcare s wide network of distributor partners The company also acquired Propeller Health  a digital therapeutics company  providing connected health solutions for COPD and asthma patients  in January 2019  Per ResMed  this is a significant value addition to its respiratory care portfolio Further  ResMed is working toward the collaboration with Verily to develop software solutions that will assist healthcare providers to discover  diagnose  treat and manage individuals with sleep apnea and other breathing related sleep conditions End Market Growth Strong  The company is expecting strong growth for the atrial fibrillation and chronic disease management segments  It has been witnessing robust growth in its Brightree service portfolio and additional contribution from MatrixCare and HEALTHCAREfirst buyouts  It is also concentrating on the development of homecare ventilation for COPD  Amyotrophic Lateral Sclerosis   ALS   and other respiratory disorders for the emerging markets in China  India and Brazil Which Way Are Estimates Heading The estimate revision trend for the company for the current year is impressive  Over the past 30 days  the Zacks Consensus Estimate for its earnings has moved up 2 6  to  4 02 The Zacks Consensus Estimate for 2020 revenues is pegged at  2 86 billion  suggesting 9 9  rise from the year ago reported number Other Key PicksSome other top ranked stocks from the broader medical space are Aphria Inc    TSX APHA    Owens   Minor  Inc    NYSE OMI   and LeMaitre Vascular  Inc    NASDAQ LMAT   Aphria  currently carrying a Zacks Rank  2  has projected first quarter 2020 earnings growth rate at 113 33   You can see Owens   Minor estimates earnings growth rate of 300  for third quarter 2019  It currently sports a Zacks Rank  1 LeMaitre Vascular s long term earnings growth rate is projected at 10   The stock currently carries a Zacks Rank of 2 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-resmed-rmd-to-your-portfolio-200479767,200479767
146527,368042,CERN,SYNH Or CERN  Which Is The Better Value Stock Right Now ,opinion,"Investors with an interest in Medical Info Systems stocks have likely encountered both Syneos Health  SYNH  and Cerner  CERN   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
There are plenty of strategies for discovering value stocks  but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Currently  Syneos Health has a Zacks Rank of  2  Buy   while Cerner has a Zacks Rank of  3  Hold   Investors should feel comfortable knowing that SYNH likely has seen a stronger improvement to its earnings outlook than CERN has recently  But this is just one piece of the puzzle for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
SYNH currently has a forward P E ratio of 16 02  while CERN has a forward P E of 25 61  We also note that SYNH has a PEG ratio of 1 53  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CERN currently has a PEG ratio of 1 76 
Another notable valuation metric for SYNH is its P B ratio of 1 87  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  CERN has a P B of 4 62 
These metrics  and several others  help SYNH earn a Value grade of A  while CERN has been given a Value grade of C 
SYNH sticks out from CERN in both our Zacks Rank and Style Scores models  so value investors will likely feel that SYNH is the better option right now ",2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/synh-or-cern-which-is-the-better-value-stock-right-now-200458924,200458924
146528,368043,CERN,NextGen s  NXGN  Population Health Picked By Ohio Based UH,opinion,NextGen Healthcare  Inc    NASDAQ NXGN   recently announced that University Hospitals Health System   UH   has selected its NextGen Population Health to enhance patient care  This boosts NextGen s foothold in the global electronic health records  EHR  space Notably  the company s EHRs and health information exchanges will help better population health management by UH apart from reducing costs For investors  notice  Ohio based UH is one of the leading healthcare providers with 18 hospitals  more than 50 health centers and outpatient facilities and over 200 physician offices Population Health in FocusNextGen Population Health along with Analytics Solutions offers a comprehensive platform which examines clinical  financial and patient derived data  It also aggregates and analyzes patient data from various sources and produces a single  actionable patient record  This helps engage patients  reduce treatment costs and improve care quality Notably  an extra  192 billion is spent for treatment in a year  The Population Health platform is capable of addressing these issues through EHRs EHR Gaining Popularity in HealthcareThe advantages of EHRs in the clinical setting are numerous and significant  Considering the rapidly growing electronic interconnectivity of the health care world  EHRs dominate the headlines  thanks to time and cost saving For instance  HCIT bigwigs like Cerner Corporation   NASDAQ CERN   and Allscripts Healthcare   NASDAQ MDRX   have been gaining consistently from their coveted EHR platforms In fact   projects the global EHR market to reach  38 29 billion by 2025  at a CAGR of 5 7  Price PerformanceWe believe that positive developments such as these are likely to boost the Zacks Rank  4  Sell  company whose shares have plunged 20 2  compared with the  s 9 9  decline A Key PickA better ranked stock in the broader medical sector is Masimo Corporation   NASDAQ MASI   Masimo s long term earnings growth rate is projected at 23 9   The stock carries a Zacks Rank  2  Buy   You can see Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/nextgens-nxgn-population-health-picked-by-ohiobased-uh-200467531,200467531
146530,368045,CERN,SYNH Vs  CERN  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical Info Systems sector have probably already heard of Syneos Health  SYNH  and Cerner  CERN   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Currently  Syneos Health has a Zacks Rank of  2  Buy   while Cerner has a Zacks Rank of  4  Sell   This means that SYNH s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is just one piece of the puzzle for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
SYNH currently has a forward P E ratio of 17 45  while CERN has a forward P E of 25 46  We also note that SYNH has a PEG ratio of 1 66  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  CERN currently has a PEG ratio of 1 93 
Another notable valuation metric for SYNH is its P B ratio of 2 03  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  CERN has a P B of 4 60 
These metrics  and several others  help SYNH earn a Value grade of B  while CERN has been given a Value grade of C 
SYNH sticks out from CERN in both our Zacks Rank and Style Scores models  so value investors will likely feel that SYNH is the better option right now ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/synh-vs-cern-which-stock-is-the-better-value-option-200474526,200474526
146554,368069,CERN,Cerner  CERN  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Cerner  CERN  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 24  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health care information technology company is expected to post quarterly earnings of  0 64 per share in its upcoming report  which represents a year over year change of  3 2  
Revenues are expected to be  1 44 billion  up 5 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cerner 
For Cerner  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination makes it difficult to conclusively predict that Cerner will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cerner would post earnings of  0 61 per share when it actually produced earnings of  0 61  delivering no surprise 
Over the last four quarters  the company has beaten consensus EPS estimates just once 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cerner doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200440748,200440748
146555,368070,CERN,NextGen Inks Deal With Appriss Health  Boosts EHR System,opinion,NextGen Healthcare  Inc    NASDAQ NXGN   recently announced the integration of Appriss Health prescription monitoring and tracking analytics into NextGen Office   the company s cloud based  small practice electronic health record  EHR  solution  With this amalgamation  NextGen aims to detect  prevent and manage substance use disorder more effectively and efficiently In fact  this integration is likely to provide a significant boost to NextGen s EHR system A Glimpse into the U S  Opioid CrisisNotably  an opioid epidemic is plaguing the United States and has been traumatizing families  According to a report by   more than 130 people in the United States lose their lives owing to opioid overdose  The misuse of and addiction to opioids has become a national crisis impacting public health  and social and economic welfare Going by the projections of the Centers for Disease Control and Prevention  the total economic impact of prescription opioid misuse itself in the United States is  78 5 billion a year and this includes the cost of healthcare  addiction treatment  lost productivity and even criminal justice involvement Deal RationaleThe integration will enable prevention of illegal acquisition of controlled substances from multiple sources through enhanced prescription capabilities The providers will now be equipped with advanced capabilities to effectively prescribe and dispense controlled substances  The technology will help in maximization of patient health and safety by checking state records for controlled substances that have been prescribed by multiple providers for an individual patient  This will be available within one system at the point of care Through this deal  both NextGen Office and Appriss Health will ensure that the smaller providers receive the critical tools and information necessary to bolster patient outcomes EHR Gaining Popularity in HealthcareThe latest trend of EHR services has been gaining prominence in the U S  MedTech space  NextGen s NextGen Enterprise and NextGen Office  formerly  MediTouch  software technology and solutions accommodate the unique needs of ambulatory practices of all sizes  These EHR solutions cater to demands like Merit Based Incentive Payment System  MIPS  requirements  population health needs  and other value based care initiatives Per   the global EHR market is estimated to reach  38 29 billion by 2025 at a CAGR of 5 7   Reports suggest that MedTech companies with a strong exposure to big data automated EHRs will excel in terms of operations and margins In this regard  it is imperative to mention that Cerner Corporation   NASDAQ CERN   has been dominating the headlines  courtesy of efforts to digitize EHR systems Market PotentialAccording to a report by   the healthcare IT market is anticipated to reach  390 7 billion by 2024 from  187 6 billion in 2019 at a CAGR of 15 8  during the forecast period  The increase in the volume of patient data  rise in technological know how  and demand for quick and efficient healthcare processes and systems are fueling the demand for HCIT solutions Price PerformanceYear to date  this Zacks Rank  2  Buy  stock has advanced 31 2  compared with the  s and the S P 500 Index s growth of 25 3  and 18 4   respectively Other Key PicksInvestors interested in some other top ranked stocks from the broader medical space can consider Penumbra  Inc    NYSE PEN   and NuVasive  Inc    NASDAQ NUVA    both sporting a Zacks Rank  1  Strong Buy   You can see  Penumbra has a long term earnings growth rate of 21 5  NuVasive has a long term earnings growth rate of 11 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/nextgen-inks-deal-with-appriss-health-boosts-ehr-system-200440930,200440930
146557,368072,CERN,Cerner  CERN  Q2 Earnings Top Estimates,opinion,"Cerner  CERN  came out with quarterly earnings of  0 66 per share  beating the Zacks Consensus Estimate of  0 64 per share  This compares to earnings of  0 62 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 13   A quarter ago  it was expected that this health care information technology company would post earnings of  0 61 per share when it actually produced earnings of  0 61  delivering no surprise 
Over the last four quarters  the company has surpassed consensus EPS estimates just once 
Cerner  which belongs to the Zacks Medical Info Systems industry  posted revenues of  1 43 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 0 40   This compares to year ago revenues of  1 37 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cerner shares have added about 37 5  since the beginning of the year versus the S P 500 s gain of 19 9  
What s Next for Cerner 
While Cerner has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cerner was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 69 on  1 44 billion in revenues for the coming quarter and  2 67 on  5 74 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical Info Systems is currently in the top 34  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-q2-earnings-top-estimates-200444303,200444303
146558,368073,CERN,MDRX Or CERN  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in stocks from the Medical Info Systems sector have probably already heard of AllScripts Healthcare  MDRX  and Cerner  CERN   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
AllScripts Healthcare has a Zacks Rank of  1  Strong Buy   while Cerner has a Zacks Rank of  2  Buy  right now  This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that MDRX is likely seeing its earnings outlook improve to a greater extent  But this is just one factor that value investors are interested in 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
MDRX currently has a forward P E ratio of 15 81  while CERN has a forward P E of 27 01  We also note that MDRX has a PEG ratio of 1 54  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  CERN currently has a PEG ratio of 1 88 
Another notable valuation metric for MDRX is its P B ratio of 1 23  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  CERN has a P B of 4 58 
Based on these metrics and many more  MDRX holds a Value grade of A  while CERN has a Value grade of C 
MDRX sticks out from CERN in both our Zacks Rank and Style Scores models  so value investors will likely feel that MDRX is the better option right now ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/mdrx-or-cern-which-is-the-better-value-stock-right-now-200444702,200444702
146559,368074,CERN,OptimizeRx  OPRX  To Report Q2 Earnings  What s In Store ,opinion,OptimizeRx Corp    NASDAQ OPRX   is scheduled to report second quarter 2019 results on Aug 7 In the last reported quarter  the company came up with a positive surprise of 100    In fact  the company s earnings history is impressive  having trumped the Zacks Consensus Estimate in each of the trailing four quarters  the average being 133 33  Meanwhile  revenues of  5 million in the same period matched the Zacks Consensus Estimate  The same  however  improved 27  from the year ago quarter The Zacks Consensus Estimate for second quarter 2019 revenues is pegged at  6 8 million  indicating a nearly 32 9  increase from the year ago reported figure The Zacks Consensus Estimate for earnings stands at 8 cents  suggesting a 300  surge from the number reported in the prior year quarter Let s see how things are shaping up for the upcoming announcement Factors to ConsiderOptimizeRx s performance in the upcoming quarterly results is likely to be driven by its diversified revenue streams  broader provider reach  scalable technology and strong operational efficiency The company s focus on expanding its channel partners is also likely to expand transaction volume this earnings season  Increased sales of core financial and brand messaging products are expected to boost the quarterly results Moreover  the CareSpeak buyout is a positive  Additionally  expanded platform integrations with leading electronic health record systems  such as Epic and Cerner   NASDAQ CERN   in the last reported quarter make us optimistic Further  a favorable product mix shift is expected to boost gross margins in the soon to be reported quarter  However  expenses related to the integration of CareSpeak are an overhang OptimizeRx Corp  Price and EPS Surprise   What Our Model SaysThe proven Zacks model shows that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has maximum chances of beating estimates if it also has a positive   Zacks Rank  4  Sell  or 5  Strong Sell  stocks are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  OptimizeRx currently carries a Zacks Rank  2  which increases the predictive power of ESP  However  its Earnings ESP of 0 00  in the combination makes surprise prediction difficult for the stock Stocks to ConsiderHere are a couple of stocks worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases Ciena Corporation   NYSE CIEN   has an Earnings ESP of  5 26  and a Zacks Rank of 2  You can see  GTT Communications  Inc    NYSE GTT   has an Earnings ESP of  144 44  and a Zacks Rank  3 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/optimizerx-oprx-to-report-q2-earnings-whats-in-store-200450087,200450087
146560,368075,CERN,Cerner  CERN  Down 1 7  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Cerner  CERN   Shares have lost about 1 7  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Cerner due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Cerner Q2 Earnings Beat Estimates  Revenues MissCerner Corporation  NASDAQ CERN  delivered second quarter 2019 adjusted earnings of 66 cents per share  which beat the Zacks Consensus Estimate of 64 cents by 3 1   The bottom line also improved from the prior year quarter s figure by 6 5   The company reported revenues of  1 43 billion  which increased 4 6  year over year but missed the Zacks Consensus Estimate of  1 44 billion by 0 4  Revenues by Geography Per management  U S  revenues grossed  1 27 billion  up 5  from the prior year quarter Non U S  revenues remained flat from the year ago quarter figure at  165 million  Per management  Cerner s international revenue growth was impacted by foreign exchange rates  Bookings In the reported quarter  the company s bookings totaled  1 43 billion  down from  1 78 billion in the same quarter of the last year Segmental PerformanceLicensed software revenues shot up 14 3  to  197 1 million  driven by strong bookings and growth in both traditional software and SaaS offerings  Technology resale revenues were  60 7 million  down 19 3  on a year over year basis  Revenues from Subscriptions grossed  89 8 million  up 8 2  year over year  Professional services  revenues totaled  485 3 million  up 8 5  from the prior year quarter number  on the back of solid growth in implementation services  Revenues at the Managed services unit summed  297 7 million  up 4 2  from the prior year quarter  Support and maintenance revenues were  276 4 million  down 0 9  year over year  Reimbursed travel revenues amounted to  24 1 million  reflecting a year over year decline of 4 9   Margins In the quarter under review  gross profit summed  1 16 billion  up 3  year over year  Gross margin was 81 2   down 130 bps on a year over year basis  General and administrative expenses increased 56 9  to  149 8 million  Further  software development expenses rose 7 6  to  181 million  Adjusted operating margin contracted 68 bps to 18  during the reported quarter  Guidance For the third quarter of 2019  Cerner expects revenues between  1 41 billion and  1 46 billion  The Zacks Consensus Estimate for revenues stands at  1 44 billion  towards the upper end of management s guided range  Adjusted earnings per share are expected between 65 cents and 67 cents  The Zacks Consensus Estimate stands at 69 cents  above the company s guided range  Cerner maintained 2019 revenue guidance  The company continues to expect revenues between  5 65 billion and  5 85 billion  The Zacks Consensus Estimate for revenues in 2019 stands at  5 74 billion  within the company s guided range  The company reiterated 2019 earnings per share outlook  The company continues to project the metric to be  2 64  2 72 per share  The Zacks Consensus Estimate for earnings stands at  2 67  within the company s estimated range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates revision  The consensus estimate has shifted  5 36  due to these changes 
VGM Scores
At this time  Cerner has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Cerner has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-down-17-since-last-earnings-report-can-it-rebound-200458028,200458028
146576,368091,CERN,Here s Why You Should Add Hologic  HOLX  To Your Portfolio,opinion,Hologic  Inc    NASDAQ HOLX   has been on a solid growth trajectory of late  courtesy of strong pipeline of products as well as huge prospects in the GYN Surgical and Molecular Diagnostics segmentsThe company has outperformed the in the past year  The stock has improved 24 3  compared with the industry s 1 8  rise and the S P 500 s 5  rise The global leader of women s healthcare has a market cap of  13 19 billion  The company s expected growth rate for three to five years is 8 9  Banking on solid prospects  this Zacks Rank  2  Buy  stock has solid prospects in the near term You can see  Molecular Diagnostics Sees Consistent Growth  Hologic s management is impressed with consistent growth in the core Molecular Diagnostics sub segment  Global growth is driven by expanding market share and utilization of fully automated Panther system  Also  strong uptake of Aptima women s health products is driving the segment GYN Surgical Continues to See Growth   The company has registered solid quarterly results on the back of MyoSure  The company is seeing strong market adoption of its advanced three in one modular scope   Omni hysteroscope   following its U S  launch in December 2018 Growth Initiatives  In order to streamline operations and reduce cost of revenues  the company is adopting a few significant strategies over the past few years  These include Hologic s Genius marketing campaign in Breast Health  cervical cancer co testing initiatives in Diagnostics along with efforts to gain competitive market share with NovaSure  Moreover  the company is strengthening product portfolio through recent launches of 3Dimensions and 3D Performance gantries  Intelligent 2D  Clarity HD  SmartCurve  Affirm prone biopsy system and Brevera biopsy system  Moreover  the company announced the global commercial availability of the Trident HD specimen radiography system Which Way are Estimates Treading For the third quarter of fiscal 2019  the Zacks Consensus Estimate for earnings is pegged at 61 cents  which indicates 5 2  growth from the year ago quarter s figure  The same for revenues is pegged at  834 6 million  calling for year over year growth of 1 3  For 2019  the Zacks Consensus Estimate for earnings is pegged at  2 42  suggesting 8 5  year over year growth  The same for revenues is pegged at  3 33 billion  indicating 3 5  rise from the prior year quarter s level Other Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each of these stocks carry a Zacks Rank  2 Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-21,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-hologic-holx-to-your-portfolio-200433608,200433608
146577,368092,CERN,Bruker  BRKR  Hits A 52 Week High On Solid Growth Drivers,opinion,On Jun 24  shares of Bruker Corporation   NASDAQ BRKR   scaled a new 52 week high of  49 88  closing the session a tad bit lower at  48 60  The upside followed after the impressive first quarter 2019 results Bruker had a great run on the bourses in the past year  The stock has gained 63 7  compared with the S P 500 index s increase of 7   The return is also higher than the broader  s growth of 26  Considering the above factor  one may expect the company  to scale new highs in the upcoming quarters  Further  it delivered average positive earnings surprise of 10  in the trailing four quarters Factors Driving the StockNew Product Launches  Market seems to be upbeat about a gamut of product launches Bruker has been investing in recently  In June  the company announced the launch of the innovative mass spectrometry  MS  and Nuclear Magnetic Resonance  NMR  systems and high value solutions for molecular phenomics and clinical metabolomics research  This apart  the company launched the MALDI Biotyper sirius system for all previously FDA cleared and all research use only  RUO  MALDI Biotyper  MBT  reference libraries  which are used for near universal  fast and cost effective microbial identification from cultures in microbiology  Bruker also launched the novel timsTOF fleX mass spectrometer  which includes a software switchable MALDI source adapted to the ESI timsTOF Pro platform  Key Acquisitions  Investors are optimistic about Bruker s growth prospects since its announcement of the acquisition of the semiconductor mask repair and cleaning business of RAVE LLC  a leading provider of nanomachining and laser photomask repair equipment  The company has also acquired Arxspan LLC  a provider of cloud based scientific software and workflow solutions  based in Southborough  MA Zacks Rank   Other Key PicksBruker currently sports a Zacks Rank  1  Strong Buy  Some other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra    NYSE PEN   and The Cooper Companies   NYSE COO    Each of these stocks carries a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Cooper Companies  long term earnings growth rate is estimated at 10 8  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/bruker-brkr-hits-a-52week-high-on-solid-growth-drivers-200434441,200434441
146578,368093,CERN,Teleflex  TFX  Shares Down On Respiratory Care Product Recall,opinion,Shares of Teleflex Incorporated   NYSE TFX   dropped 0 58  to close at  332 80 yesterday  after the news of the global recall of certain lots of Hudson RCI Sheridan Endotracheal Tubes surfaced  The recalled products had been designed for oral or nasal intubation and were supposed to enable efficient airway management  These recalled products were distributed from October 2016 to May 2019 More About the Product RecallThis voluntary recall is due to reported complaints   0 0025  of all in scope distributed product  about an increased occurrence of specific batches of the 15 mm Sheridan connector becoming disconnected from the endotracheal tube  ETT   The immediate aftermath of this hazard for patients is disconnection from the breathing circuit  which may lead to insufficient oxygenation  thereby necessitating medical intervention Four cases of death and additional cases of serious injury have been reported  where ETT disconnection may have been a factor  The FDA has classified the recall of Hudson RCI Sheridan Endotracheal Tubes as a Class I recall  Teleflex issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products to the company or its distributor  The company has also requested consumers  experiencing any negative effects or quality issues with the use of this product  to report to the FDA s MedWatch Adverse Event Reporting program either online  through regular mail or fax Price PerformanceIn the past year  the stock has improved 20 7  compared with the  s growth of 3  Zacks Rank and  Key PicksTeleflex currently carries a Zacks Rank   3  Hold  Some other better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While the first two currently carry a Zacks Rank  2  Buy   Bruker sports a Zacks Rank  1  Strong Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/teleflex-tfx-shares-down-on-respiratory-care-product-recall-200434440,200434440
146579,368094,CERN,Boston Scientific Strong On Growth Goals And Future Launches,opinion,At an investment community meeting in New York City of late  Boston Scientific Corporation   NYSE BSX   presented a review of its long term growth strategy and offered plans for product pipeline and strategic investments  According to the company  this is aimed at improving its clinical and economic outcomes  sustaining category leadership in served markets and expanding into high growth  adjacent markets Overall  this long range strategy is expected to help the company deliver a strong financial performance across its MedSurg  Rhythm and Neuro  and Cardiovascular segments An Outline of the StrategyThe plan focuses on spaces like category leadership strategy  product diversification into faster growth markets and expansion of portfolio and capabilities across geographies  In this regard  Boston Scientific noted that last year  it invested approximately  1 billion in R D and also announced 10 strategic acquisitions in support of its category leadership scheme Based on these investments  the company expects to introduce approximately 75 products by 2022  Going by the company s report   many of these innovations are focused on adjacencies that are expected to expand our leadership in  22 billion in high growth markets by 2022   According to the company  by 2022  these product launches will help 80  of its sales to reach high and moderate  growth markets Per a  report   The company is looking to shift about 35  of its sales to high growth markets  compared with about 25  today  and to cut low margin sales to roughly 20   versus about 30  today  In terms of geographic growth  Boston Scientific is working on widening its footprint in the  emerging markets along with increasing patient access to care and supporting steady broad based progress through physician training capabilities  channel explosion and local partnerships Financial GoalsDuring the period from 2019 to 2022  the company is targeting double digit adjusted earnings per share via the company s ongoing adjusted operating margin improvement initiatives  which is projected to drive 50 100 basis points of expansion annually  The company has also targeted an organic revenue CAGR of 6 9  during the 2020 2022 time frame Share Price PerformanceOver the past year  shares of Boston Scientific have outperformed the  it belongs to  The stock has rallied 27 3  compared with 6 9  rise of the industry Zacks Rank   Key PicksBoston Scientific carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and The Cooper Companies   NYSE COO    each with a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Cooper Companies  long term earnings growth rate is estimated at 10 8  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/boston-scientific-strong-on-growth-goals-and-future-launches-200435316,200435316
146581,368096,CERN,Walgreens Boots  WBA  Q3 Earnings Top Estimates  Margins Dip,opinion,Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 47 for third quarter fiscal 2019  down 3 9  year over year  down 2 4  at constant exchange rate or CER   However  the figure exceeded the Zacks Consensus Estimate by 3 5  On a reported basis  net earnings came in at  1 billion  reflecting a 23 6  decline from the prior year quarter  Reported EPS came in at  1 13  down 16 2  on a year over year basis Sluggishness in Retail Pharmacy International and margin contractions put pressure on the bottom line during the quarter Total SalesWalgreens Boots recorded total sales of  34 59 billion in the fiscal third quarter  up 0 7  year over year and 2 9  at constant exchange rate or CER  The top line edged pastthe Zacks Consensus Estimate of  34 53 billion  Year over year growth was led by improvements within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions  partially offset by a dull performance within Retail Pharmacy International Segments in DetailWalgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment s sales came in at  26 5 billion in the third quarter  highlighting an improvement of 2 3  year over year  Excluding the impact of store optimization following the acquisition of Rite Aid stores  organic sales growth was 2 9  year over year Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise   Pharmacy sales  accounting for 73 9  of the Retail Pharmacy USA division s sales in the quarter  increased 4 3  from the year ago quarter on higher brand inflation  prescription volume and growth in central specialty  Pharmacy sales at comparable stores improved 6  while prescriptions filled in comparable stores rose 4 7  year over year in the quarter  The impact of store optimization following the acquisition of Rite Aid stores caused a 2 9  dip in retail sales  Comparable retail sales slid 1 1  year over year Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division decreased 7 3  on a year over year basis to  2 8 billion in the fiscal third quarter  Sales were down 1 6  at CER considering a 1  slip in Boots UK In the United Kingdom  comparable pharmacy sales inched up 0 8  and comparable retail sales declined 2 6  in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division s quarterly sales were  5 9 billion  down 1 7  year over year  up 8 3  at CER  banking on growth in the emerging markets  MarginsGross profit in the reported quarter fell 4 2  year over year to  7 45 billion  However  gross margin contracted 111 basis points  bps  to 21 5  Selling  general and administrative  SG A  expenses remained relatively flat year over year at  6 24 billion  Adjusted operating income deteriorated 21 2  to  1 21 billion  Overall  operating margin shrank 98 bps to 3 5  Financial ConditionWalgreens Boots exited the fiscal third quarter with cash and cash equivalents of  839 million compared with  818 million at the end of second quarter fiscal 2019  Long term debt was  12 13 billion compared with  12 69 billion at the end of the fiscal second quarter  Year to date  the company generated operating cash flow of  3 22 billion compared with  5 45 billion in the year ago period Guidance IntactWalgreens Boots maintained its earlier provided adjusted EPS guidance for fiscal 2019  flat with the year ago period s figure at CER The Zacks Consensus Estimate for this metric is pegged at  5 99 Our TakeWalgreens Boots  fiscal third quarter adjusted earnings as well as revenues outpaced the respective Zacks Consensus Estimate Overall  the Retail Pharmacy USA division witnessed comparable prescription growth and also benefited from a strong retail prescription market  Within this segment  Walgreens Boots has been making a good progress on account of expanding prescription volumes  Meanwhile  tough market conditions  particularly in retail  have been inducing sluggishness in the Retail Pharmacy International division  However  the company is taking steps to accelerate the digitalization and transformation initiatives of its business  Margin pressure persists as a major overhang on the stock Zacks Rank   Key PicksWalgreens currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and The Cooper Companies   NYSE COO    each with a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Cooper Companies  long term earnings growth rate is estimated at 10 8  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-q3-earnings-top-estimates-margins-dip-200435312,200435312
146585,368100,CERN,MDRX Vs  CERN  Which Stock Should Value Investors Buy Now ,opinion,"Investors with an interest in Medical Info Systems stocks have likely encountered both AllScripts Healthcare  MDRX  and Cerner  CERN   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
AllScripts Healthcare and Cerner are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that MDRX is likely seeing its earnings outlook improve to a greater extent  However  value investors will care about much more than just this 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
MDRX currently has a forward P E ratio of 17 07  while CERN has a forward P E of 27 91  We also note that MDRX has a PEG ratio of 1 66  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CERN currently has a PEG ratio of 2 07 
Another notable valuation metric for MDRX is its P B ratio of 1 33  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  CERN has a P B of 4 73 
These metrics  and several others  help MDRX earn a Value grade of A  while CERN has been given a Value grade of C 
MDRX has seen stronger estimate revision activity and sports more attractive valuation metrics than CERN  so it seems like value investors will conclude that MDRX is the superior option right now ",2019-07-08,Zacks Investment Research,https://www.investing.com/analysis/mdrx-vs-cern-which-stock-should-value-investors-buy-now-200438062,200438062
146606,368121,CERN,Haemonetics  Plant Sell Off To CLS Plasma To Be Strategic Fit,opinion,Haemonetics Corporation   NYSE HAE   recently entered into a strategic asset sell off agreement with CSL Plasma Inc  The former has announced that it willtransfer its ownership of Haemonetics  Union  SC manufacturing facility  operating assets and certain inventories to CSL Plasma  The transaction is expected to be completed in the current quarter  subject to fulfilment of certain customary closing conditions According to Haemonetics  this impending divestment remains integral to the company s asset optimization strategy that aims at improving its operating performance and focusing on core competencies Haemonetics  Union  SC manufacturing facility produces liquid saline and sodium citrate  which are solutions used in the plasmapheresis or plasma collection process  Per the terms of the deal  on the transaction s closure  the ownership and operational control of the facility including property and equipment will be transferred to CSL Plasma  Further  approximately 200 Haemonetics employees  currently working in the Union  SC plant will get an opportunity to be inducted to CSL Plasma workforce Haemonetics Plasma Business at a GlanceGoing by  Data  the global Blood Plasma market holds immense potential and is projected to register strong growth seeing a CAGR of 10 18  during the 2018 2023 period Haemonetics has been witnessing a solid uptrend in the Plasma franchise for quite some time  In the global plasma market  Haemonetics holds 80  shares approximately  In fiscal 2019  the plasma continued to witness a sturdy progress  driven primarily by robust demand for disposables in North America Haemonetics is currently observing plasma market growth above historic rates  attributable to an industry striving to double its collections by 2025 and the spurt in demand for plasma based medicines  Per management  NexSys is the best positioned platform to support this industry growth  Further  pricing from NexSys PCS and strength in liquids have started contributing to the top line  The company is advancing well with the development and launch of NexSys PCS plasmapheresis system Earlier  Haemonetics projected fiscal 2020 organic revenue growth in the band of 11 13  under its Plasma arm Share Price PerformanceOver the past three months  shares of Haemonetics have outperformed its   The stock has surged 30 5  against the 0 3  dip of the industry Zacks Rank   Other Key PicksHaemonetics sports a Zacks Rank  1  Strong Buy   Some other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank of 1  Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-plant-selloff-to-cls-plasma-to-be-strategic-fit-200432536,200432536
146607,368122,CERN,NuVasive Grows On Strong Product Adoption Amid Pricing Woe,opinion,On Jun 17  we issued an updated research report on NuVasive  Inc    NASDAQ NUVA    The company continues to witness strength in the global business  However  persistent decline in product prices due to intense competition in the spine market is a concern  NuVasive currently carries a Zacks Rank  3  Hold  In the past three months  shares of NuVasive have underperformed the  it belongs to  The stock has rallied 20 4  compared with the industry s 13 3  rise  Launch of several products in the Spinal Hardware business  balanced revenue growth across all key operating segments and robust sales figures in the international markets contributed to the surge in the company s share price  Within the U S  Spinal Hardware business  a consistent adoption of NuVasive s expandable cages  such as TLX 20 Degree expandable cage  its proprietary Porous PEEK implants and the X360 System  has been a major boost  Within the Surgical Business  closing of the Safe Passage acquisition was crucial Per NuVasive  the International region holds tremendous growth opportunity for the company  In the first quarter  the company delivered strong international revenues  reflecting 16  year over year growth at CER  The EMEA region witnessed a solid uptick  driven by a strong contribution from the United Kingdom  Southern  NYSE SO  Europe and Benelux  The tender  secured last year in Germany and Benelux  generated international revenues in the reported period  Revenues earned from the Asia Pacific region grew on the back of a sturdy recognition from Japan  Australia and New Zealand Meanwhile  unfavorable pricing persists to be a major headwind as NuVasive experiences declining prices for products due to stiffening competition in the spine market  adverse pricing pressure experienced by hospital customers from managed care organizations  insurance providers as well as other third party payers  and higher market power of hospital customers as the medical device industry consolidates  Further  escalating costs and expenses are other major concerns Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-grows-on-strong-product-adoption-amid-pricing-woe-200432535,200432535
146608,368123,CERN,NuVasive Launches Titanium Spine Implant Modulus TLIF O,opinion,NuVasive  Inc    NASDAQ NUVA   recently announced the commercial launch of Modulus TLIF O  a porous titanium spine implant  The system is designed for the transforaminal lumbar interbody fusion  TLIF  procedure  The move broadens the application of the Advanced Materials Science  AMS  portfolio to more of its procedural offerings More About the Spine ImplantBased on pre clinical data  Modulus TLIF O is equipped with a porous surface technology that facilitates bone in growth and bone on growth  Also  it can achieve stronger osseointegration compared with solid implants that have smooth or rough surfaces  The porous and roughened endplate design promotes new bone on growth at four weeks  This marks the greatest integration strength by 12 weeks compared with alternative implant materials  The optimized lattice structure enables enhanced imaging for visualization of spinal fusion compared with solid titanium interbody implants Complying to the AMS core principles of surface  structure and imaging  NuVasive continues to innovate design as well as manufacture procedures that combine the intrinsic benefits of porosity with the advantageous material properties of polyetheretherketone  PEEK  and titanium  This provides surgeons with a suite of advanced material implant options that help them cater to patient s needs Market ProspectsPer   the global market for spinal implants is estimated to witness a CAGR of approximately 5 5  during the forecast period of 2017 2023  Hence the launch of the product is strategic Recent developmentsOf late  NuVasive has been investing in several developments which are expected to strengthen its position in the spine implant market For investors  note  the company plans to launch the Modulus TLIF A spine implant later this summer  This integrates the Modulus surface technology with a specific design for anterior implant positioning for the TLIF procedure In April  2019  NuVasive announced the first case uses of Cohere XLIF  the first of its kind lateral Porous PEEK implant for XLIF and lateral single position surgery  The incorporation of the Porous PEEK technology into implants for lateral single position surgery is a major boost to the Advanced Materials Science implant portfolio Recently  the company announced that it is on track to launch the X360 system integrated with Pulse for lateral single position surgery Apart from these developments  the company announced the results of a clinical study that concludes that the NuVasive proprietary Cohere Porous polyetheretherketone  PEEK  implant highlights a clear benefit in promoting early outcomes over structural allograft and smooth PEEK in anterior cervical discectomy as well as fusion  ACDF  procedures Price PerformanceIn the past three months  the stock has improved 3 1  compared with the  s decline of 0 3  Zacks Rank and Key PicksNuVasive currently carries a Zacks Rank   3  Hold  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    The stocks currently carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-launches-titanium-spine-implant-modulus-tlifo-200432439,200432439
146613,368128,CERN,Teleflex  TFX  Hits New 52 Week High On Solid Growth Drivers,opinion,On June 17  shares of Teleflex Incorporated   NYSE TFX   scaled a new 52 week high of  326 59  closing the session a tad bit lower at  325 53  The upside followed after a series of recent strategic developments by Teleflex                                              Teleflex had a great run on the bourses in the past year  The stock has improved 17 8  compared with the S P 500 index s rise of 3 2   The return is also higher than the broader  s decline of 1 4  Considering the above factor  theprovider of medical technology products is expected to scale new highs in the upcoming quarters  Further  the company delivered average positive earnings surprise of 2 60  in the trailing four quarters Estimate revision for the current year looks impressive  In the past two months  seven estimates have moved up with no downward movement Factors Driving the StockNeoTract Inclusion Contributes to Top Line  Investors are currently anticipating a strong integration synergy from NeoTract   the acquired business of Teleflex  This business has already started to contribute to the company s revenues  NeoTract s FDA cleared UroLift System witnessed increased adoption in the first quarter Positive study results  The market is upbeat about Teleflex s announcement of positive data outcomes from five studies of the UroLift System for patients with benign prostatic hyperplasia  BPH   The results highlight the safety and efficacy of the minimally invasive treatment in real world patient populations Vascular Solution Synergy Continues  The acquisition of Vascular Solutions has already started to accelerate growth of Teleflex s vascular and interventional access product portfolios through expansion into the coronary and peripheral vascular market  The market is optimistic about the portfolios being driven by higher cross portfolio selling opportunities Regulatory Clearance  Investors are optimistic about the prospects of the company since it announced the receipt of premarket approval  PMA  from the FDA for the MANTA Vascular Closure Device  The product is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure Business in Asia Grows Strong  Considering higher demand for its wide product line in emerging economies  Teleflex is currently focusing on expansion in densely populated geographies like Asia  Of late  Asia is generating double digit year over year growth at CER on strong rollout of the company s Vascular  Interventional Access and Surgical products  From a geographical perspective  business in China has been registering solid growth  Moreover  the company is witnessing strength in Korea and Southeast Asia Zacks Rank   Other Key PicksTeleflex currently carries a Zacks Rank   2  Buy  Some other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each currently carries a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/teleflex-tfx-hits-new-52week-high-on-solid-growth-drivers-200432437,200432437
146615,368130,CERN,Here s Why You Should Invest In Haemonetics  HAE  Stock Now ,opinion,Haemonetics Corporation   NYSE HAE   is enjoying investors  rising optimism  courtesy of the NexSys PCS plasmapheresis system The company has outperformed the  in the past year  The stock has improved 24 1  compared with the industry s 5 9  rise and the S P 500 composite s 4  increase This renowned global provider of blood management solutions to customers encompassing blood and plasma collectors as well as hospitals has a market cap of  5 84 billion  The company has an earnings growth rate of 13 5  for the next three to five years Banking on solid prospects  this Zacks Rank  1  Strong Buy  stock is an attractive pick for investors at the moment  You can see  Potential Upsides of Plasma Franchise   Throughout fiscal 2019  the company s plasma franchise continued to witness strong growth driven primarily by robust demand for disposables in North America  In the region  the company registered double digit revenue growth from the year ago period  The company is progressing well with the development and launch of NexSys PCS plasmapheresis system Huge Potential of Hemostasis Management Franchise  Under Hospital business  Hemostasis Management is witnessing strong growth of late  In May 2019  Haemonetics received FDA clearance to expand the medical indication of its TEG 6s Hemostasis Analyzer System for use in adult trauma settings Strong Balance Sheet  Haemonetics exited fiscal 2019 with cash and cash equivalents of  169 4 million compared with  154 9 million at the end of third quarter fiscal 2019  For the fiscal  the company generated operating cash flow of  159 3 million compared with  220 4 million a year ago  This indicates promising return to shareholders Which Way are Estimates Treading For the first quarter of fiscal 2020  the Zacks Consensus Estimate for earnings is pegged at 63 cents  which indicates 6 8  fall from the year ago quarter s figure  The same for revenues is pegged at  238 5 million  calling for year over year growth of 3 9  For 2019  the Zacks Consensus Estimate for earnings is pegged at  2 9  suggesting 22 6  year over year growth  The same for revenues is pegged at  1 01 billion  indicating 4 2  rise from the prior year quarter s level Other Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each of these stocks carry a Zacks Rank  2 Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-haemonetics-hae-stock-now-200433036,200433036
146616,368131,CERN,Haemonetics On A High Owing To Firm Plasma Arm  Global Growth,opinion,On Jun 18  we issued an updated research report on Haemonetics Corporation   NYSE HAE    The company has been witnessing strong growth in Plasma and Hemostasis Management units for quite some time now  The stock currently sports a Zacks Rank  1  Strong Buy  Shares of this leading provider of hematology products and solutions have outperformed its   over the past year  The stock has surged 30 4  against the industry s 0 3  dip Haemonetics exited fourth quarter fiscal 2019 on a promising note with solid year over year improvements in revenues and earnings  Per the company  benefits from complexity reduction and investments along with strength in market demand and success from early launches helped the company perform impressively A steady momentum in new business generation and geographical expansion are also contributing to the company s performance of late  During the last reported quarter  the company received regulatory approvals  launched products and successfully continued to execute corporate wide transformation  This ongoing positive trend further aided the company to outdo its initial expectations and project additional growth for fiscal 2020 Haemonetics Corporation Price   Haemonetics has been witnessing a sturdy uptick in Plasma franchise for quite some time  In the global plasma market  Haemonetics holds 80  shares approximately  In fiscal 2019  plasma witnessed consistent growth  driven primarily by robust demand for disposables in North America where revenues grew 18  from the year ago period The company is progressing well with the development and launch of NexSys PCS plasmapheresis system  To date  Haemonetics converted roughly 20  of its North American install fleet to the NexSys PCS device Under Hospital business  Hemostasis Management benefited from progress in the last few quarters  Also  TEG emerged as the global leader in Hemostasis Management  led by solid disposable growth and amplified TEG success capital sales However  we are disappointed with the fact that despite generating encouraging growth at the Plasma and Hospitals segments  Haemonetics  sluggish Blood Center business moderated overall growth in the reporting cycle Other Key PicksA few other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner flaunts a Zacks Rank of 1  Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-on-a-high-owing-to-firm-plasma-arm-global-growth-200433034,200433034
146623,368138,CERN,IDEXX  IDXX  Gains Traction From Solid CAG  Global Strength,opinion,On Jun 20  we issued an updated research report on IDEXX Laboratories  Inc    NASDAQ IDXX    The company s robust worldwide commercial capabilities and best in class products including the next generation chemistry analyzer  Catalyst One  are key growth drivers over the near term  The stock carries a Zacks Rank  2  Buy  Over the past three months  this leading molecular diagnostic company has outperformed its   The stock has rallied 21 6  versus the 4 3  dip of the industry IDEXX continues to demonstrate strong organic growth  driven by robust sales at the Companion Animal Group  CAG  business  fueled by a firm global Catalyst uptake  Solid growth in organic revenues and a raised 2019 EPS guidance are also encouraging  Further  the company witnessed strong gains in CAG  Companion Animal Group  Diagnostics recurring revenues as well as in global premium instrument installed base in the last reported quarter IDEXX Laboratories  Inc  Price   The companion animal market fundamentals remain solid with a tremendous global runway for growth  This innovation based  multi modality global strategy  enabled by an enhanced commercial capability  accelerated recurring CAG Diagnostics revenue growth International revenues in the first quarter of 2019 were up 11  organically  driven by 14  organic gains in CAG Diagnostics recurring revenues  This includes more than 20  organic growth in consumable revenues as the company is benefiting from 30  year over year growth in global catalyst install base outside the United States Additionally  the company boasts a strong cash balance  allowing it to carry out share repurchases Meanwhile  a majority of IDEXX s consolidated revenues is being derived from the sale of products in the international markets  Thus  the strengthening of the U S  dollar s exchange rate  relative to other currencies  left a negative impact on the revenues derived in currencies other than the U S  money as well as on profits drawn from products manufactured in the United States and sold internationally  Also  the company s heavy dependence on third party distributors is a drag Other Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    each stock carrying a Zacks Rank of 2 Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/idexx-idxx-gains-traction-from-solid-cag-global-strength-200433635,200433635
146626,368141,CERN,Hologic  HOLX  Inks Deal To Acquire SuperSonic Imagine,opinion,Hologic  Inc    NASDAQ HOLX   has recently made a binding offer to acquire  directly or through an affiliate  SuperSonic Imagine   a France based innovator in cart based ultrasound products   Also  the company announced that it has signed an exclusive negotiation deal with SuperSonic Imagine and its primary shareholders The acquisition is in sync with the company s strategy to provide wide ranging screening  interventional and surgical solutions across the spectrum of breast health care Financial Terms Under the terms of the binding offer  Hologic has agreed to acquire SuperSonic Imagine s outstanding shares at  1 50 per share  This corresponds to all outstanding shares of approximately  39 million  or  42 million assuming dilution of all outstanding warrants and options   Further  Moreover  Hologic will generate funds to repay SuperSonic Imagine s net debt of  43 million  Summing up  this equates to a maximum enterprise value of  85 million About the AcquisitionThrough the acquisition of SuperSonic Imagine  the company is likely to foray into the  450 million cart based global breast ultrasound market  which is expanding at a high single digit rate  The upside can be attributed to the technology being adopted as an adjunct to mammography in women with dense breast tissue  SuperSonic Imagine s product portfolio will strengthen the utility of Viera  the wireless  handheld ultrasound scanner that Hologic is commercializing through a development and distribution agreement with Clarius Mobile Health Market ProspectsPer   breast cancer therapeutics market size was valued at more than  416 22 billion in 2018 and is estimated to witness a CAGR of 9 5  from 2019 to 2025 Recent DevelopmentsIn February 2019  Hologic announced that its LOCalizer wireless radio frequency identification  RFID  breast lesion localization system has been granted the CE Mark  The system is designed for convenient and accurate marking as well as targeting of lesions for breast conserving surgery guidance  In January  the company announced that the FDA has approved the LOCalizer radiofrequency identification  RFID  marker for long term placement  With this regulatory go ahead  the marker can now be implanted more than 30 days prior to a breast conserving surgery  This will provide greater flexibility and convenience to patients as well as providers Earlier this year  Hologic announced the launch of Unifi Analytics in the United States  a business intelligence tool  The device enables healthcare facilities to manage their mammography devices  monitor technologist performance and avert unprecedented downtime via predictive tube replacement technology  Price PerformanceThe company has outperformed the in the past year  The stock has improved 24 3  compared with the industry s 1 8  rise and the S P 500 s 5  rise Zacks Rank and Other Key PicksHologic currently has a Zacks Rank  2  Buy  Some other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each of these stocks carry a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-21,Zacks Investment Research,https://www.investing.com/analysis/hologic-holx-inks-deal-to-acquire-supersonic-imagine-200433816,200433816
146639,368154,CERN,Insulet  PODD  Hits 52 Week High On Solid Growth Prospects,opinion,"On June 12  shares of Insulet Corporation   NASDAQ PODD   scaled a new 52 week high of  116 41  closing the session a tad bit lower at  115 85  The upside followed after impressive first quarter 2019 earnings results Insulet had a great run on the bourses in the past year  The stock has surged 13 7  compared with the S P 500 index s rise of 2 5   The return is also higher than the broader  s rise of 5 5  Considering the above factor  one may expect theleading developer of end to end automation solutions for the medication use process  to scale new highs in the upcoming quarters  Further  the company delivered average positive earnings surprise of 135 9  in the trailing four quarters Estimate revision trends for the current year look impressive  In the past two months  nine estimates have moved upwards and two estimates have moved in the opposite direction Factors Driving the StockProgress of U S  Manufacturing Facility  Management seems to be particularly upbeat about the manufacturing unit in Acton  Massachusetts  The company was building the facility to reduce manufacturing costs  increase capacity to accelerate growth and overcome supply shortfall issue  Per management  one line in the new manufacturing facility in the United States will deliver up to 50  of the capacity of its total China operations along with around 90  less headcount  In this regard  the company opened its new worldwide headquarters and the U S  manufacturing facility in May  2019 Omnipod s market expansion continues  Since the full commercial launch of the Omnipod DASH system in the United States in the last reported quarter  the company has consistently generated revenues  Steady global expansion and rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system have enabled the company to penetrate into the Type 1 and Type 2 insulin dependent diabetes market Omnipod Horizon  a New Focus  Insulet is making progress with respect to the development of the Omnipod Horizon automated insulin delivery system  The market seems to be upbeat about the company s significant progress with its Horizon clinical development work  Insulet is currently on track to start pivotals in the fourth quarter of 2019 Insulet continues to offer support to Tidepool s efforts to achieving an open source  iOS based loop app and algorithm approved by the FDA  The company is also collaborating to secure FDA s approval for Omnipod as a component of the Tidepool Loop automated insulin delivery system Zacks Rank and Key PicksInsulet currently carries a Zacks Rank   3  Hold  
Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each currently carries a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/insulet-podd-hits-52week-high-on-solid-growth-prospects-200431225,200431225
146640,368155,CERN,Here s Why You Should Invest In Teleflex  TFX  Stock Now ,opinion,Teleflex  Inc    NYSE TFX   is enjoying high investors  optimism  courtesy of recent NeoTract acquisition and strong business in Asian markets The company has outperformed its  in the past year  The stock has improved 13   against the industry s 3 2  fall and the S P 500 composite s 2 2  increase The provider of medical technology products has a market cap of  14 81 billion  The company primarily designs  develops  manufactures as well as supplies single use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications Banking on solid prospects  this Zacks Rank  2  Buy  stock is an attractive pick for investors at the moment  You can see  NeoTract Inclusion an Upside  NeoTract   the acquired business of Teleflex   has already started to contribute to the top line  For the full year  this business is expected to register 30  growth on NeoTract  The business  FDA cleared UroLift System witnessed increased adoption in the first quarter  Vascular Solution Synergy Continues  The acquisition of Vascular Solutions  acquired in February 2017  has already started to accelerate growth of Teleflex s vascular and interventional access product portfolios through expansion into the coronary and peripheral vascular market  The portfolios are also being driven by higher cross portfolio selling opportunities Business in Asia Grows Strong  Observing strong demand for the company s wide product line in emerging economies  Teleflex is currently focusing on expansion in densely populated geographies like Asia  During the last reported quarter  Asia generated double digit year over year growth at CER on strong rollout of the company s Vascular  Interventional Access and Surgical products  From a geographical perspective  business in China registered solid growth  Moreover   the company witnessed strength in Korea and Southeast Asia Which Way are Estimates Treading For the second quarter of 2019  the Zacks Consensus Estimate for earnings is pegged at  2 59  which indicates 4 9  fall from the year ago quarter s figure  The same for revenues is pegged at  636 7 million  calling for year over year growth of 4 4  from the prior year quarter s number For 2019  the Zacks Consensus Estimate for earnings is pegged at  11 1  suggesting 11 6  year over year growth  The same for revenues is pegged at  2 58 billion  suggesting 5 6  rise from the prior year quarter s level Zacks Rank and Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    Each of these stocks carry a Zacks Rank  2 Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-14,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-teleflex-tfx-stock-now-200431703,200431703
146657,368172,CERN,Integra LifeSciences  Organic Growth Strong On New Products,opinion,On Jun 7  we issued an updated research report on Integra LifeSciences Holdings Corporation   NASDAQ IART    The company has been noticing certain major developments overseas  However  a tough competitive landscape is a concern This New Jersey based company is a leading developer  manufacturer and marketer of surgical implants and medical instruments for use in neurosurgery  extremity reconstruction  orthopedics and general surgery Shares of this Zacks Rank  3  Hold  company have outperformed its  on a year to date basis  The stock has rallied 9 2  compared with the industry s 3 6  rise Integra LifeSciences exited the first quarter of 2019 with a strong organic revenue performance  Within Orthopedics business  organic growth was generated one quarter ahead of schedule  banking on an improved sales force effectiveness  product introductions and double digit growth in both ankle and shoulder product lines Benefiting from product launches and an enhanced sales force performance  the company expects faster organic growth during the second half of 2019  Within Codman Specialty Surgical segment  it is currently working on the introduction of seven products including an intracranial pressure monitor called CereLink In this segment  the company realigned 100  of in patient wound reconstruction and orthopedic territories as part of its channel extension strategy  At the end of the first quarter of this year  Integra LifeSciences noted that the operating performance of each franchise was in line or slightly better than the management s expectations  Per Integra LifeSciences  strategic planning  it is now running the entire Codman Specialty Surgical business  independently across the United States  Canada  Australia  New Zealand and China Meanwhile  the company faces severe competition in the surgical implants and medical instruments market  It needs consistent innovation to deflect rivalry  Moreover  consolidations in the industry could induce an intense pricing pressure Key PicksSome better ranked stocks in the broader medical space areCerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-09,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-organic-growth-strong-on-new-products-200430156,200430156
146658,368173,CERN,Tandem Releases Positive Results Of T slim X2 Pump Studies,opinion,Tandem Diabetes Care  Inc    NASDAQ TNDM    recently announced positive results from two studies of the t  slim X2 insulin pump with Control IQ advanced hybrid closed loop technology  Details from the two studies  which included Protocol 3  DCLP3  of the National Institutes of Health  NIH  funded International Diabetes Closed Loop  iDCL  trial and provisional data from the Freelife Kid AP study  were presented recently at the 79th Scientific Sessions of the American Diabetes Association  ADA  The results of the studies are considered to be a major breakthrough by the company in the field of diabetes management Results in DetailsThe t slim X2 insulin pump with Control IQ technology uses Dexcom G6 CGM sensor values to forecast glucose levels and adjust insulin delivery to ensure the prevention of erratic highs and lows The NIH funded DCLP3 study was performed on people with and without prior experience with insulin pump therapy  Those using Control IQ technology also saw statistically significant improvements in HbA1c and reductions in mean glucose  A case of diabetic ketoacidosis  DKA  was reported in the Control IQ study arm due to an infusion set failure   Moreover  no severe hypoglycemia was reported in the study The Freelife Kid AP study is a multi center  randomized evaluation of the proficiency of closed loop insulin therapy in prepubertal children  The study participants using Control IQ technology showcased a reduction in mean glucose   Moreover  no case of severe hypoglycemia was reported in this case as well The results prove that t slim X2 insulin pump with Control IQ technology helps to  improve glycemic control and is convenient for patients to use Market prospectsPer   the global insulin pumps market is projected to reach around  9 50 billion by the end of 2025  The market is anticipated to witness a CAGR of 9 80  during 2017 2025  Hence  the outcomes of these studies are well timed Recent DevelopmentsLately  Tandem Diabetes is investing in several developments pertaining to the t slim X2 insulin pump In March 2019  the company announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program  ADP  NASDAQ ADP   in Ontario  Canada  In October 2018  the company received a Heath Canada Medical Device License for the t slim X2 Insulin Pump   Equipped with a Dexcom G5 Mobile continuous glucose monitoring  CGM  integration  it is the only CGM integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks  Recently  the company also announced that FDA has classified the t slim X2 insulin pump as the first in a new device category   Alternate Controller Enabled Infusion Pumps  ACE pumps  Price PerformanceIn the past one year  the company s shares have outperformed the   The stock has improved 339 1  compared with the industry s 3  decline Zacks Rank and Key PicksTandem Diabetes currently carries a Zacks Rank  3  Hold  Some other better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/tandem-releases-positive-results-of-tslim-x2-pump-studies-200430057,200430057
146659,368174,CERN,Cern Continues To Make Gains With More To Come ,opinion,"Following up on another stock  namely CERN which I posted about 3rd of April when the stock was trading at  65 88 per share 

So where next for Cern  and here two things are key  First  we need to see the price continue to break away from the volume point of control  VPOC  on rising volume and clear the top of the volatility indicator in the  66 area but expect to see some consolidation first  Once through here the  67 57 level of August last year becomes the next objective  and finally  if this is taken out  a longer term return to the  74 area  The region from  66 to  74 is also key for another reason  as volumes on the VPOC indicator are falling away the higher we move  thereby presenting less resistance to the advance which is confirmed with the trend monitor below 

And this is precisely where we are following last week s solid price action for the stock which closed with a wide spread up candle and closing at  72 74 on Friday  The key now for the  longer term  is whether the highs of October and December 2018 will now be taken out in the  74 per share region  It was at these levels the stock reversed with volume confirming the weakness on each occasion 
However  there are some very positive signs which suggest we will not witness a triple top  First  volume on the volume point of control histogram is once again thin with low and falling volume immediately ahead  suggesting the price will move through here rapidly  Second  we have two minor price based resistance levels  which were both cleared last week and denoted with the red dashed line  Third and last  the trend monitor remains bright blue confirming the continued bullish momentum for this stock  And with US equity markets looking to make further gains driven by the broader fundamental landscape  along with an easing in the trade wars with Mexico  this week may see the stock climb through these and so on to the next level at  74 per share and beyond ",2019-06-10,Anna Coulling,https://www.investing.com/analysis/cern-continues-to-make-gains-with-more-to-come-200430067,200430067
146660,368175,CERN,Here s Why You Should Hold On To QIAGEN  QGEN  Stock Now,opinion,QIAGEN N V    NYSE QGEN   is progressing well with its strategic collaborations  international market expansion and NGS platform projection In the past year  the company s shares have outperformed the    The stock has improved 4 6  compared with the industry s 19 5  fall and the S P 500 s 2 5  rise This leading provider of innovative technologies and products for pre analytical sample preparation as well as molecular diagnostics solutions has a market cap of  8 79 billion  The company has an expected earnings growth rate of 11 70  for the next three to five years Riding on solid prospects  this Zacks Rank  3  Hold  stock is worth holding on to What s Favoring the Stock Progress with test menu expansion  QIAGEN is progressing well with its testing menu expansion strategy  The company is currently establishing its European footprint for the QIAstat Dx system  which is gaining recognition as the next generation solution for providing accurate insights into complex disease syndromes like respiratory and gastrointestinal conditions Strategic collaborations to drive growth  In terms of long term business strategy  we are currently upbeat about QIAGEN s partnership with NeoGenomics in the field of cancer genetic testing services  Apart from this  the company is significantly raising its bar of automated TB testing through the partnership with DiaSorin Solid Next Generation Sequencing  NGS  Platform Projection  Management aims to expand the NGS platform by scaling up the new Enterprise Genomics Services  The company is also working on the launch of a range of proprietary Digital NGS technology based new gene panels within the GeneReader system However  there are some factors which are deterring the growth of the stock Reliance on commercial relationships  QIAGEN s personalized Healthcare business comprises formation of projects with pharmaceutical and biotechnology companies to co develop companion diagnostics paired with drugs that are marketed currently or are being developed  Future level of sales for companion diagnostics depends on the commercial success of the related medicines  Tests for the medicines have been designed to be used for determining their use in patients Competitive headwinds  Considering QIAGEN s huge gamut of services  the company is also susceptible to competitive headwinds  The company is facing increasing competition from firms that provide competitive pre analytical solutions and other products used by QIAGEN s customers Which Way are Estimates Treading For the second quarter of 2019  the Zacks Consensus Estimate for earnings is pegged at 34 cents  which indicates 3 03  growth from the year ago quarter s figure  The same for revenues is pegged at  386 4 billion  calling for year over year growth of 2 4  from the prior year quarter s number For 2019  the Zacks Consensus Estimate for earnings is pegged at  1 43  suggesting 6 7  year over year growth  The same for revenues is pegged at  1 57 billion  suggesting 4 7  rise from the prior year quarter s level Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-qiagen-qgen-stock-now-200430520,200430520
146661,368176,CERN,Chemed s VITAS Business Strong  Weak Acuity Mix Shifts A Woe,opinion,On Jun 10  we issued an updated research report on Chemed Corporation   NYSE CHE    The company currently operates two wholly owned subsidiaries   VITAS Healthcare and Roto Rooter Over the past three months  shares of Chemed have consistently outperformed its   The stock has gained 7 4  compared with the industry s 2 5  rise  Chemed exited 2018 on a promising note  The company registered strong year over year growth in revenues  It is optimistic to note that the company witnessed a solid revenue rise across its key subsidiaries VITAS has been registering an expanded average daily census  Meanwhile  the Roto Rooter business has been seeing growth on the back of a strong performance by the core plumbing and drain cleaning service segments as well as a robust trend in water restoration Chemed Corporation Price   Moreover  we are upbeat about Roto Rooter  which is currently the nation s leading provider of plumbing and drain cleaning services  Through its network of company owned branches  independent contractors and franchises  Roto Rooter offers plumbing and drain cleaning services to more than 90  of the U S  population On the flip side  Chemed exited first quarter 2019 on a dull note  Both earnings and revenues missed the respective Zacks Consensus Estimate in the reported quarter  An unfavorable acuity mix shift  fluctuations in net room and board plus contractual adjustments dented the top line during the quarter Chemed s capital deployment policy is based on its suitable acquisitions and a solid return of cash to shareholders through dividends and buybacks  Zacks Rank   Key PicksChemed currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/chemeds-vitas-business-strong-weak-acuity-mix-shifts-a-woe-200430551,200430551
146662,368177,CERN,Boston Scientific  BSX  Announces Vertiflex Acquisition ,opinion,Boston Scientific Corporation   NYSE BSX   recently closed the acquisition of Vertiflex  Inc   a private company that manufactured and commercialized the Superion Indirect Decompression System  The acquisition  which was initiated on May 9  is part of Boston Scientific s strategy of expanding the pain management portfolio The transaction has been valued at  465 million in upfront cash and additional payments contingent on commercial milestones for the next three years More About the AcquisitionThe Superion Indirect Decompression System is a minimally invasive device designed to enhance physical function and eradicate pain in patients suffering from lumbar spinal stenosis  LSS   The complication is the narrowing of spinal canal  which can result in compression of nearby nerves With this consolidation  the Superion Indirect Decompression System has been incorporated to the pain management portfolio of Boston Scientific  which already comprises spinal cord stimulation and radiofrequency ablation  The system is the only FDA approved  commercially available and minimally invasive interspinous spacer The addition of Vertiflex s device to the pain management portfolio of Boston Scientific provides physicians with additional non opioid pain management solutions that can improve the quality of lives of increasing number of chronic pain patients Market ProspectsPer   the global medical devices market is expected to reach a worth of  303 billion at a CAGR of 7 1  between 2012 and 2017  Hence  this acquisition is strategically timed Recent DevelopmentsBoston Scientific s recent acquisitions have added numerous products to its portfolios In late 2018  the company closed the acquisition of Millipede  within Structural Heart   With the completion of BTG acquisition  the company expects to gain an enhanced category leadership position in interventional oncology  arterial and venous therapies  Earlier  the company completed three tuck in acquisitions   Claret Medical  VENITI and Augmenix  These acquisitions all target high growth markets  enhance the company s category leadership strategy  leverage existing lobal capabilities and further enhance short term and long term growth profile  The Augmenix acquisition will enhance the company s category leadership strategy in Urology  Meanwhile  the integration of Claret Medical will broaden the company s structural heart portfolio  Other important tuck in acquisitions of 2018 are Cryterion  nVision  and Securus Price PerformanceIn the past year  the company s shares have outperformed the   The stock has improved 29 8   against the industry s 5 4  rise Zacks Rank and Key PicksBoston Scientific currently carries a Zacks Rank   3  Hold  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/boston-scientific-bsx-announces-vertiflex-acquisition-200430981,200430981
146668,368183,CERN,Boston Scientific s New Products  Acquisitions Boost Growth,opinion,On Jun 11  we issued an updated research report on Boston Scientific Corporation   NYSE BSX    The company s recent acquisitions have added various products  though many are under development  with immense potential to its portfolio  The stock carries a Zacks Rank  3  Hold  Over the past year  shares of Boston Scientific have outperformed the  it belongs to  The stock has rallied 22 5  compared with the industry s the 4  rise Growth across majority of its business lines and geographies was promising  The company is leaving no stone unturned to strengthen its core businesses and invest in new technologies as well as the global markets  After a long wait since the suspension of the Lotus valve in Europe  we are relieved with the news of the company receiving a regulatory approval in the United States and commencing a controlled launch of the LOTUS Edge Aortic Valve System in Europe Boston Scientific Corporation Price   This apart  the company received a nod for the WATCHMAN Left Atrial Appendage Closure  LAAC  Device from the Pharmaceuticals and Medical Devices Agency in Japan and also obtained the CE Mark  Besides  it initiated a limited market release for the next generation WATCHMAN FLX LAAC Device in Europe We are also looking forward to the company s buyouts of late  which are NxThera  Claret Medical  VENITI and Augmenix  These have already started to strongly contribute to the company s inorganic growth profile On the flip side  declining worldwide pacemaker sales over the recent past persisted to weigh on Boston Scientific s CRM results  In the first quarter of 2019  the company witnessed a mid single digit deterioration in its pacemaker performance due to certain product gaps between CRT D pacing and the MRI line  The company currently anticipates a modest pacemaker headwind for the full year  However  pacemaker sales should gradually improve with product launches  including the launch of RESONATE platform  and easier comps An unfavorable currency movement and product recall were major dampeners during the reported quarter  Tough competitors in the large medical device market also pose a difficult challenge to Boston Scientific Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/boston-scientifics-new-products-acquisitions-boost-growth-200430964,200430964
146680,368196,CERN,Myriad Genetics   MYGN  POLO Study Shows Positive Results ,opinion,Myriad Genetics  Inc    NASDAQ MYGN   recently announced that its BRACAnalysis CDx companion diagnostic test has successfully identified metastatic pancreatic cancer patients  who have received benefits from being treated with Lynparza  olaparib  in the Phase III POLO study For investors  notice  Lynparza is a novel PARP inhibitor that is being commercially developed by AstraZeneca and Merck  However  the inhibitor is yet to receive FDA s approval for gBRCAm pancreatic cancer The outcome further fortifies Myriad Genetics  foothold in the global pancreatic cancer therapy market About the BRACAnalysis TestBRACAnalysis CDx is an in vitro diagnostic device intended for the qualitative detection and categorization of variants in the protein coding regions as well as intron exon boundaries of the BRCA1 and BRCA2 genes  The device uses genomic DNA obtained from whole blood specimens collected in EDTA Other DevelopmentsRecently  Myriad Genetics has collaborated with AstraZeneca  which led to several regulatory go aheads for BRACAnalysis CDx test For instance  last December  FDA approved BRACAnalysis CDx as a companion diagnostic to identify patients diagnosed with advanced ovarian cancer who are eligible for first line maintenance treatment with olaparib  Recently  the Japanese Ministry of Health  Labor  and Welfare approved BRACAnalysis CDx as a companion diagnostic to identify patients with germline BRCAm metastatic breast cancer who have  previously received  t chemotherapy treatment  and are eligible for treatment with Lynparza Market ProspectsChronic inflammation of the pancreas  pancreatitis   diabetes  smoking and obesity have caused increasing incidences of pancreatic cancer  Per the   the global pancreatic cancer therapy market is estimated to reach  a market worth of  4 05 billion in 2025 at a CAGR of 8 1   Hence  the outcome of this study is well timed Price PerformanceMyriad Genetics has underperformed its  in the past year  The stock has declined 38 4  compared with the industry s 22  dip Zacks Rank and Key Picks Myriad Genetics currently holds a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-mygn-polo-study-shows-positive-results-200427832,200427832
146682,368198,CERN,Abbott  ABT  Grows On EPD Amid Rhythm Management Challenges,opinion,On Jun 3  we issued an updated research report on Abbott Laboratories   NYSE ABT    The company has been delivering consistent solid organic growth in the Established Pharmaceuticals  EPD  and Diabetes segments  The stock currently carries a Zacks Rank  3  Hold  This leading developer  manufacturer and seller of a diversified line of health care products has outperformed its over the past six months  The stock has gained 7 7  versus the industry s 0 2  dip Abbott exited the first quarter of 2019 with better than expected earnings and revenue figures  We are optimistic about the strong and steady performance in the company s EPD and Medical Devices segments on an organic basis  Particularly  Abbott has been riding high on a healthy growth trajectory within its Diabetes Care business Abbott Laboratories Price   The company has been gaining prominence with developments in the flagship  sensor based continuous glucose monitoring  CGM  system   FreeStyle Libre System  Also  solid contributions from Diagnostics were encouraging wherein sales were led by core laboratory growth of 10   Alinity  the company s family of next generation diagnostics systems  is driving solid growth internationally Within Nutrition  the company is witnessing sturdy underlying market demand and is successfully achieving above market growth in several geographies  particularly across Asia and Latin America Within Structural Heart  the worldwide robust uptake of MitraClip therapy improves further  In this regard  the company received an FDA approval of a new expanded indication pertaining to MitraClip  which has significantly broadened its customer base  Already  the formal process seeking Medicare reimbursement for this new indication has been initiated  The company has also filed for a CE Mark in relation to its new TriClip device  a first of its kind minimally invasive device for repairing a leaky tricuspid heart valve  and plans to initiate the U S  pivotal trial for TriClip in the coming months This apart  synergies from Alere consolidation in the form of revenues from Rapid Diagnostics are boosting the company s business  Meanwhile  the emerging market performance has been extremely promising on several strategic developments Meanwhile  a sluggish Rhythm Management arm in the United States persistently impedes growth  Also  increasing currency headwinds to some extent dented Abbott s global performance in the last reported quarter Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-grows-on-epd-amid-rhythm-management-challenges-200428309,200428309
146683,368199,CERN,Here s Why You Should Invest In Omnicell  OMCL  Stock Now,opinion,Omnicell  Inc    NASDAQ OMCL   is progressing well with its three legged strategy that covers market expansion through delivery of differentiated  innovative solutions  expansion into new markets  primarily outside the United States  as well as expansion through strategic partnerships and acquisition of new technologies In the past year  the company s shares have outperformed the   The stock has rallied 62 7   against the industry s 3 2  rise and the S P 500 s 1  fall This leading developer and marketer of end to end automation solutions for the medication use process has a market cap of  3 28 billion  The company has an expected earnings growth rate of 15  for the next three to five years Riding on solid prospects  this Zacks Rank  2  Buy  stock is an attractive pick for investors at the moment Product Innovation Driving Growth  Recently  the company is witnessing strong adoption of its G4 platform  It is upbeat about the launch of the XR2 Central Pharmacy Robot and the IVX Workflow Autonomous Pharmacy Model Holds Potential   Omnicell believes that automation tools like the XR2 Central Pharmacy Robot and the IV technology will lower medication dispensing and compounding costs  One notable example of customer integrating the Autonomous Pharmacy solution is Inova Health Care   Northern Virginia s leading nonprofit healthcare provider   that serves more than 2 million individuals annually  Focus on Geographic Expansion  The company is focusing on its strategy of expanding into new markets  The initiative is driving significant growth in the Non Acute Care segment  While the company continues to focus on the Middle East and South Africa  it sees greater adoption of technologies in Australia  the U  K   parts of Asia  Germany and France Strategic Acquisitions and Partnerships Add Value  The company s most recent buyout is InPharmics  a Mississippi based technology and services company  This is likely to enable Omnicell to expand the capabilities of its Performance Center  In the first quarter  Omnicell inked several strategic deals with healthcare providers based on its XT platform Which Way are Estimates Heading For the second quarter of 2019  the Zacks Consensus Estimate for earnings is pegged at 64 cents  which indicates 39 13  growth from the year ago quarter s figure  The same for revenues is pegged at  213 2 million  calling for year over year growth of 12 9  from the prior year quarter s number For 2019  the Zacks Consensus Estimate for earnings is pegged at  2 77  suggesting 32 54  year over year growth from the year ago quarter s figure  The same for revenues is pegged at  891 9 million  suggesting 13 3  rise from the prior year number Other Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-omnicell-omcl-stock-now-200428160,200428160
146684,368200,CERN,QIAGEN DiaSorin Union To Enhance QuantFERON For Lyme Disease,opinion,QIAGEN N V    NYSE QGEN   recently announced a development under its long standing partnership with In Vitro Diagnostics  IVD  player  DiaSorin on QuantiFERON  This time  the alliance is set to invent an ultra sensitive diagnostic test for Lyme disease on DiaSorin LIAISON Platforms QIAGEN expects multi site clinical validations for this new system during 2020 Lyme disease season  Regulatory submissions are expected at the end of 2020 in the United States and Europe The System at a GlanceQIAGEN s QuantiFERON test has two components  namely the QuantiFERON sample collection component  with the proprietary assay stimulus initiation  and QuantiFERON read out component  this measures the signal  Per QIAGEN  the QuantiFERON read out component will be run on DiaSorin s LIAISON family of fully automated analyzers and both components will be designed for use on these platforms Huge Market Potential of this DealAccording to both companies  the latest QuantiFERON Test running on LIASON platform has huge prospects as it will successfully address a significant unmet medical need  Per data  incidence of Lyme disease is growing rapidly  Approximately  30 000 confirmed cases of Lyme disease per year are reported to the U S  Centers for Disease Control  CDC   Meanwhile  CDC estimates about 300 000 individuals to be afflicted with Lyme disease annually in the United States In Europe  the latest available ECDC data shows roughly 35 000 confirmed cases in 2010  However  considering a 100  spurt in the spread of this disease in Europe over the past decade  this data seems to be significantly underestimated by many experts Of late  QIAGEN has been witnessing substantial demand for the QuantiFERON test kit  This test is registered across more than 75 countries in North America  Europe  Asia  Africa and Latin America  QIAGEN expects to exceed  300 million of sales with the QuantiFERON portfolio by 2020  We believe  its relationship with DiaSorin  which has a huge global customer base for LIASON platform  is perfectly strategic and has a financial benefit for its business Other Recent QIAGEN DiaSorin DevelopmentsEarlier  the companies teamed up to offer a fully automated CE Marked testing for latent tuberculosis  TB  infection with QuantiFERON TB Gold Plus Blood Collection Tubes  QFT Plus BCT  on DiaSorin LIAISON Platforms Share Price PerformanceQIAGEN has been gaining investor confidence from consistently encouraging results  Over the past six months  the company s share price has outperformed its   The stock has rallied 10 2  versus the industry s 4 2  decline Zacks Rank and Key PicksQIAGEN currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/qiagendiasorin-union-to-enhance-quantferon-for-lyme-disease-200429062,200429062
146689,368205,CERN,Walgreens  Weak Market Trends A Woe  Strategic Deals A Boon,opinion,On Jun 4  we issued an updated research report on Walgreens Boots Alliance  Inc    NASDAQ WBA    The company faces headwinds in the form of a fierce competition and tough industry conditions  However  at the same time  it consistently reaps benefits from its growth initiatives and major business tie ups  The stock carries a Zacks Rank  4  Sell  Walgreens Boots suffered dismal second quarter fiscal 2019 results  mainly due to disturbance in the U S  and UK consumer markets  lower generic deflation  soft brand inflation and higher reimbursement pressure  The company anticipates these pharmacy trends  which are impacting the overall market  to persist in the coming months Accordingly  it has trimmed its fiscal 2019 adjusted EPS growth expectations  Over the past month  shares of the company have underperformed its   The stock has declined 10 2   wider than the industry s 1 3  fall Walgreens Boots Alliance  Inc  Price   On a positive note  in the last reported quarter  the Retail Pharmacy USA division saw comparable prescription growth and benefited from a strong retail prescription market  Within this segment  Walgreens Boots has been making a good progress owing to its expanding prescription volumes The company is currently making concerted efforts to fix specific areas of operational weakness and is bolstering its managerial efficiency to improve operational excellence with a deepened focus The company has been gaining traction from strategic partnerships as well  We are looking forward to Walgreens Boots  recent alliance with Alphabet s life sciences and healthcare segment   Verily   to coordinate on multiple projects related to chronic ailments  Also  the company s collaborations with Express Scripts  NASDAQ ESRX  and Kroger  NYSE KR  are aimed to fortify its existing group purchasing efforts and product offerings  respectively Key PicksSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/walgreens-weak-market-trends-a-woe-strategic-deals-a-boon-200429198,200429198
146692,368208,CERN,LHC Group Finalizes Joint Venture Agreement With AtlantiCare,opinion,LHC Group  Inc    NASDAQ LHCG   recently announced that it has finalized a joint venture  JV  agreement and purchase deal with AtlantiCare   A Member of Geisinger  a health services organization in Pennsylvania and New Jersey  The transaction involves purchase of home health and hospice services of AtlantiCare in Atlantic County  New Jersey The deal  which was initiated in February  is expected to expand LHC Group s reach in New Jersey  Notably in April  LHC Group and Geisinger had finalized their JV partnership for home health and hospice services at Geisinger locations in Pennsylvania The deals are in line with the company s current strategy of collaborating with JV partners to expand service capabilities in core markets LHC Group is a prominent national provider of in home healthcare services and a preferred JV partner for 350 hospitals in the United States More About the TransactionThe home health and hospice service of Geisinger and AtlantiCare are known for delivering efficient patient focused care  The service is aimed for patients who need access to healthcare within the comfort of their homes and for patients in need of end of life care LHC Group and its Healthcare JV partners provide healthcare services that have industry wide renown for consistent quality and efficient patient care  They offer cost effective care options that include resources and support to guide families of patients Market ProspectsPer   the global home healthcare market is estimated to reach   353 56 billion by 2022 from  237 05 billion in 2016 at a CAGR of 8 3   Hence  this JV partnership is strategically timed Other Recent JV partnershipsIn May  JV partners LHC Group and Capital Region Medical Center   CRMC   signed an agreement to purchase from SSM Health the assets of one home health agency and one hospice agency in Mexico  Mo   and one home health agency in Jefferson City  Mo Through this partnership  the companies will continue working with SSM Health providers in the region to provide enhanced services for patients At the beginning of this year  LHC Group and Unity Health announced that they have finalized an equity partnership agreement to buy and share ownership of two home health providers in Arkansas  Unity Health   White County Medical Center Home Health in Searcy and Unity Health   Harris Medical Center Home Health in Newport  Once the joint venture agreement is closed  the LHC Group will supervise the daily operations of agencies that will continue services from their current locations under a new name  Unity Health   HomeCare Price PerformanceIn the past year  the company s shares have outperformed the   The stock has gained 48 8  compared with the industry s 18 8  dip  Zacks Rank and Key PicksLHC Group currently caries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  Buy  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-06,Zacks Investment Research,https://www.investing.com/analysis/lhc-group-finalizes-joint-venture-agreement-with-atlanticare-200429037,200429037
146712,368228,CERN,Cerner  CERN  Up 9 3  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Cerner  CERN   Shares have added about 9 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Cerner due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Cerner Earnings Meet Estimates in Q1  EPS View Raised Cerner reported first quarter 2019 adjusted earnings of 61 cents per share  in line with the Zacks Consensus Estimate  The bottom line increased from the prior year quarter s figure by 5 2   The company posted revenues of  1 39 billion  which improved 7 5  year over year and met the Zacks Consensus Estimate  Revenues by Geography Per management  U S  revenues grossed  1 24 billion  in line with the company s expectations  Non U S  revenues increased  1 million from the year ago quarter figure to  159 million  Per management  Cerner s international revenue growth was impacted by foreign exchange rates  Bookings In the reported quarter  the company s bookings totaled  1 24 billion  down from  1 40 billion in the same quarter of the last year  Segmental Performance Licensed software revenues shot up 14 6  to  154 5 million  with growth in traditional software and SaaS offerings  Technology resale revenues were  55 5 million  down 12 4  on a year over year basis  Revenues from Subscriptions grossed  84 3 million  up 10  year over year  Professional services  revenues totaled  490 4 million  up 11 1  from the prior year quarter number  driven by solid growth in implementation services and Cerner s works businesses  Revenues at the Managed services unit summed  304 4 million  up 13 5  from the prior year quarter  Support and maintenance revenues were  277 million  down 2 7  year over year  Reimbursed travel revenues amounted to  23 8 million  mirroring a 0 5  decline year over year  Margins In the quarter under review  gross profit summed  1 14 billion  up 7 1  year over year  Gross margin was 81 8   down 30 basis points  bps  on a year over year basis  General and administrative expenses rose 4 2  to  96 2 million  Further  software development expenses increased 11 6  to  180 4 million  Adjusted operating margin contracted 130 basis points  bps  to 17 5  during the reported quarter  Guidance For the second quarter of 2019  Cerner expects revenues between  1 41 billion and  1 46 billion  Adjusted earnings per share are expected to be 63 65 cents  Cerner kept its 2019 revenue guidance intact  The company continues to expect revenues between  5 65 billion and  5 85 billion  Cerner raised 2019 earnings per share view  Notably  the company now expects the metric to be  2 64  2 72 per share  above the previously mentioned  2 57  2 67 How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months 
VGM Scores
At this time  Cerner has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Cerner has a Zacks Rank  1  Strong Buy   We expect an above average return from the stock in the next few months ",2019-05-24,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-up-93-since-last-earnings-report-can-it-continue-200425110,200425110
146713,368229,CERN,QIAGEN  QGEN  Launches PIK3CA Kit For Breast Cancer Patients,opinion,QIAGEN N V    NYSE QGEN   recently announced the launch of therascreen PIK3CA RGQ PCR Kit  also known as therascreen PIK3CA Kit  for the treatment of breast cancer  The kit has received regulatory approval from the FDA as a companion diagnostic which treats with PIQRAY  alpelisib   a therapy developed and marketed by Novartis  The launch fortifies QIAGEN s foothold in the field of cancer diagnosis More on therascreen PIK3CA KitThe therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA for identification of activating mutations in the PIK3CA gene  It is also the first FDA approved test using plasma specimens as a liquid biopsy  which can enable one to make treatment decisions in breast cancer  The kit is equipped to identify 11 PIK3CA mutations  which are assumed to be present in approximately 40  of hormone receptor positive advanced or metastatic breast cancer patients The real time qualitative PCR kit is processed on QIAGEN s Rotor Gene Q MDx  a member of the modular QIAsymphony suite of automation solutions  The test uses QIAGEN s global co exclusive license from Johns Hopkins University for PCR based companion diagnostics based on mutations in the PIK3CA gene QIAGEN collaborated with Novartis to develop the therascreen PIK3CA Kit and received FDA clearance along with the pharma company s PIQRAY Recent DevelopmentsOf late  QIAGEN has been investing in some crucial developments which are expected to strengthen its foothold in the cancer diagnosis and treatment market Earlier this month  QIAGEN collaborated with Inovio Pharmaceuticals to co develop a companion diagnostic which can guide clinical decision making for the use of Inovio s DNA based immunotherapy to treat cervical dysplasia caused by human papillomavirus  HPV   This Precision Medicine partnership focuses on Inovio s VGX 3100  a late stage investigational product with possibility to become the first treatment for HPV infection of the cervix and the first non surgical treatment for precancerous cervical lesions associated with the virus Last month  QIAGEN announced the U S  launch of its novel therascreen FGFR RGQ RT PCR Kit as a companion diagnostic which can provide guidance in the use of the recently approved FGFR kinase inhibitor  BALVERSA  developed by Janssen Biotech  The test will enable the identification of patients with urothelial cancer whose tumors have certain alterations in the fibroblast growth factor receptor 3 gene  The FDA co approved the new test with BALVERSA Market prospectsPer   the global cancer diagnostics is expected to see a CAGR of 7  from 2019 to 2026  Hence QIAGEN s latest launch is a well timed one Price PerformanceOver the past year  QIAGEN has outperformed its   The stock has rallied 5 2  against the industry s 16 4  fall Zacks Rank and Key PicksQIAGEN currently carries a Zacks Rank   3  Hold  Some better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/qiagen-qgen-launches-pik3ca-kit-for-breast-cancer-patients-200425646,200425646
146714,368230,CERN,Masimo s Technologies To Be Deployed To Boost Pediatric Care,opinion,Masimo Corporation   NASDAQ MASI   recently announced that NuVision Management Healthcare Consulting Company is deploying a variety of Masimo technologies at its four pediatric care facilities in New Jersey and Florida More on the DealNuVision will be equipping Voorhees Pediatric  Weisman Children s Rehabilitation Hospital  Plantation Kidz Korner and Clark Nursing and Rehabilitation Center will be equipped with Masimo SET  Root with Radical 7  NomoLine Capnography and Patient SafetyNet Notably  every patient at the locations would be having access to Masimo Root Patient Monitoring and Connectivity Hubs equipped with Radical 7 Pulse CO Oximeters  allowing patients to be monitored using Masimo SET Measure through Motion and Low Perfusion pulse oximetry Additionally  a variety of other rainbow SET parameters  NomoLine capnography  available as a MOC 9 expansion module for Root  will be used to support the management of children on ventilators Other Recent DevelopmentsMasimo recently announced 510 k  clearance from the FDA for Radius PPG  This will prove beneficial for the company as Radius PPG utilizes the power of the clinically proven Masimo SET technology that delivers accurate measurement while patients are on the move  This in itself is expected to be a significant breakthrough in patient monitoring Earlier this month  Masimo along with Mdoloris Medical Systems announced the CE marking of the Mdoloris Analgesia Nociception Index module for the Masimo Root Patient Monitoring and Connectivity Hub   Read More     Price PerformanceBanking on the above developments  shares of the Zacks Rank  2  Buy  company have rallied 38 6  against the  s 4 2  decline  The current level also compares favorably with the S P 500 index s 3 1  rise Other Stocks that Warrant a LookOther top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   the other two stocks carry a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-28,Zacks Investment Research,https://www.investing.com/analysis/masimos-technologies-to-be-deployed-to-boost-pediatric-care-200426085,200426085
146715,368231,CERN,Medtronic Receives FDA Nod For SelectSite Catheter System,opinion,Medtronic plc   NYSE MDT   recently announced the FDA clearance for SelectSite C304 HIS deflectable catheter system and its market launch  The system will be used in procedures that involve His bundle pacing   HBP    The launch of the catheter is in line with the company s goal to expanding its cardiac care portfolio For investors  notice  HBP is a physiologic substitute to right ventricular pacing  in which a pacing lead is positioned at or near the bundle of His  using the heart s innate His Purkinje conduction system to reinstate normal rhythm More About the SelectSiteThe SelectSite C304 HIS deflectable catheter system is equipped with a deflectable  out of plane curve to reach the bundle of His and is capable of offering enhanced range maneuverability  fixation as well as implant success for a broader variety of patient anatomies  Its adjustable form enables the accommodation and securing of the pacing lead in more complex anatomies  including patients with a large right atrium The new catheter system ensures positioning of the Medtronic SelectSecure MRI SureScan Model 3830 cardiac pacing lead  It is the only pacing lead available in the U S  market which has been approved for HBP Market prospectsPer   the global cardiovascular catheters market is estimated to register  a CAGR of 7 4  during the period 2017 2021  Hence  the launch of the product is well timed Recent DevelopmentsOf late  a few of Medtronic s crucial developments are likely to strengthen the cardiovascular portfolio For instance  the company recently announced its foray into the guide extension catheter market with the global launch of the TelescopeGuide Extension Catheter  It is a newly designed catheter used to provide additional backup support and access to distal lesions  Guide extension catheters enable the delivery of coronary stents  balloons and other interventional devices during angioplasty procedures that help to reinstate blood flow through the coronary and peripheral arteries In May  Medtronic attained FDA approval for the Attain Stability Quad MRI SureScan left heart lead  Paired with Medtronic quadripolar cardiac resynchronization therapy defibrillators  CRT D  and pacemakers  CRT P   the Attain Stability Quad lead is the sole active fixation left heart lead  It is known for offering for precise lead placement and stability Price PerformanceBuoyed by these developments  Medtronic has outperformed its  in the past year  The stock has improved 8 3   against the industry s 1 7  rise  Zacks Rank and Key Picks Medtronic currently holds a Zacks Rank  3  Hold   Few better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank  2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/medtronic-receives-fda-nod-for-selectsite-catheter-system-200426505,200426505
146717,368233,CERN,Is Cerner  CERN  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors focused on the Medical space have likely heard of Cerner  CERN   but is the stock performing well in comparison to the rest of its sector peers  A quick glance at the company s year to date performance in comparison to the rest of the Medical sector should help us answer this question 
Cerner is one of 844 individual stocks in the Medical sector  Collectively  these companies sit at  3 in the Zacks Sector Rank  The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  CERN is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past three months  the Zacks Consensus Estimate for CERN s full year earnings has moved 2 97  higher  This shows that analyst sentiment has improved and the company s earnings outlook is stronger 
Based on the most recent data  CERN has returned 34 10  so far this year  At the same time  Medical stocks have gained an average of 1 94   This shows that Cerner is outperforming its peers so far this year 
Breaking things down more  CERN is a member of the Medical Info Systems industry  which includes 20 individual companies and currently sits at  60 in the Zacks Industry Rank  On average  stocks in this group have gained 24 89  this year  meaning that CERN is performing better in terms of year to date returns 
Going forward  investors interested in Medical stocks should continue to pay close attention to CERN as it looks to continue its solid performance ",2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/is-cerner-cern-stock-outpacing-its-medical-peers-this-year-200427114,200427114
146720,368236,CERN,Luminex XMAP Picked By EDP Biotech To Boost Cancer Diagnostics,opinion,Luminex Corporation   NASDAQ LMNX   recently entered an agreement with EDP Biotech Corporation  wherein EDP will have the rights to develop  market and sell its blood based colorectal cancer diagnostic assay  ColoPlex  using Luminex s xMAP technology  The latest move fortifies Luminex s foothold in the cancer diagnostics space For investors  notice  EDP Biotech is a privately held in vitro diagnostics company  which focuses on the development and commercialization of simple and cost effective diagnostics that detect diseases early in humans and animals On xMAPLuminex s xMAP Technology combines advanced fluidics  optics  and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities  xMAP Technology can be configured to perform a wide variety of protein or nucleic acid assays quickly  cost effectively  and accurately The company s xMAP revenues are included in the core Systems revenues which nearly doubled in the last reported quarter  Notably  management expects to see robust demand for Luminex s xMAP technology in 2019  In recent times  the company announced plans to introduce a next generation xMAP platform  Management plans to commercialize the platform in the second half of 2019 It is encouraging to note that Luminex s solid product portfolio consists of other flagship products like xTAG and Multi Code technology Market ProspectsPer management at Luminex  colorectal cancer is the second most pervasive terminal cancer in the world  World Cancer Research Fund suggests that there were 1 8 million new colorectal cancer cases in 2018 Grand View Research opines that the global cancer diagnostics market is expected to see a CAGR of 7  from 2019 to 2026  Growing prevalence of oncologic cases and increasing demand for effective screening tests drive market growth Price PerformanceWe believe that positive developments such as these are likely to boost the Zacks Rank  3  Hold  stock  which has declined 27 2  compared with the  s 5 9  fall in a year s time Stocks that Warrant a LookSome better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   the other two stocks carry a Zacks Rank  2  Buy   You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/luminex-xmap-picked-by-edp-biotech-to-boost-cancer-diagnostics-200426992,200426992
146732,368248,CERN,Medidata  MDSO  Surges  Stock Moves 7 5  Higher,opinion,Medidata Solutions  Inc    NASDAQ MDSO   was a big mover last session  as the company saw its shares rise nearly 8  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  72 18 to  80 02 in the past one month time frame The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Medidata currently has a Zacks Rank  4  Sell  while its  is 0 00  Medidata Solutions  Inc  Price   Investors interested in the Medical Info Systems industry may consider Cerner Corporation   NASDAQ CERN    which has a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Is MDSO going up  Or down  Predict to see what others think Up or DownWill you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/medidata-mdso-surges-stock-moves-75-higher-200407189,200407189
146739,368255,CERN,CERN Vs  TRHC  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical Info Systems sector have probably already heard of Cerner  CERN  and Tabula Rasa Healthcare  TRHC   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Currently  Cerner has a Zacks Rank of  2  Buy   while Tabula Rasa Healthcare has a Zacks Rank of  3  Hold   The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that CERN has an improving earnings outlook  However  value investors will care about much more than just this 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
CERN currently has a forward P E ratio of 24 33  while TRHC has a forward P E of 67 68  We also note that CERN has a PEG ratio of 1 82  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  TRHC currently has a PEG ratio of 2 71 
Another notable valuation metric for CERN is its P B ratio of 4 22  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  TRHC has a P B of 7 69 
These are just a few of the metrics contributing to CERN s Value grade of B and TRHC s Value grade of D 
CERN has seen stronger estimate revision activity and sports more attractive valuation metrics than TRHC  so it seems like value investors will conclude that CERN is the superior option right now ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/cern-vs-trhc-which-stock-is-the-better-value-option-200410831,200410831
146740,368256,CERN,Cern Remains A Buy ,opinion,"It is always dangerous to blindly follow the herd  but the consensus among the analysts is that Cerner Corporation  NASDAQ CERN  remains a strong buy  and on this occassion  I agree with them  which is unusual  There are several reasons for my opinion 
First  the recovery in the stock price from the start of the year has seen some classic volume price analysis relationships at work with Wyckoff s third law in evidence  Here we see the effort and result in agreement with steadily rising prices supported by steadily rising volume as the price of the stock recovered off the lows of  48 78 to move to test resistance at the  58 price level  denoted with the red dashed line of the accumulation and distribution indicator  As this level was tested  note how the market makers stepped in on candles 1 and 2  buying into the weakness  Notice also how the selling pressure then diminishes  until we see the sharp move higher on extreme volume  which also triggers the volatility indicator  Since then further positive signals have followed  in particular  last week s price action supported with excellent volume as the stock breached resistance in the  65 50 area as denoted by the red dashed line immediately above the volume point of control in yellow 
So where next for Cern  and here two things are key  First  we need to see the price continue to break away from the volume point of control  VPOC  on rising volume and clear the top of the volatility indicator in the  66 area but expect to see some consolidation first  Once through here the  67 57 level of August last year becomes the next objective  and finally  if this is taken out  a longer term return to the  74 area  The region from  66 to  74 is also key for another reason  as volumes on the VPOC indicator are falling away the higher we move  thereby presenting less resistance to the advance which is confirmed with the trend monitor below ",2019-05-01,Anna Coulling,https://www.investing.com/analysis/cern-remains-a-buy-200413459,200413459
146762,368278,CERN,CPSI Vs  CERN  Which Stock Is The Better Value Option ,opinion,"Investors with an interest in Medical Info Systems stocks have likely encountered both Computer Programs and Systems  CPSI  and Cerner  CERN   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Computer Programs and Systems and Cerner are sporting Zacks Ranks of  2  Buy  and  4  Sell   respectively  right now  Investors should feel comfortable knowing that CPSI likely has seen a stronger improvement to its earnings outlook than CERN has recently  But this is just one factor that value investors are interested in 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
CPSI currently has a forward P E ratio of 11 82  while CERN has a forward P E of 20 93  We also note that CPSI has a PEG ratio of 1 14  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  CERN currently has a PEG ratio of 1 52 
Another notable valuation metric for CPSI is its P B ratio of 2 43  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  CERN has a P B of 3 76 
These are just a few of the metrics contributing to CPSI s Value grade of A and CERN s Value grade of C 
CPSI stands above CERN thanks to its solid earnings outlook  and based on these valuation figures  we also feel that CPSI is the superior value option right now ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/cpsi-vs-cern-which-stock-is-the-better-value-option-200384980,200384980
146763,368279,CERN,Cerner  CERN  Down 1 5  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Cerner  CERN   Shares have lost about 1 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Cerner due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Cerner s Q4 Earnings In Line With Estimates  Guidance StrongCerner reported fourth quarter 2018 adjusted earnings of 63 cents per share  in line with the Zacks Consensus Estimate  The bottom line increased from the prior year quarter s figure by 8 6  Revenues totaled  1 37 billion  which improved 3 9  year over year but fell short of the Zacks Consensus Estimate of  1 39 billion Revenues by GeographyPer management  U S  revenues grossed  1 21 billion  up 4  year over year Non U S  revenues surged by  1 million from the year ago quarter figure to  161 million  The uptick was mainly driven by strong results in the United Kingdom and Sweden Bookings DetailIn the reported quarter  Cerner s bookings totaled  1 96 billion  down from  2 33 billion in the same quarter last year However  this is the second highest bookings quarter in Cerner s history Per management  Cerner registered bookings from long term contracts  including 6 contracts that were more than  75 million  and multiple transactions Segmental PerformanceLicensed software revenues fell 1 8  to  166 5 million  Per management  the small scale of the EHR replacement market reduces Cerner s opportunity in the traditional software sector  However  the company expects SaaS to continue growing Technology resale revenues came in at  46 1 million  down 42  on a year over year basis  The metric also came below management s expectations Revenues from Subscriptions grossed  87 million  down 24 1  year over year Professional services revenues totaled  466 2 million  up 13 9  from the prior year quarter number  Per management  this upside was mainly driven by Cerner s Works business Revenues at the Managed services unit summed  299 1 million  up 14 1  from the prior year quarter  Per management  the improvement was driven by solid year to date bookings Support and maintenance revenues came in at  276 8 million  up 5 8  year over year Reimbursed travel revenues amounted to  24 1 million  mirroring a 14 5  decline year over year MarginsIn the quarter under review  gross profit summed  1 13 billion  up 4 1  year over year  Gross margin was 82 6   flat on a year over year basis General and administrative expenses rose 7 4  to  98 9 million  Further  Software development expenses increased 11 7  to  181 5 million Adjusted operating margin contracted 180 basis points  bps  to 18 7  during the quarter GuidanceFor the first quarter of 2019  Cerner expects revenues between  1 37 billion and  1 42 billion  Adjusted earnings per share is expected to be 60 62 cents  Business bookings are expected in the range of  1 10  1 30 billion  The midpoint of this range reflects a 14  decrease year over year For 2019  revenues are expected between  5 65 billion and  5 85 billion  Adjusted earnings per share is expected between  2 57 and  2 67 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Cerner has a great Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Cerner has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-06,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-down-15-since-last-earnings-report-can-it-rebound-200395510,200395510
146764,368280,CERN,CERN Or TRHC  Which Is The Better Value Stock Right Now ,opinion,"Investors with an interest in Medical Info Systems stocks have likely encountered both Cerner  CERN  and Tabula Rasa Healthcare  TRHC   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Cerner and Tabula Rasa Healthcare are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  This means that CERN s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is only part of the picture for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
CERN currently has a forward P E ratio of 21 82  while TRHC has a forward P E of 73 98  We also note that CERN has a PEG ratio of 1 71  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  TRHC currently has a PEG ratio of 2 96 
Another notable valuation metric for CERN is its P B ratio of 3 76  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  TRHC has a P B of 8 13 
Based on these metrics and many more  CERN holds a Value grade of B  while TRHC has a Value grade of D 
CERN sticks out from TRHC in both our Zacks Rank and Style Scores models  so value investors will likely feel that CERN is the better option right now ",2019-04-08,Zacks Investment Research,https://www.investing.com/analysis/cern-or-trhc-which-is-the-better-value-stock-right-now-200405055,200405055
146782,368298,CERN,CPSI Or CERN  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in Medical Info Systems stocks are likely familiar with Computer Programs and Systems  CPSI  and Cerner  CERN   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Computer Programs and Systems has a Zacks Rank of  2  Buy   while Cerner has a Zacks Rank of  4  Sell  right now  This means that CPSI s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  However  value investors will care about much more than just this 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
CPSI currently has a forward P E ratio of 11 46  while CERN has a forward P E of 22 33  We also note that CPSI has a PEG ratio of 1 11  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CERN currently has a PEG ratio of 1 62 
Another notable valuation metric for CPSI is its P B ratio of 2 47  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  CERN has a P B of 3 58 
Based on these metrics and many more  CPSI holds a Value grade of A  while CERN has a Value grade of C 
CPSI is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that CPSI is likely the superior value option right now ",2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/cpsi-or-cern-which-is-the-better-value-stock-right-now-200367384,200367384
146783,368299,CERN,Cerner   Christiana Care Unite To Offer Bariatric Services,opinion,Cerner Corporation   NASDAQ CERN   recently announced a tie up with Christiana Care Health System to provide bariatric services to Cerner s health plan members  Notably  it is a safe weight loss surgery program with personalized support that will help members through each stage of the process Following the announcement  shares of Cerner inched up 0 1  to  53 88 at close More on the ProgramAvailable since Jan 1  the weight loss surgery program is expected to deliver improving health outcomes for patients after bariatric surgery  It also curates a comprehensive and personalized education for members to promote long term engagement For investors  notice  Delaware based Christiana Care focuses on improving health outcomes and makes high quality care more accessible with its extensive network of outpatient services  home health care and medical aid units Obesity on a Rise in USCenters for Disease Control suggests that an average American is very close to being obese  In fact  going by a recent report in CNBC  there are more than 97 million people with obesity in the United States  which is set to increase nearly 3  annually on average  Thus  demand for bariatric services is expected to rise in the times ahead An article in SNN News predicts the global bariatric surgery market to see a CAGR of 5 2  between 2019 and 2023 Hence  the latest development has been a well timed one for Cerner Another key player in the space is Weight Watchers International   NASDAQ WTW   whose weight loss and wellness programs deserve a mention in this regard  The company offers both digital and personal coaching to customers Price PerformanceWe believe such positive developments will boost Cerner s shares  which have slipped 26 1  compared with the  s 15 4  decline  The current level is also lower than the S P 500 index s 6 7  decline Zacks Rank   Key PicksCerner currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Veeva Systems Inc    NYSE VEEV   and OPKO Health  Inc    NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently flaunts a Zacks Rank  1  Strong Buy   You can see  OPKO Health s long term earnings growth rate is projected at 12   The stock presently sports a Zacks Rank of 1 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/cerner--christiana-care-unite-to-offer-bariatric-services-200375179,200375179
146784,368300,CERN,Cerner  CERN  Earnings Expected To Grow  Should You Buy ,opinion,"Cerner  CERN  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 5  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health care information technology company is expected to post quarterly earnings of  0 63 per share in its upcoming report  which represents a year over year change of  8 6  
Revenues are expected to be  1 39 billion  up 6 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cerner 
For Cerner  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Cerner will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cerner would post earnings of  0 63 per share when it actually produced earnings of  0 63  delivering no surprise 
Over the last four quarters  the company has beaten consensus EPS estimates just once 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cerner doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-earnings-expected-to-grow-should-you-buy-200380635,200380635
146786,368302,CERN,Cerner  CERN  Q4 Earnings Meet Estimates,opinion,"Cerner  CERN  came out with quarterly earnings of  0 63 per share  in line with the Zacks Consensus Estimate  This compares to earnings of  0 58 per share a year ago  These figures are adjusted for non recurring items 
A quarter ago  it was expected that this health care information technology company would post earnings of  0 63 per share when it actually produced earnings of  0 63  delivering no surprise 
Over the last four quarters  the company has surpassed consensus EPS estimates just once 
Cerner  which belongs to the Zacks Medical Info Systems industry  posted revenues of  1 37 billion for the quarter ended December 2018  missing the Zacks Consensus Estimate by 1 99   This compares to year ago revenues of  1 31 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cerner shares have added about 6  since the beginning of the year versus the S P 500 s gain of 8 7  
What s Next for Cerner 
While Cerner has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cerner was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 64 on  1 39 billion in revenues for the coming quarter and  2 70 on  5 80 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical Info Systems is currently in the top 44  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-q4-earnings-meet-estimates-200384018,200384018
146799,368315,CERN,Why Is Cerner  CERN  Up 3 9  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Cerner Corporation   NASDAQ CERN    Shares have added about 3 9  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is CERN due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsCerner reported adjusted first quarter 2018 earnings of 58 cents per share  down 1 7  from the year ago quarter  The figure was in line with the Zacks Consensus Estimate Revenues of  1 29 billion rose 2 6  year over year but missed the Zacks Consensus Estimate of  1 34 billion Bookings DetailThe year over year upside in revenues can be primarily attributed to an increase in bookings in the first quarter  Bookings were  1 40 billion  up 12  on a year over year basis  The company registered strong bookings on business office services  However  subscription bookings were lower than expected Segment DetailsInstead of reporting in three revenue categories   system sales  support maintenance and services   Cerner reported in six segments in the first quarter Licensed software in the first quarter fell 5 3  to  134 8 million  on a year over year basis  Lower than expected subscription bookings marred growth in the segment Subscriptions accounted for revenues worth  76 6 million  down 32 4  on a year over year basis Professional services increased 11 3  year over year to  441 3 million  Per management  strong performance in the segment is likely to enhance revenue cycle position Managed services segment revenues were  268 3 million  up 3 3  year over year Support and maintenance revenues were  284 6 million  up 8 6  year over year Reimbursed Travel sales amounted to  23 9 million  up 6  from the year ago quarter MarginsGross margin in the first quarter was 82 1   almost flat year over year  Operating margin for the reported quarter was 15 1   which contracted 427 basis points  bps  on a year over year basis The downside was caused by surge in operating expenses  which rose 6  year over year  The growth was driven by personnel expense related to revenue generating associates and non cash items Financial PositionCerner exited the first quarter with free cash flow of  255 7 million  Operating cash flow totaled  409 million Long term debt  including capital lease obligations  was  527 million  down slightly on a sequential basis View DownbeatCerner expects second quarter 2018 revenues between  1 31 billion and  1 36 billion The second quarter of 2018 adjusted earnings per share is projected in the range of 59 61 cents For 2018  revenues are projected in the range of  5 33  5 45 billion  down from a range of  5 45 billion to  5 65 billion Full year 2018 adjusted earnings per share is estimated in the range of  2 45  2 55  Further  the company expects second quarter 2018 new business bookings in the range of  1 35  1 55 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been 11 revisions lower for the current quarter  In the past month  the consensus estimate has shifted downward by 8 3  due to these changes 
Cerner Corporation Price and Consensus   VGM Scores
At this time  CERN has an average Growth Score of C  though it is lagging a bit on the momentum front with a D  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks  style scores indicate that the company s stock is suitable for value and growth investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  It s no surprise CERN has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2018-05-31,Zacks Investment Research,https://www.investing.com/analysis/why-is-cerner-cern-up-39-since-its-last-earnings-report-200321456,200321456
146806,368322,CERN,Cerner Collaborates With Salesforce  Focuses On AI Trends ,opinion,"In a bid to enhance population health  clinical and administration portfolio  Cerner Corporation   NASDAQ CERN   recently announced a collaboration with Salesforce  the global leader in customer relationship management  CRM  Lately  Cerner has been dominating the headlines owing to its efforts to digitize electronic health record systems  With the latest development  the company is planning to integrate the Salesforce Health Cloud and Marketing Cloud with its HealtheIntent to use artificial intelligence  AI  and reach  the next phase of health care delivery transformation   Notably  HealtheIntent is Cerner s flagship big data platform Per management  leveraging on Cerner s data  EHR and intelligent solutions  the addition of Health Cloud and Marketing Cloud will bring  game changing solutions to consumers   The new solution is expected to help patients participate in their physician s decision making process   supporting a personalized consumer experience Cerner Corporation Price     
Cerner Riding the Big Data   AI TrendsAI has been enhancing the healthcare space with EHR systems  practice workflows  clinical applications and more  The role of big data in medicine is very important in creating health profiles and better predictive models around individual patients to better diagnose and treat any disease  Per CISION  big data in healthcare industry has currently 7  market share in terms of revenues in Global Big Data market and is estimated to become the third largest in 2020 We believe that the new solution will not only be having the leverage of data and clinical content within Cerner HealtheIntent  it will also have the world s leading Salesforce CRM platform  Undoubtedly  Cerner is going to have a competitive edge in MedTech through this collaboration The recent collaboration with Virginia based Surescripts also deserves a mention in this regard  With this deal  Cerner will be able to integrate Surescripts  Real Time Prescription Benefit functionality into the  Cerner Millennium  EHR  read more    Notably  stocks with strong exposure to AI have been providing handsome returns  higher than the broader market  Research firm Tractica expects AI market revenues to reach  59 8 billion by 2025  If such an optimistic forecast is to be relied on  it would be a quantum leap over the 2016 level of only  1 4 billion Price PerformanceIn the past year  Cerner s shares have gained 17 8  compared with the  s rally of 18 3   Regulatory headwinds and cutthroat competition have dented the performance Zacks Rank   Key PicksCerner has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are MEDNAX  Inc    NYSE MD    ICU Medical  Inc    NASDAQ ICUI   and athenahealth  Inc    NASDAQ ATHN    All the stocks have a Zacks Rank  1  Strong Buy   You can see athenahealth has a projected long term growth rate of 20 7   The stock delivered a positive earnings surprise of 73 4  in the last quarter MEDNAX has an expected long term growth rate of 10   The stock delivered a positive earnings surprise of 3 6  in the last quarter ICU Medical has an expected long term growth rate of 10   The stock delivered a positive earnings surprise of 204 1  in the last quarter Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/cerner-collaborates-with-salesforce-focuses-on-ai-trends-200296130,200296130
146815,368331,CERN,Why Is Cerner  CERN  Up 2 5  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Cerner Corporation   NASDAQ CERN    Shares have added about 2 5  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is CERN due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsCerner reported adjusted fourth quarter earnings of 58 cents per share  down from 61 cents in the year ago quarter  The figure also lagged the Zacks Consensus Estimate by 3 cents Revenues in the reported quarter is  1 314 billion  up 4  on year over year basis  marginally missing the Zacks Consensus Estimate of  1 33 billion The upside in revenues can be primarily attributed to an increase in bookings in the fourth quarter  Bookings in the quarter were  2 329 billion  up 62  on a year over year basis  Full year bookings were at a record of  6 325 billion  up 16  compared with the 2016 bookings Hence  Cerner is well positioned for a strong first quarter performance based on solid bookings guidance for the same  The company further anticipates first quarter 2018 new business bookings between  1 250 billion and  1 450 billion Segment DetailsSystem Sales in the fourth quarter rose 3 2  to  363 5 million  on a year over year basis  It was driven primarily by growth in licensed software Support  Maintenance and Services accounted for revenues worth  922 million  up 4 7  on year over year basis and in line with management s expectations Reimbursement Travel sales is  28 million which is also an increase of 12 2  compared to the year ago quarter Margin   Balance Sheet DetailsGross margin in fourth quarter is 82 6   flat compared to the prior year quarter Operating margin for the reported quarter is 20 5   which contracted 280 basis points on year over year basis The fall is owing to the surge in operating expenses  which increased 9  year over year  The growth is driven by personnel expense related to revenue generating associates and non cash items Operating cash flow in the fourth quarter is  384 9 million  compared to  338 million from the year ago quarter Cerner exited the fourth quarter with cash and cash equivalents of  371 million Long term debt  including capital lease obligations is  527 million  down slightly on a sequential basis  in the quarter under review GuidanceCerner expects first quarter 2018 revenue between  1 315 billion and  1 365 billion Full year 2018 revenues are expected within  5 450 billion and  5 650 billion First quarter 2018 Adjusted earnings per share between  0 57 and  0 59 Full year 2018 adjusted earnings per share between  2 57 and  2 73 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been three revisions lower for the current quarter Cerner Corporation Price and Consensus    VGM Scores
Currently  CERN has a nice Growth Score of B  though it is lagging a lot on the momentum front with an F  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregte VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for growth investors than value investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  CERN has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-cerner-cern-up-25-since-its-last-earnings-report-200296677,200296677
146816,368332,CERN,IRCCO Picks Cerner s HealtheIntent For Patients Of Illinois,opinion,Cerner Corporation   NASDAQ CERN   has been recently selected by Illinois Rural Community Care Organization  IRCCO  to deploy Cerner HealtheIntent  the company s big data platform across IRCCO s accountable care organization  ACO   Notably  IRCCO is a state wide accountable care organization  functioning through 24 critical access and small rural hospitals  The development is likely to manage population health to ensure proper medical care for 20 000 Medicare patients throughout the state of Illinois  Further  the population health management approach will provide both the organisations an opportunity to exemplify improved healthcare  Per management  this move will ensure usable health data at the fingertips of clinicians to support improved patient care and coordination   Furthermore  member hospitals and providers will be able to use Cerner HealtheIntent to identify gaps in care  analyze population and enterprise data  as well as improve clinical decision making  Analysts believe that these developments will provide cushion to Cerner s stock that has declined 3 5  in a year s time against its  s gain of 8    Cerner HealtheIntent  A Pivotal Ground Cerner HealtheIntent is a real time  flagship population health management platform of Cerner that enables health care systems to aggregate and analyze data  thereby creating a health record for individual members of the population  In this regard  it can be noted that in the fourth quarter  HealtheIntent had played a significant role in adding to Cerner s earnings  The company ended the year with 144 HealtheIntent clients  Resultantly  population health bookings grew  42  and revenues surged 20   Furthermore  Cerner signed its first commercial health plan  according to which HealtheIntent will be the medium of serving more than 300 000 Medicaid and Medicare patients  Market Prospects Per a research by MarketsandMarkets  the healthcare analytics market is expected to reach  29 84 billion by 2022 from  8 92 billion in 2017  at a CAGR of 27 3   The growth of the market is attributed to increasing government initiatives to increase EHR  Electronic Health Record  adoption and growing pressure to curb healthcare costs  Zacks Rank   Key Picks Cerner carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are athenahealth  Inc    NASDAQ ATHN    Bio Rad Laboratories  Inc    NYSE BIO   and Centene Corporation   NYSE CNC    each sporting a Zacks Rank  1  Strong Buy   You can see  athenahealth has an expected long term growth rate of 17 7  and earnings per share growth rate of 21 5   Bio Rad has a projected long term growth rate of 20  and earnings per share growth rate of 20   Centene has an expected long term growth rate of 14 4  and earnings per share growth rate of 14 4   The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-02,Zacks Investment Research,https://www.investing.com/analysis/ircco-picks-cerners-healtheintent-for-patients-of-illinois-200302768,200302768
146817,368333,CERN,MedTech Takes To Big Data Analytics  3 Stocks Catch Eye,opinion,After the phenomenal rise of Artificial Intelligence  AI   big data analytics is taking the world by storm Be it technology  auto  retail or the banking sector  big data has been the core of all industries  In fact  the global big data market is expected to see a CAGR of 10  to reach a value of  76 billion by 2020  Research and Markets  The MedTech sector under healthcare is no exception  A fresh report by Research and Markets shows that big data in healthcare raked in  11 45 billion in 2016 and is expected to grow double digits in the 2017 2025 period Thus  focusing on MedTech stocks that are leveraging from the fast growing big data trend seems prudent  Here  we should also know that MedTech bigwigs already have a strong footing in the U S  market  courtesy of R D innovation  increasing consolidation and tax abatement Now  let s take a look at the major factors that are driving the importance of big data in the MedTech space Electronic Health RecordsThe latest trend of electronic health records  EHR   electronic medical records  predictive analytics  real time alerting and revenue cycle management services in the U S  MedTech space has been gaining prominence Of these  the cloud based EHR model is the most common application of big data in healthcare  According to Transparency Market Research  the global EHR market is expected to see a CAGR of 5 7  from 2017 to 2025  to reach an estimated value of  38 29 billion Reports suggest that MedTech companies with strong exposure to big data automated EHRs will excel in terms of operations and margins Of the major companies in the space  athenahealth Inc   NASDAQ ATHN   has been hogging the limelight on its cloud based big data network   athenaNet  The company also recently launched a machine learning model to automate faxes Three other companies are also poised to gain from the rising influence of big data on MedTech  These stocks have a  of A or B and a Zacks Rank  3  Hold  Notably  the VGM Score is a comprehensive tool that helps investors screen winning stocks from the broader sectors  Further  the score highlights the determining elements in a stock that can drive it higher Allscripts Healthcare Solutions   NASDAQ MDRX   has a VGM Score of A and a long term expected earnings growth rate of 13 8  The company is known for its comprehensive suite of fully integrated EHR platforms like Allscripts Sunrise and Paragon  While Sunrise connects all clinical and financial aspects of a hospital or health system for inpatient  emergency and outpatient care  Paragon is an EHR and administrative solution for smaller hospitals  serving a single community Last month  Allscripts had launched a new EHR solution   Avenel In a bid to revamp EHR  Allscripts has invested extensively in the Avenel user interface and created the app like functionality  featuring tablet friendly swipe and tap navigation with easy to configure dashboards Allscripts Healthcare Solutions  Inc  Price and Consensus    Quality Systems  Inc   QSII  has a VGM Score of B and a long term expected earnings growth rate of 7 9  The company  also known as NextGen Healthcare to clients  received the 2018 Best in KLAS Award as the best vendor for EHR in United States Per management  the company has more than 100 clients integrated into the national care quality framework for interoperability Interestingly  Quality Systems  EHR solutions range from machine learning algorithms for health care to large scale genome and health record analysis for cancer research Quality Systems  Inc  Price and Consensus    Cerner Corporation  NASDAQ CERN   CERN  has been dominating the headlines of late  courtesy of its efforts to digitize EHR systems  The stock has a VGM Score of B and a projected long term earnings growth rate of 14 2  Cerner s HealtheIntent is a big data platform  which provides the company with significant exposure to AI trends in the medical world HealthIntent can fetch data from any EHR system  pharmacy benefits managers and insurance claims At the end of the fourth quarter  management announced that developments like these are likely to drive the company s operating costs along with R D investments Cerner Corporation Price and Consensus     Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-05,Zacks Investment Research,https://www.investing.com/analysis/medtech-takes-to-big-data-analytics-3-stocks-catch-eye-200303405,200303405
146820,368336,CERN,Texas Hospital Administers Cerner s  CERN  Millenium System,opinion,Cerner Corporation s   NASDAQ CERN   coveted electronic health record  EHR  system   Cerner Millennium   has been recently administered by Texas based Rankin County Hospital District   RCHD    The platform will ensure improved patient experience Notably  RCHD is a health and wellness body  which serves the West Texas community  The Cerner Millennium EHR offers sophisticated health care technology to help doctors and nurses streamline their operations for better results RCHD will deploy the new EHR through the Cerner CommunityWorks model  Notably  the model uses cloud technology to deliver the power of Cerner Millennium  It is customized to support the unique needs of community  critical access and specialty hospitals  RCHD staffs can now access a digital record of their patients  health history  including real time clinical and financial data Cerner Corporation Price and Consensus   Cerner s EHR is providing comprehensive care to RCHD s 15 bed critical access hospital  Resultantly  this has impacted RCHD s daily revenue cycle meetings  allowing management to handle operations Additionally  the platform will ensure improved patient engagement through its new online portal for communication between patients and the hospital Latest Developments in Cerner s EHR FrontCerner s EHR  comprising electronic patient record  EPR  or electronic medical record  EMR   is the basis of all core clinical solutions  Lately  the EHR platform has witnessed a glut of developments Cerner Millennium and Cerner HealtheIntent were recently implemented at California based Kern Medical  a 222 bed acute care teaching center Cerner HealtheIntent was recently picked by Illinois Rural Community Care Organization  across its units to coordinate care for Medicare patients throughout the state In February  Cerner Millennium was selected by University of Missouri Health Care  Columbia  to help manage revenue cycle performance across its five hospitals and more than 50 primary and specialty care clinics Price PerformanceWe believe  these developments are going to provide a cushion to Cerner s stock that has declined 5 1  in a year s time  against the  s gain of 3 7  Zacks Rank   Key PicksCerner carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space are  BIOHAVEN PHARM   NYSE BHVN    Bio Rad Laboratories  Inc    NYSE BIO   and Envision Healthcare Corporation   NYSE EVHC    While BIOHAVEN and Bio Rad sport a Zacks Rank  1  Strong Buy   Envision carries a Zacks Rank  2  Buy   You can see BIOHAVEN has an expected growth rate of 50  for the current quarter and a growth rate of 42 1  for the next quarter Bio Rad has an expected long term growth rate of 20  and that for the current year is 42 9  Centene has an expected long term growth rate of 13  and that for the next quarter is 10 6  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/texas-hospital-administers-cerners-cern-millenium-system-200304424,200304424
146867,368383,CERN,Why Cerner  CERN  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Cerner Corporation   NASDAQ CERN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Cerner is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for CERN in this report In fact  the Most Accurate Estimate for the current quarter is currently at 58 cents per share for CERN  compared to a broader Zacks Consensus Estimate of 57 cents per share  This suggests that analysts have very recently bumped up their estimates for CERN  giving the stock a Zacks Earnings ESP of  1 75  heading into earnings season Cerner Corporation Price and EPS Surprise    Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that CERN has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Cerner  and that a beat might be in the cards for the upcoming report The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-26,Zacks Investment Research,https://www.investing.com/analysis/why-cerner-(cern)-might-surprise-this-earnings-season-200203613,200203613
146885,368401,CERN,Cerner  CERN   Moving Average Crossover Alert,opinion,"Cerner Corporation   NASDAQ CERN   could be a stock to avoid from a technical perspective  as the firm is seeing unfavorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for CERN broke out below the 200 Day Simple Moving Average  suggesting short term bearishness 
This has already started to take place  as the stock has moved lower by 12 6  in the past four weeks  And with the recent moving average crossover  investors have to think that more unfavorable trading is ahead for CERN stock 
If that wasn t enough  Cerner isn t looking too great from an earnings estimate revision perspective either  It appears as though many analysts have been reducing their earnings expectations for the stock lately  which is usually not a good sign of things to come 
Consider that in the last 30 days  12 estimates have been reduced  while none have moved higher  Add this in to a similar move lower in the consensus estimate  and there is plenty of reason to be bearish here 
That is why we currently have a Zacks Rank  4  Sell  on this stock and are looking for it to underperform in the weeks ahead  So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for CERN  You can see  
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2016-11-27,Zacks Investment Research,https://www.investing.com/analysis/cerner-(cern):-moving-average-crossover-alert-200166917,200166917
146886,368402,CERN,Are S P 500 Sectors A Suitable Portfolio Range  Not Right Now,opinion,"The USA is the world s biggest free market economy  Over many years  the value of all stocks traded on US stock markets  as judged by market cap  have traditionally fluctuated between 33  and 43  of all publicly traded issues worldwide 
Not only that  in terms of the quality of the regulatory environment  the US is among the nations where we can most trust the reported revenues and various filings   Earnings  which are regrettably the most reported upon numbers released to the public  can however be manipulated in any number of ways  no matter where the company is domiciled   Taking the mid point of that range US markets look like this 

During bear markets  history shows that very few investors elect to stick with their index funds  But in bull markets  there is a preponderance of advice given that individual investors and active managers cannot keep pace with simply buying the lowest cost passive index fund that mimics one index  Many investors have short memories and forget the carnage of previous bear markets  like March 2000   March 2003 and October 2007   March 2009  
As a result  many of us are quick to jump on the index bandwagon  The index most often employed is  I believe  the most appropriate one if investors are inclined to hand responsibility to one index  the most popular index is the SPX  the S P 500 Index  It should be  The S P 500 Index consists of all the large cap stocks  some mid cap stocks and a few REITs  in the aggregate  it is a fine cross representation of America s biggest and best  or  since we are talking market capitalization rather than corporate assets  revenues  etc   it is comprised more accurately of the  most popular   companies 
So popular have US equities become  in fact  and so disrespected are equities in the rest of the world right now that  according to the latest numbers from S P  specifically  us  spindices com  US markets now comprise 52  of total global markets 

Some may read this chart and say   Go USA  We re  1   I look at it and wonder given that this is a position beyond what it has typically been if there might be a reversion to the mean  That doesn t mean US stocks will have to fall  It might be just as likely that foreign stocks will rise  In either case  it is the biggest reason why we are diversifying our holdings at this point to include more foreign based multinationals 
I certainly haven t given up on US securities  Indeed  the biggest single position in my family accounts and many client accounts  as well as in our sample portfolio for Investor s Edge   subscribers here  is the Gotham Index Plus Fund  GINDX   I wrote about it here 
It seems the current popular opinion makes discussions of mutual funds moot   Mutual funds bad  ETFs good  Active management bad  Passive good  Lowest expense ratio  even if total return is not as good  totally excellent  Higher expense  even if after expenses total return is better  bad  bad  very bad  
The interesting thing is that GINDX is an index fund  albeit one with a twist  Its foundation is a straight S P 500 index fund  It is also a 130 30 fund  or in this case  190 90  co managed by value investors Joel Greenblatt  author of The Little Book That Beats the Market  and his partner and Co Chief investment Officer  Robert Goldstein   A caveat  this fund has a  250 000 minimum investment  but many online brokerage firms have negotiated a much lower entry price  like  5000  
I own a number of US stocks  ETFs  mutual funds and CEFs and always will  But for me the mix is changing in two ways  Here s why I believe a straight S P 500 fund is simply not the way to create an all seasons  best performing portfolio  all markets revert to the mean  RTM    For those inclined to pillory me for trying to protect client and reader portfolios from a possible decline  please remember that RTM is classic Jack Bogle  If you have 20 or 30 years until you need to tap your portfolio then RTM  even if it leaves your mouth dry and your heart beating loudly as it traces its bottom  will ultimately trace higher above the mean as well  
However  I don t personally want to own only one asset class   US stocks   even if they are divided into the subsets of US large cap  some US midcap and a few US REITs  Here are the asset classes I consider investing in 

And below  highlighted in yellow  are the most popular S P 500 asset classes that are the most popular investment choice of the greatest number of American investors 

This may look complicated at first glance  but it isn t  Just because we have that full smorgasbord from which to choose doesn t mean we have to use every one of them  Sometimes I m quite satisfied to be in only one or two of them 
There are certainly times in the investing cycle when it would be a good thing to put all your eggs in the basket defined by all US large caps  a number of US mid caps and a few REITs  Heck  for most of the past eight years that would have been as good a choice as any and better than most 
But I am a value investor  So today I have selected the primary asset classes of US and international developed market securities  be they stocks  funds or ETFs   US REITs  specific income holdings and alternatives   five broad classes that provide growth  income and risk management 
Eight years ago  companies that were selling for 11 times earnings are now selling at 33 times earnings  companies selling at a price to book ratio of 1 1 are now at 2 5  And as for investor sentiment  too many people are whistling past the graveyard hoping nothing jumps out and grabs them  These people will stick with their narrow band of asset classes defined by the S P 500 
For the rest of us  might I suggest you at least consider doing what we are doing for clients and suggesting for readers  Right now and this will change if trailing stops execute or I decide to change the allocation parameters we are about 35  long US all cap  mid cap and value funds as well as US health care stocks like Cerner Corp  NASDAQ CERN   Enzo Biochem  NYSE ENZ   and Tekla Health Sciences  NYSE HQL  
We have also purchased natural gas firms like Range Resources  NYSE RRC   Southwestern Energy  NYSE SWN   and Chesapeake Energy  NYSE CHK  which I suggested for purchase recently  and tech companies like Cisco  NASDAQ CSCO  and HP Inc  NYSE HPQ   We also have about 8  of the sample portfolio in US REITs like Physicians Realty  NYSE DOC  and Ladder Corp  NYSE LADR  
We own about 10   and will own more  in the international equities arena  Some examples are Roche Holdings  OTC RHHBY   Mexico Fund  NYSE MXE  and ETF Europe Hedged Equity  NYSE DBEU   At this stage of the market cycle  we also own another 13  or so in income holdings like ETF First Trust Preferred and Income  NYSE FPE  and T Rowe Price Floating Rate Fund  PRFRX  and another 14  in smart beta funds like AQR Long Short  QLEIX  and Vivaldi Merger Arbitrage  VARAX  
It really isn t that complicated to truly diversify to protect against market risk  I happen to love doing the reading  research and analysis of common stocks  so I have quite a mix  But you could do much the same  with hopefully similar results  using just 6 or 7 funds or 6 or 7 ETFs 
As Sgt  Phil Esterhaus used to say   Let s be careful out there  
Good investing 
Disclaimer 
 1  Do your due diligence  What s right for me may not be right for you 
 2  Past performance is no guarantee of future results  Rather an obvious statement  but too many investors look solely at periodic past performance rather than implementing a rational plan that is right for them ",2017-04-03,Joseph L. Shaefer,https://www.investing.com/analysis/does-the-s-p-500-constitute-a-portfolio-200180978,200180978
146887,368403,CERN,What s In The Cards For Cerner  CERN  This Earnings Season ,opinion,"North Kansas City  MO based Cerner Corporation   NASDAQ CERN    a leading global provider of healthcare information technology solutions  HCIT   is set to report first quarter 2017 results  after the closing bell on Apr 27 Last quarter  the company reported adjusted earnings of 57 cents  in line with the Zacks Consensus Estimate  However  the company s earnings did not top the Zacks Consensus Estimate in any of the last four quarters  resulting in an average miss of 0 45   Delving deeper into the fundamentals of the stock  let s see how things are shaping up prior to this release Factors at PlayWe believe that Cerner s strong product portfolio will help it to boost its customer base  The frequent contract wins reflect growing traction  Furthermore  the company has strong growth opportunities in the revenue cycle management  RCM  and ambulatory space The company forecasts revenues between  1 200 billion and  1 275 billion for first quarter 2017  Booking revenues are projected in the band of  1 125 billion and  1 275 billion  Adjusted earnings are expected at 57 cents to 59 cents per share However  the HCIT market is highly competitive and Cerner  a major player in this space  has been facing cut throat competition from other reputed players  This has impacted the company s pricing and margins to a great extent  Stringent hospital budgets exert further pressure on pricing  We do not expect the first quarter to have been an exception Also  overall activities of Cerner during the first quarter were inadequate to win analysts  confidence  As a result  the Zacks Consensus Estimate for the quarter to be reported fell 2 cents to 53 cents per share in the last 90 days 
Cerner Corporation Price and EPS Surprise    Earnings WhispersOur quantitative model doesn t point to an earnings beat for Cerner this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for Cerner is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 53 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cerner currently carries a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of ESP  the company s 0 00  ESP makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Stocks to ConsiderHere are three companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Proteostasis Therapeutics   NASDAQ PTI   has an Earnings ESP of  5 17  and a Zacks Rank  1  You can see  Anthem  Inc    NYSE ANTM   has an Earnings ESP of  7 79  and a Zacks Rank  2 Preferred Bank   NASDAQ PFBC   has an Earnings ESP of  1 33  and a Zacks Rank  2 Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-24,Zacks Investment Research,https://www.investing.com/analysis/what's-in-the-cards-for-cerner-(cern)-this-earnings-season-200185140,200185140
146888,368404,CERN,Cerner  CERN  Earnings And Revenues Beat Estimates In Q1,opinion,"Cerner Corp   NASDAQ CERN   reported adjusted first quarter 2017 earnings of 56 cents per share  beating the Zacks Consensus Estimate of 53 cents  Notably  earnings inched up from 49 cents from the year ago quarter The company reported net revenues of  1 260 billion  beating the Zacks Consensus Estimate of  1 226 billion  Meanwhile  revenues rose from  1 138 billion in the year ago period Stock PerformanceOver the last three months  the stock added 17 11   higher than the Zacks classified  sub industry s gain of 10 03   Additionally  the current level is above the S P 500 s return of 5 57  over the same time frame However  a modest long term expected earnings growth rate of 14 30  instills confidence in the stock Quarter HighlightsBookings in the first quarter of 2017 were  1 25 billion  up 7  on a year over year basis Revenue Cycle was a strong contributor to the company s results  courtesy of strong sales and solid contribution from RevWorks services  revenue management services   Population Health service businesses also drove revenues in the first quarter on the back of solid growth in the company s flagship HealtheIntent solutions  The company also posted an impressive performance in the ambulatory and small hospital market System sales increased from  279 4 million in the year ago quarter to  319 9 million  owing to stable performance in technology resale and software Total services revenues  including professional and managed services  rose 11  from the year ago quarter  This is in line with management s guidance and reflects solid execution by the company s service organizations Due to higher equipment maintenance revenues as a result of technology resale  support and maintenance revenues increased 4  Geographically  domestic revenues increased 13  from the year ago quarter to  1 13 billion and non U S  revenues fell 3  to  129 million Margin DetailsGross margin in the reported quarter was flat year over year totaling 84 2   courtesy of the lower mix of technology resale and improving service margins Cerner registered adjusted operating margin of 22 9  in the reported quarter  unchanged year over year As a percentage of revenues  sales and client services expanded 110 basis points  bps  to 42 7   Meanwhile  both software development and general and administrative expenses contracted roughly 40 bps and 20 bps  respectively Balance SheetCerner had a total backlog of  16 098 billion  up 10  on a year over year basis Cerner ended the first quarter of 2017 with  531 9 million of total cash and investments Total debt for Cerner  including capital lease obligations  was  532 7 million Operating cash flow for the quarter was  303 6 million  Cerner Corporation Price  Consensus and EPS Surprise
    GuidanceFor second quarter 2017  Cerner forecasts revenues between  1 265 billion and  1 335 billion  Adjusted earnings are now expected in the band of 60 cents to 62 cents per share For full year 2017  management expects revenues between  5 100 billion and  5 300 billion  Cerner currently forecasts 2017 adjusted earnings in the band of  2 44 and  2 56 per share Stocks to ConsiderCerner carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are Glaukos Corporation   NYSE GKOS    Avinger  Inc    NASDAQ AVGR   and Fluidigm Corporation   NASDAQ FLDM    Notably  Glaukos Corporation and Fluidigm sport a Zacks Rank  1  Strong Buy   while Avinger has a Zacks Rank  2  Buy   You can see  Glaukos Corporation has a long term expected earnings growth rate of approximately 25   Notably  the stock registered an impressive one year return of 197  Fluidigm Corporation has a long term expected earnings growth rate of 25   The stock added 11 4  over the last three months Avinger projects sales growth of 2 3  for the current year  Additionally  the company delivered a positive earnings surprise of 27  last quarter Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-28,Zacks Investment Research,https://www.investing.com/analysis/cerner-(cern)-earnings-and-revenues-beat-estimates-in-q1-200185944,200185944
146910,368426,CERN,5 Top Trade Ideas For This Week  AZN  BRFS  CERN  IRWD  MRO,opinion,"Here are the Rest of the Top 10 
AstraZeneca PLC  NYSE AZN 

AstraZeneca  AZN  has been moving sideways in a channel since falling below a prior channel in February  Friday saw the price move back to the top of the range with strong momentum behind it 
The RSI is in the bullish zone and rising while the MACD is turning up  The 200 day SMA is above and it has not connected with that since January  Look for a break over the top of the range to participate in the upside   
BRF SA  NYSE BRFS 

BRF  BRFS  formerly Brasil Foods  fell from a double top in the summer of 2014  It found a bottom with the market in January and has drifted  mostly sideways  since  The price action since May has seen rising trend resistance and it ended the week peeking over that Friday 
It also moved over the 200 day SMA for the first time since January 2015 Friday  The RSI is bullish and rising and the MACD is crossed up and rising  both supporting more upside  Look for continuation to participate to the upside   
Cerner Corporation  NASDAQ CERN 

Cerner  CERN  morphed from a long trend lower into a consolidating bottom in February  The bottoming process has been playing out for 5 months here as well  Friday saw a continuation higher to resistance after it moved over the 200 day SMA Thursday for the first time since August 2015 
The RSI is rising and in the bullish zone while the MACD moves higher  both supporting further upside price action  Look for a break above resistance to participate to the upside  
Ironwood Pharmaceuticals Inc  NASDAQ IRWD 

Ironwood Pharmaceuticals  IRWD  had been moving sideways for months when it broke higher in November  That proved to be a failed break out and it dropped lower precipitously to a bottom in February  It was a quick bottom with a  V  shaped recovery to the SMA confluence before a move higher in May 
It pulled back slightly to the lower Bollinger Band  and started higher again  to short term resistance last week  The RSI held in the bullish zone and is rising while the MACD is about to cross up  Look for a break of resistance to participate to the upside   
Marathon Oil  NYSE MRO 

Marathon Oil  MRO  finally started its bottoming process in January  setting a double bottom in February  confirming it at the start of March  With the push higher in April it seemed ready to race higher  but met resistance as it moved over the 200 day SMA  It pulled back the 50 day SMA and bounced slowly rising back to resistance 
Another pullback and it turned back higher  As this was happening the 50 day SMA crossed above the 200 day SMA in a Golden Cross  Friday saw a move over resistance that has support for move upside from the rising and bullish RSI and MACD  Look for a hold over prior resistance and continuation to participate to the upside   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into the holiday shortened week sees the equity markets showing some strength with a strong rebound 
Elsewhere look for Gold to continue higher while Crude Oil consolidates with a bias lower  The US Dollar Index is also consolidating but with a bias higher while US Treasuries are set to continue higher  The Shanghai Composite looks to continue its bottoming process and Emerging Markets look to continue higher in consolidation 
Volatility has fallen back and looks to remain in the normal zone keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts all agree with this on the shorter timeframe  and the IWM on the longer timeframe  while the SPY and QQQ remain in consolidation longer term  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2016-07-05,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-july-5,-2016:-the-rest-200139866",200139866
146911,368427,CERN,Can Cerner  CERN  Spring A Surprise This Earnings Season ,opinion,"Cerner Corporation   NASDAQ CERN   is expected to report second quarter 2016 results on Aug 2  Last quarter  the company reported earnings of 58 cents per share  which was in line with the Zacks Consensus Estimate Notably  the company s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 1 87  Let s see how things are shaping up for this quarter Factors at PlayWe believe that Cerner s strong product portfolio will help it boost its customer base  The frequent contract wins reflect growing traction  Moreover  the company has strong growth opportunities in the revenue cycle management  RCM  and ambulatory market  CERNER CORP Price and EPS Surprise
   For the second quarter of 2016  Cerner forecasts revenues between  1 175 billion and  1 25 billion  The mid point of the guided range reflects 8  year over year growth Cerner also projects new business bookings between  1 35 billion and  1 48 billion  At mid point  this reflects 10  growth on a year over year basis Adjusted earnings  before share based compensation expense and acquisition related adjustments  are now expected in the range of 56 cents to 58 cents  At mid point  this reflects 10  growth on a year over year basis However  the HCIT market is highly competitive which exerts considerable pressure on both pricing and margins  Moreover  a growing proportion of low margin services and technology resale may affect margins  Further  stringent hospital budgets continue to exert pressure on pricing  which is an added concern Earnings WhispersOur proven model does not conclusively show that Cerner is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Cerner has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 53 cents Zacks Rank  Cerner has a Zacks Rank  3 which increases the predictive power of ESP  but when combined with a 0 00  ESP  it makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter Nektar Therapeutics   NASDAQ NKTR   with an Earnings ESP of  50 00  and Zacks Rank  1 GlycoMimetics Inc    NASDAQ GLYC   with an Earnings ESP of  13 64  and Zacks Rank  1 ANI Pharmaceuticals Inc    NASDAQ ANIP   with an Earnings ESP of  2 63  and a Zacks Rank  1 ",2016-07-29,Zacks Investment Research,https://www.investing.com/analysis/can-cerner-(cern)-spring-a-surprise-this-earnings-season-200145130,200145130
146912,368428,CERN,Cerner  CERN  Beats Q2 Earnings  Revises  16 Revenue View,opinion,"Cerner Corp    NASDAQ CERN   reported strong second quarter 2016 earnings  After a miss in the previous quarter  bookings recovered  increasing 9  year over year to  1 40 billion However  the company lowered the high end of its guidance for revenues but reiterated the earnings guidance for the full year of 2016 Cerner reported adjusted earnings of 54 cents per share  including stock based compensation   which beat the Zacks Consensus Estimate by a penny and increased 11 5  on a year over year basis driven by 8  growth in revenues  Excluding stock based compensation  earnings were 58 cents  up 11 5  year over year in the quarter Meanwhile  revenues of almost  1 22 billion also beat the consensus mark of  1 21 billion and were well within the management s guided range of  1 175 billion to  1 25 billion   
Revenues in the U S  increased 8  from the year ago quarter to  1 073 billion  while non U S  revenues grew 9  to  143 million Cerner believes the replacement market will remain active due to higher number of hospitals on legacy platforms providing a significant growth prospect for the company  Management also noted that its products continue to seize market share from the clutches of its competitors Cerner stated that most of the new electronic health record  EHR  clients selected the Revenue Cycle product as part of their purchase  Several large clients also chose Cerner s acute Revenue Cycle and ambulatory business office services during the quarter  The company also made several new client additions to the HealtheIntent platform Quarter DetailsSystem sales increased 5 7  year over year to  333 1 million  supported by strong growth in software partially offset by a decline in hardware sales  CERNER CORP Price  Consensus and EPS Surprise
   Total services revenue  including professional and managed services  was up 12  on a year over year basis to  604 million  Support and maintenance revenues improved 1  to  257 million Bookings were within management s guided new business bookings range of  1 35 billion to  1 48 billion  In the last quarter  long term bookings comprised 28  of total bookings  Cerner noted that bookings included 45 large contracts worth over  5 million  of which 28 deals were valued at over  10 million Cerner stated that non long term bookings grew 20  from the year ago quarter  In the second quarter  34  of bookings came from outside the company s core Millennium installed base In this regard  management expects the replacement market to remain strong over the next two to three years  which will provide Cerner ample opportunities to win contracts at the cost of its competitors Backlog increased 13  from the year ago quarter to  15 billion Gross margin expanded 20 basis points  bps  on a year over year basis to 83 1   primarily driven by favorable business mix and strong services revenues  Notably  system sales margin expanded 150 bps to 68 1  in the quarter Adjusted operating expenses  excluding share based compensation expense  Health Services related amortization  acquisition related deferred revenue  and other acquisition related adjustments  increased 9  to  721 million  driven by personnel expenses related to revenue generating associates Sales and client service expense jumped up 13   general   administrative expense increased 6   while software development expense declined 2  on a year over year basis in the quarter Adjusted operating margin  excluding share based compensation expense  Health Services related amortization  acquisition related deferred revenue  and other acquisition related adjustments  contracted 40 bps to 23 8   in line with management expectations GuidanceFor the third quarter 2016  Cerner forecasts revenues between  1 20 billion and  1 275 billion  The mid point of the guided range reflects 10  year over year growth Cerner also projects new business bookings between  1 45 billion and  1 60 billion  At mid point  this reflects a slight decline on a year over year basis Adjusted earnings are now expected in the range of 59 cents to 61 cents  At mid point  this reflects 11  growth on a year over year basis For full year 2016  Cerner revised down its revenue guidance at the range of  4 9 billion to  5 billion  previous guided range was  4 9 billion to  5 1 billion   reflecting 12   down from 13   improvement over full year 2015  The decline resulted due to lower hardware revenues in the first half 2016 Notably  revenues from support and maintenance are up 5  year to date  Cerner predicts similar mid single digit growth for the rest of the year Adjusted diluted earnings are still expected in the band of  2 30 to  2 40 per share  representing almost 11  growth over 2015 Cerner anticipates margin expansion to be limited for full year 2016  However  the company expects to expand margins by 50 to 100 bps annually after 2016 Cerner expects capital expenditures to increase in 2016  primarily due to construction of a new campus  However  the company still expects to generate solid free cash flow For full year 2017  management expects a decline in capital expenditures  resulting in stronger free cash flow Our TakeWe believe Cerner s strong product portfolio will help it to win customers in the rest of 2016 and beyond  The company has growth opportunities in the revenue cycle management  RCM   Population Health and ambulatory market based on its product strength and enviable track record  Additionally  growing percentage of higher margin software in the business mix is expected to drive margins However  the HCIT market is highly competitive  which exerts considerable pressure on both pricing and margins  Moreover  a growing proportion of low margin services and technology resale may affect margins  Meanwhile  stringent hospital budgets exert further pressure on pricing Zacks Rank   Key PicksCurrently  Cerner carries a Zacks Rank  3  Hold  Better ranked stocks in the broader medical sector include AMN Healthcare services   NYSE AHS    The Advisory Board   NASDAQ ABCO   and Streamline Health Solutions   NASDAQ STRM    While AMN Healthcare and The Advisory Board sports Zacks Rank  1  Strong Buy   Streamline has a Zacks Rank  2  Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-03,Zacks Investment Research,"https://www.investing.com/analysis/cerner-(cern)-beats-q2-earnings,-revises-'16-revenue-view-200145843",200145843
146913,368429,CERN,Cerner To Manage Revenue Cycle At MCHS And Its Affiliates,opinion,"Cerner Corp    NASDAQ CERN   announced that it would now offer professional revenue cycle management for Miami Children s Health System   MCHS   and its affiliates  Pediatric Specialists of America and Nicklaus Children s Hospital Per the agreement  the company would provide the service through its Business Office Services  BOS  across MCHS s 200 member physician group practice  Notably  BOS is the company s in house billing service that uses Cerner Ambulatory practice management solutions to cater to clients  front and back office tasks  Cerner s BOS provides holistic and proactive revenue cycle management services at practices of all sizes and specialties Going forward  we believe Cerner s strong product portfolio will help it to win customers in the rest of 2016 and beyond  The company has growth opportunities in revenue cycle management  Population Health and ambulatory market based on its product strength and an enviable track record  Additionally  the growing percentage of higher margin software in the company s business mix is expected to drive margins However  the HCIT market is highly competitive  which exerts considerable pressure on both pricing and margins  Moreover  a growing proportion of low margin services and technology resale may affect margins  Meanwhile  stringent hospital budgets exert further pressure on pricing  CERNER CORP Price
    Cerner designs  develops  markets  installs and supports information technology and content solutions for healthcare organizations and consumers  The company s integrated suite of solutions enable healthcare providers to improve operating effectiveness  reduce costs and improve the quality of care as measured by clinical outcomes Zacks Rank   Key PicksCurrently  Cerner carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are CryoLife Inc    NYSE CRY    IDEXX Laboratories Inc    NASDAQ IDXX   and Masimo Corporation   NASDAQ MASI    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  CryoLife has recorded a year to date return of 63 0   better than the S P 500 s 6 1  over the same time frame  In fact  the company posted positive earnings surprises in the last four quarters  the average being 502 50  IDEXX has a strong year to date return of 54 6   The company also surpassed estimates in the last four quarters at an average rate of 12 7  Masimo has an impressive long term expected earnings growth rate of 15  and a solid year to date return of 43 3  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-02,Zacks Investment Research,https://www.investing.com/analysis/cerner-to-manage-revenue-cycle-at-mchs-and-its-affiliates-200156711,200156711
146914,368430,CERN,3 Top Earnings Charts In A Busy Week ,opinion,"Earnings season is still going strong with some of the biggest names about to report 
These three companies have good earnings track records even though they ve each missed one time in the last 5 years  That s still an impressive earnings surprise record 
Here are three you should be watching early this week 1     Pfizer  NYSE PFE  has missed just once  You have to love this big cap drug company s consistency 2     Cerner Corporation  NASDAQ CERN  is a company you might not have heard of even though it has a market cap of  19 billion  It handles healthcare information technology 3     Western Union  WU  has only missed once but it has a choppy chart 
All three of these companies should be on your short list if you re trading the earnings report 
What else should you know about these earnings charts  Tune into the short video to find out 
Want to Know How to Trade Options During Earnings Season 
Dave Bartosiak takes you through the Alibaba  NYSE BABA  options trade on 
Check it out below ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/3-top-earnings-charts-in-a-busy-week-200161825,200161825
146936,368452,CERN,This Cloud Stock s Bubble Could Be About To Pop,opinion,"Athenahealth Inc  NASDAQ ATHN   stylized as athenahealth  is a cloud based provider of software and services to the health care industry  Specifically  athenahealth is an electronic health record management company with cloud based practice management and patient communication services  Although the stock has fallen 39  from its highs in February 2014  we think it has much further to fall 
It s hard to short cloud stocks in this environment  and we ve been burned before  However  there are a few tailwinds that athenahealth has been benefitting from that have disappeared  making this stock s short prospects even better  Increased competition in the healthcare cloud services space has eroded athenahealth s profitability and the company s future looks much less profitable than it did several years ago 
What is athenahealth 
Athenahealth operates in a subset of the Technology sector that serves the health care industry through the provision of electronic health records  or EHRs  This market is further broken down into companies that serve primarily inpatient customers  think large hospitals and institutions  and ambulatory customers  physician practices and clinics   Athenahealth s customers are primarily in the ambulatory market 
Athenahealth has four main segments that collect payments from physicians  customers  manage EHRs  communicate with patients and manage referral cycles  All four of these together are referred to as  Business Services   and comprise a majority of the company s revenue  Athenahealth s revenue is generated by charging a service fee based on the percentage of a physician s bills collected 
Revenue Growth is Becoming Too Expensive
Athenahealth  like many cloud companies  has seen some impressive revenue growth over its lifetime  However  while athenahealth was once growing revenues by 39  annually  growth in 2014 slowed to 27  annually 
Not only is athenahealth s revenue growth slowing  but it s also becoming more expensive  Since 2011  athenahealth s after tax profit  NOPAT  has declined each year by 43  compounded annually  The company earned a NOPAT of just  4 million in 2014  well below the company s IPO NOPAT of  7 million in 2007  As a result  athenahealth s return on invested capital  ROIC  has fallen from 14  in 2011 to 0 5  in 2014 
What s been happening to athenahealth s profits  Two words  margin compression 
Athenahealth s NOPAT margins have fallen each year from 6  in 2011 to 0 5  in 2014  Revenue growth that once came cheap and easy is now expensive  The company has a cumulative   652 million in free cash flow since going public in 2007 
A classic lesson from Finance 101 is that a highly profitable business attracts new entrants  This is undoubtedly what s been happening at Athenahealth  as a multitude of EHR companies have entered the market  which has placed pricing pressure on athenahealth s offerings 
As shown in Figure 1 below  competition has destroyed athenahealth s economic profit 
Figure 1  Competition Erodes Growth

Sources  New Constructs  LLC and company filings 
Where d Those Tailwinds Go 
Athenahealth s growth had benefitted from two tailwinds 
The first is government subsidies  EHR providers have been riding a wave thanks mostly to Uncle Sam as acts such as the Health Information Technology for Economic and Clinical Health Act  HITECH  resulted in  to upgrade EHRs  Athenahealth especially has been cashing in on the adoption of EHRs  However  this short term tailwind is set to disappear  as the bill s funding is running out  A few years ago when HITECH was enacted  doctors were paid  44 000 to implement and use an EHR  Late last year this dropped to  24 000  and in a few months the incentive will disappear altogether 
The second tailwind is positive publicity in the eyes of the health care industry  In 2005  EHR giant Cerner  CERN  and other companies paid for a report by the RAND Corporation that predicted substantial efficiencies resulting from the adoption of electronic health records  This report helped drive growth in the EHR business and the billions of dollars from the HITEC act  Cerner s revenue tripled from 2005 to 2013  while athenahealth s increased six fold from 2007 to 2013 
However  a 2013  by the RAND Corporation said that the conversion to EHRs had failed to produce savings and had mixed results in terms of efficiency and patient care  Accordingly  the revenue growth of many EHR companies   Cerner  athenahealth  and Allscripts  MDRX   for example   is slowing or has stopped altogether  In athenahealth s case  revenue growth has slowed for each of the past six quarters  from 30  in 1Q14 to 24  in 1Q15  The company is projecting around 20  revenue growth for all of 2015  far below its 30  target from 2012 
Weak Competitor
While athenahealth is focused on the smaller ambulatory market  companies like Cerner  NASDAQ CERN  and Epic Systems  a private company  have the larger inpatient customers  Allscripts  NASDAQ MDRX  is perhaps the most similar competitor to ATHN given that they both have large market shares in the ambulatory EHR space and not within large hospitals 
Figure 2 below compares athenahealth with Allscripts  and then the two with Cerner  which focuses on large inpatient clients 
Figure 2  No True Competitor
Sources  New Constructs  LLC and company filings  
Note how low margins are in the ambulatory EHR space  Allscripts is seeing very similar margin compression to athenahealth with NOPAT margins having declined every year since 2010 
Now note Cerner s margins  This is the market athenahealth must break into if it is to achieve anywhere close to what its stock s valuation implies  Athenahealth will have a lot harder time attacking larger customers  which are already hooked by Cerner and Epic s complex systems that will be costly to change over 
Allscripts has more than 180 000 physician users and has solutions in 2 700 hospitals and 13 000 extended care organizations  while athenahealth has just over 62 000 users  As a comparison  nearly 190 million   more than half of the United States population  are already stored using Epic Software Solutions  Roughly 275 000 doctors are already using the software as well  which illustrates the uphill battle that athenahealth has to break into this market 
These Adjustments Impact Our Thesis on athenahealth
We made several adjustments to athenahealth s reported financials in 2014 to ensure that our picture of the company s fundamentals is as clear as possible  Our NOPAT calculation of  4 million is actually higher than athenahealth s reported loss of   3 million due to the removal of  5 million in non operating expenses and  5 million in implied interest expense from operating leases  In other words  even though our data shows that the company made money last year  we re still bearish 
In addition  athenahealth has  209 million in reported debt  but  110 million in off balance sheet debt from operating leases brings athenahealth s total debt to  319 million  or over 7  of the company s market value 
Valuation Ignores Current State of the Business
Despite athenahealth s evaporating profits  competitive struggles and fading tailwinds  the stock s valuation has continued to climb higher 
To justify its current price of  127 share  athenahealth  by 60  compounded annually for the next 12 years  Under this scenario  we assume that athenahealth will achieve 10  pretax margins going forward  equal to its all time high margins achieved in 2010 
If athenahealth can  instead  achieve pre tax margins of 5   still five times higher than its current margins  and grow NOPAT by 23  compounded annually for the next 20 years    an 88  downside from current levels  Remember that athenahealth is on track to achieve around 23  revenue growth this year after six consecutive quarters of revenue decline  23  extended profit growth looks optimistic when considering the competition in the space and the downward trend in athenahealth s revenue growth and profits 
Little Stupid Money Risk
Athenahealth currently has no dividend and no buyback  It s possible that a larger competitor will buy out the company  but that looks unlikely at these inflated valuations  An acquirer will likely wait until some of the investor optimism around the stock subsides  or until athenahealth acquires even more clients at a loss to make what is perhaps the company s largest asset   its client list   even more valuable 
These Catalysts Make ATHN Far Too Dangerous
We can identify a few forces that might cause athenahealth s bubble to pop  As we mentioned earlier  revenue growth slowed to 24  in the most recent quarter  If this continues to lag behind athenahealth s promised rate of 30   investors will jump ship  A catalyst for this event is the existing HITEC subsidies for EHR adoption running dry  Finally  athenahealth insiders could dump even more stock  see below  
Follow the Insiders  Lead
In the past six months  insiders have bought no shares and sold 161 000 shares  a net decrease of 26  of insiders  total holdings  Included in this group is the company s CEO Jonathan Bush  who has continuously dumped  4 million in stock since the beginning of 2014 
High Short Interest
Short interest stands at 9 7 million shares  or almost 26  of float 
Dangerous Funds That Hold ATHN
The following ETFs and mutual funds allocate significantly to ATHN and earn our Dangerous or Very Dangerous ratings  Note that we recently featured ARKK in our  
Ark Innovation ETF  ARKK    5 9  allocation to ATHN and Very Dangerous rating
Ark Web x 0 ETF  ARKW    5 3  allocation to ATHN and Dangerous rating
Transamerica Growth Opportunities Fund  ITSLX  ITSAX  ITCBX  TGPIX    3 5  allocation to ATHN and Very Dangerous rating
Allen Jackson contributed to this report 
Disclosure  Andr  Rouillard and Allen Jackson receive no compensation to write about any specific stock  sector  or theme ",2015-04-14,David Trainer,https://www.investing.com/analysis/this-cloud-stocks-bubble-could-be-about-to-pop-248297,248297
146964,368480,CERN,Top 5 Trade Ideas For The Week Of October 22  2012,opinion,Aetna  AET Aetna  AET  is building a bull flag just under resistance created by the gap down in April  The Relative Strength Index  RSI  is working off the technically overbought condition while the Moving Average Convergence Divergence indicator  MACD  is positive but fading  which is normal in a flag  A break of the flag higher carries Measured Moves to 46 and 50  This stock reports earnings Thursday morning  Cerner  CERN Cerner  CERN  is testing support for the third time in 3 months  and just above the gap up from February  The RSI is bearish and running lower with a MACD that is negative and growing  All signs point lower  A gap fill would take it to 63 21 and the 3 box reversal Point and Figure Chart  PnF  carries an even lower price objective of 60  This name reports Thursday after the close  Comerica  CMA Comerica  CMA  is moving lower with expanding Bollinger bands  a RSI that is bearish and falling and a MACD that is negative and growing  The price by volume shows that there is a void under 28 80 as well  Ugly  Covanta  CVA Covanta  CVA  broke above the consolidation zone and back tested that break out Friday  It has a bullish RSI and a MACD that is positive to support more upside  The channel break carries a target higher to 18 75 Gilead Science  GILD Gilead Science  GILD  is testing support within a consolidation zone  The RSI is still in the bullish zone but is retreating fast with a MACD that is negative and growing  both supporting a downside push  This name reports Tuesday after the close so take profits if it moves before then or wait  Up Next  Bonus IdeaAfter reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which  sees heading into the new options cycle Gold and Crude Oil ready to pullback further with the possibility that Crude Oil continues to consolidate  The US Dollar Index is poised to continue to move sideways while US Treasurys are biased lower  The Shanghai Composite is biased to the upside with the long term downtrend while Emerging Markets look to continue to consolidate  Volatility looks to remain low but is hinting at a move higher now  leaving the intermarket bias for the equity index ETF s SPY  IWM and QQQ  mixed  Longer term biases lower for the US dollar and Treasurys support the upside while potentially rising Volatilty supports more pullback  The Indexes themselves reflect this with the SPY the strongest and still consolidating while the IWM is biased lower and the QQQ the pulling back  All three are biased to the downside in the short run but the IWM and QQQ are at longer term rising trendline support  Use this information as you prepare for the coming week and trade m well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2012-10-22,Gregory W. Harmon,"https://www.investing.com/analysis/top-5-trade-ideas-for-the-week-of-october-22,-2012-140633",140633
